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Non-Covalent Protective Groups for the Modification of 
Synthetic and Natural Compounds 
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2 | P a g e  
1.1 Introduction 
Most natural products and therapeutics exhibit several functional groups, such as hydroxy-, 
amino,- olefin-, carboxy-, keto- and sulfhydryl groups. These functionalities are known to be 
essential for the biological activity and they are often targets for specific modification for the 
development of new actives with the aim of overcoming anti-drug resistance, increasing drug 
efficiency or decreasing toxicity.1,2 For example, the semi-synthetic antibiotic amikacin 1 
(Fig. 1.1) derives from acylation of a specific amino group of the natural aminoglycoside 
kanamycin A3 and is used for the treatment of multidrug-resistant tuberculosis.4,5 Similarly, 
the etherification of a hydroxy group of the immunosuppressant drug sirolimus resulted in the 
new therapeutic everolimus 2, which is applied for the treatment of renal cell carcinoma and 




























Figure 1.1: Molecular structures of modified natural compounds. Red colored structural unit indicates 
the modification of the corresponding molecule. 
 
The functional groups within such multifunctional compounds can have equal or similar 
reactivity. Therefore, reactions of these molecules resulted often in a mixture of inseparable 
derivatives.7,8 To obtain structurally complex compounds modified at a specific molecule site, 
laborious and time consuming part or total synthesis has to be employed including multiple 
Non-Covalent Protective Groups for the Modification of Synthetic and Natural Compounds  
3 | P a g e  
steps for the introduction and cleavage of covalent protective groups. For example, the 
introduction of a single hydroxy group at ring IV of neamine antibiotic neomycin B resulting 
in derivative 3 (Fig. 1.1) required more than 20 synthetic steps.9 Another way to obtain 
specific analogues of multifunctionalized compounds is to apply enzyme catalysis10,11 or 
combinatorial biosynthesis.12 For example, polyene analogue 4 (Fig. 1.1) which derives from 
macrolide antibiotic nystatin was obtained using modular polyketide synthases.2 However, all 
these techniques exhibit serious limitations, such as the availability of genetically modified 
organisms, the laborious route of multistep organic synthesis or the restricted number of 
available enzymes. One alternative approach for mastering some of these challenges is the 
application of non-covalent protective groups (Scheme 1.1).10-23 It was demonstrated that 
non-covalent protective groups can block temporally several functionalities of a compound by 
non-covalent interactions, while functional groups not in contact with the protective group can 
be transformed regioselectively (Scheme 1.1).    
(1) (2) (3)







Scheme 1.1: Site-specific modification of a multifunctionalized compound employing non-covalent 
protective groups: Introduction of protective group (1), regioselective transformation (2), removal of 
protective group (3).  
 
Non-covalent protective groups can be divided in several classes, namely transition-metal 
chelated complexes,13-17 macrocycles,18-22 polymer conjugates24 and enzymes25,26 and they 
were utilized for regioselective modification of polyamino- and polyphenolic compounds, 
amino acids, enzymes and nucleic acids. 
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1.2 Metal-Chelates as Non-Covalent Protection in Polyamines 
Polyamino compounds are represented by many important molecule classes such as 
carbohydrates, peptides, amino acids, biogenic amines and polyazamacrocycles. Due to their 
biological function many members of these classes represent therapeutics or are metabolites 
which are important as diagnostic markers.27-30 In the following paragraphs site-specific 
modifications of polyamino compounds are described employing a non-covalent protection 
strategy based on metal-chelate formation.  
 
1.2.1 Regioselective Modification of Aminoglycoside Antibiotics  
Neamine aminoglycosides represent an important class of antibiotics. They are applied 
against Gram-negative and Gram-positive bacteria14,15,27,31,32 and have anti-HIV activity.33 
Since the mechanism of bacterial resistance against these antibiotics is well understood, 
modification of aminoglycosides is becoming a promising tool to overcome antibacterial 
resistance. Zhou et al. and Yang et al. reviewed the extensive work about synthesis of new 
derivatives of aminoglycoside antibiotics.34-37 However, it has to be emphasized that 
modification of these molecular structures requires multistep synthesis frequently employing 
conventional covalent protective group strategies.9,36,37 To simplify the synthesis of novel 
antibiotic derivatives, Nagabhushan et al. and Hanessian et al. introduced a method based on 
non-covalent protection to block several amino groups in aminoglycoside antibiotics and 
enabling regioselective modification of these carbohydrates.38,39 It was demonstrated that 
divalent transition metal ions, such as zinc(II), nickel(II) and copper(II) can block vicinal and 
non-vicinal amino- and hydroxy groups by metal-chelate complex formation. Amines not 
acting as ligand for the transition metal can be transformed regioselectively.13,38,39 Recently, 
this technique was successfully employed for the development of superior aminoglycoside 
antibiotics.14 Aggen et al. established the synthesis of the neoglycoside ACHN-490 5 
(Scheme 1.2) which has shown promising broad-spectrum activity against Gram-negative 
bacterial infections, including the highly resistant Enterobacteriaceae.14 As shown in 
Scheme 1.2, the intermediate, 6´-N-trifluoroacetyl sisomycin 6 was treated with the transition 
metal salt zinc(II)acetate to block the amino groups in C3 positions of ring I and II resulting in 
complex 7. In the following step, unprotected amino groups of ring I and III were transformed 
regioselectively resulting in derivative 8. Additional synthetic steps afforded the new 
antibiotic 5.14 
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Scheme 1.2: Regioselective modification of an aminoglycoside using metal-chelate complex formation 
as non-covalent protective group: Metal-chelate complex formation (1), introduction of covalent 
protective group (2) and multi-step-synthesis to produce neoglycoside ACHN-490 (3).14 
In a similar way, Nudelman et al. derivatized paromamine 9 using zinc(II)acetate as non-
covalent protective group to obtain the 1-N-Boc protected aminoglycoside 10 (Scheme 1.3).15 
This regioselective transformation was a key-step in the synthesis of the novel antibiotic 
NB54 11 which showed reduced toxicity and enhanced suppression of disease-causing 
premature stop mutations.15 
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9 10
(1)










Scheme 1.3: Regioselective modification of paromamine 9 using Zn(II)-chelate complex formation as 
non-covalent protective group (1) and multi-step synthesis to obtain antibiotic NB54 (2).15  
 
1.2.2 Regioselective Modification of Amino Acids  
While aminoglycoside bear only hydroxy- and amino groups, the metal chelate method was 
also successfully employed for the regioselective derivatization of amino acids.13,40-43 These 
efforts have been recently summarized in a review by Lee and Cheong.13 As shown in 
Scheme 1.4, the α-amino group of amino acids 5-(R)-hydroxy-L-lysin 12a and L-lysin 12b 
was protected non-covalently by the interaction with copper(II) ions resulting in metal-chelate 
complex 13.40-43  In the next step covalent protective groups (PGs), such as benzyl- (Bn), 
carboxybenzyl- (Cbz), fluorenylmethoxycarboxy (Fmoc) and tert-butylcarboxy groups 
(tert-Boc) were introduced regioselectively at the unprotected amine in ε-position resulting in 





12a R = OH
12b R = H
14a R = OH, PG = Boc
14b R = OH, PG = CBz
14c R = H,    PG = Fmoc
 
Scheme 1.4: Regioselective modification of amino acids 12a and 12b: Non-covalent protection of α-
amino group using Cu(II)-chelate complex formation (1) and regioselective transformation of ε-amine 
(2).40-43  
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Table 1.1: Regioselective modification of ε-amino group of amino acids.  
amino acid product reagents
 
yield (%) ref. 
12a 14a a, CuCO3xCu(OH)2xH2O        b, (Boc)2O, H2O/dioxane 68 [40] 
12a 14b 
a, CuCO3, H2O, reflux            




a, CuCO3xCu(OH)2xH2O        
b, Fmoc-N3, MgO                  




1.2.3 Regioselective Modification of Polyazamacrocycles  
Macrocyclic polyamines have been extensively investigated as catalysts and transport systems 
for metal ions.44 Moreover, metal-polyazamacrocycle complexes have been also applied as 
radiopharmaceuticals and luminescence probes30,45,46 or as a model for the elucidation of 
enzymatic reactions, such as the hydrolysis of phosphate monoesters by alkaline 
phosphatase.44,47 In this sense, the synthesis of these macrocycles and their derivatization is an 
important goal, which has been the subject of several studies.48-52 Nevertheless, the 
monofunctionalization of unsymmetrical macrocylces is still a challenging process and 
required multistep synthesis.53,54 Burguete et al. established a simple method for the selective 
modification of these polyamines based on non-covalent protection (Scheme 1.5).16 It was 
demonstrated that the coordination of divalent zinc ions allowed selective protection of three 
out of four amines in tetra-aza[n]paracyclophanes 15a-c resulting in metal-chelate complex 
16. As shown in Scheme 1.5, the amino group not involved in complex formation was 
transformed regioselectively using an alkylation reagent resulting in derivatives 17a-i (Table 
1.2).  
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Scheme 1.5: Regioselective alkylation and dimerization of polyaza[n]macrocycles using metal-chelate 
complex formation as non-covalent protective group.16,17  
 
Table 1.2: Regioselective alkylation and dimerization of polyaza[n]macrocycles. 
Amino 
acid Product residue R Yield (%) Ref. 
15a 17a vinyl 60 [16] 
15a 17b phenyl 56 [16] 
15a 17c ethoxycarbonyl 72 [16] 
15a 17d p-nitrophenyl 61 [16] 
15a 17e p-methylphenyl 64 [16] 
15b 17f vinyl 52 [16] 
15c 17g vinyl 89 [16] 
15c 17h ethoxycarbonyl 73 [16] 
15c 17i phenyl 79 [16] 
15a 19a -- 87 [17] 
15a 19b -- 78 [17] 
 
Non-Covalent Protective Groups for the Modification of Synthetic and Natural Compounds  
9 | P a g e  
In further studies Burguete et al. applied this method for the dimerization of the 
polyazamacrocycle 15a.17 Using alkylation reagents 1,4-bis(halomethyl)aren 18a and 
1,3-bis(halomethyl)aren 18b the polyamines 19a and 19b were obtained, respectively 
(Scheme 1.5, Table 1.2), exhibiting two macrocyclic subunits. Their synthesis was 
particularly important, since these so called ditopic polyazamacrocycles are known to have 
anti-HIV activity.55,56 
 
1.3 Macrocycles as Supramolecular Protective Groups 
After discussing the use of small metal ions for the regioselective derivatization, in this 
paragraph the use of more complex macrocycles as non-covalent protective group is 
described. The most important classes of macrocycles are represented by calixarenes, 
cyclodextrines and crown ethers. Due to their variable cavity size these molecular 
architectures can act as host for a broad variety of guest molecules including metal cations, 
halogen anions, other charged and neutral compounds.57,58 Furthermore, it was shown that 
they can be applied as nanoreactors for various organic reactions,59,60 biomimetic receptors 
and multivalent ligands for biomolecular recognition.57,61 Since the early 80s macrocycles 
have been successfully utilized as non-covalent protective groups for amino- and hydroxy 
groups.18-22 In the following, their use as supramolecular protective groups (SPGs) is 
described for the regioselective modification of di-functionalized substrates and in peptide 
synthesis.  
 
1.3.1 Calix[4]pyrrole Derivative as Protective Group for Polyphenols 
Naphthoic acid and polyphenolic molecular structures are present in many well-known 
pharmaceuticals applied for the treatment of tuberculosis, malaria, cancer and infectious 
diseases.62-69 In course of the development of new therapeutics various methods have been 
introduced to enable site specific modification of the hydroxy group of naphthoic acids 
employing conventional synthesis70-75 and enzymatic approaches.76-79 To simplify the 
derivatization of polyphenolic substrates Valenti et al. investigated the application of 
calix[4]pyrrole derivative 20 as a macrocyclic non-covalent protective group for the 
regioselective etherification and esterification of 6-hydroxy-1-naphthol 21 (Scheme 1.6).18,80 
As shown in Scheme 1.6, macrocycle 20 showed the preference for the selective non-covalent 
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protection of the β-phenolate moiety of 21 (Scheme 1.6).18 The resulting host-guest complex 
22 based on π-π-interaction and hydrogen bonding was applied in the next step for 
regioselective alkylation and acylation of the hydroxy group in α-position. Applying one 
equivalent of benzyl bromide 23 and trans-crotonoyl chloride 24 the transformation of 21 in 
presence of calix[4]pyrrol 20 and cesium carbonate resulted mainly in alkylated naphthol 















Scheme 1.6: Regioselective modification of hydroxy naphthol 21 employing calix[4]pyrrol 20 as SPG: 
Selective complexation (1), regioselective alkylation (2) and regioselective acylation (3).18 
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1.3.2 Calix[6]pyrrole Derivative as Protective Group for a Triamine  
At the same time another example of macrocycles as SPGs was introduced acting as SPG by 
Reinaud et al. (Scheme 1.7).19 In contrast to a calix[4]arene derivative, Reinaud et al. applied 
a zinc(II)-funnel complex based on calix[6]arene ligand as SPG. Calixaren-zinc(II) complexes 
were extensively investigated in order to develop biomimetic receptors.81-86 These studies 
demonstrated that zinc(II)-macrocycles can act as hosts for a various non-charged guest 
molecules of different molecular size and properties.81,83 In 2009, Reinaud et al. applied the 
calix[6]arene-zinc(II) complex 27 substituted with pyrrole units as a non-covalent protective 
group for the unsymmetrical triamine, N-(2-aminoethyl)propane-1,3-diamine 28 













Scheme 1.7: Regioselective protection of triamine 28 using zinc-funnel complex 27: Host-guest 
complex formation using acetonitril 29 as guest molecule (1), regioselective complex formation with 
guest molecule triamine 28 (2) and acid-base controlled direction of guest 28 in zinc(II)-macrocycle 
complex (3).19 
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As shown in Scheme 1.7, host-guest complex formation was performed in two steps. First, 
macrocycle 27 was treated with acetonitril 29 resulting in complex 30. In the subsequent step 
guest 29 was replaced by triamine 28 (Scheme 1.7). It was demonstrated that the direction of 
the unsymmetrical triamine 28 in macrocycle 27 can be controlled by the protonation state of 
guest molecule 28. As shown in Scheme 1.7, in presence of protonating agents the host-guest 
complex 31b was formed, while under more basic conditions complex 31a was preferred.19  
To demonstrate that the zinc-funnel complex 27 can be applied as SPG, the host-guest 
complex 31a was reacted with tert-butyl-oxycarbonyl (Boc) anhydride at the primary amino 
group of triamine 28 protruding into the solvent (Scheme 1.8).19 After optimization of 
reaction conditions, the carbamoylation of 28 was successfully performed using 
1.2 equivalents of di-tert-butyl dicarbonate 32 resulting in complex 33. Finally, 










Scheme 1.8: Regioselective carbamoylation of triamine 28: Transformation of the solvent exposed 
amino group of triamine 28 in complex 31a (1), decomplexation of 34 under basic conditions (2).16 
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1.3.3 Crown Ether as Non-Covalent Protective Group for Amino Compounds  
Since Pederson et al. reported that crown ethers can complex ammonium ions and solubilise 
these functional groups in apolar solvents87 these macrocycles found application as non-
covalent protective groups in peptide synthesis20,21 and in regioselective derivatization of 
difunctional compounds.22 Especially, the 18-crown-6 ether 35 (Scheme 1.9) was best suited 
as ligand for ammonium ions as demonstrated by Bushmann and Mutihac.88 As shown in 
Scheme 1.9 the formation of the host-guest complex 36 is based on non-covalent hydrogen 
bonds between ether-oxygens of the macrocycle and hydrogens located at the ammonium 
group.89,90 Due to the tetrahedral configuration of complex 36, the ammonium group is 
located above the cavity of the macrocycle and the guest molecule is sterically unhindered 





Scheme 1.9:  Mode of non-covalent protection of an ammonium group by 18-crown-6 ether 35.89,90 
 
In 1990, Hyde and Masscagni applied crown ether 35 as SPG for the synthesis of the 
pentapeptide derivative 37 of the endogen peptide enkephalin (Scheme 1.10). To obtain the 
pentapetide 37, peptide bond formation between dipeptide 38 and tripeptide 39 was employes 
(Scheme 1.10).20 To avoid unspecific peptide bond formation, the α-amino group of 38 was 
protected non-covalently by crown ether 35 resulting in complex 40. In subsequent step, the 
N-terminus of tripeptide 39 was selectively coupled with the carboxy function of protected 
dipeptide 38 resulting in complex 41. Decomplexation of the amino group applying saturated 
potassium chloride solution yielded the enkephalin derivative 37.20  
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Scheme 1.10:  Synthesis of enkephalin derivative 37 employing crown ether 35 as non-covalent 
protective group for blocking a terminal amino group: Crown ether complex formation (1), selective 
peptide coupling reaction (2) and deprotection of the terminal amine (3).20 
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Exploiting the crown ether protection further, Mascagi et al. demonstrated that 18-crown-6 
ether 35 can also be applied as non-covalent protective group in solid-phase peptide 
synthesis.21 In order to maximize the coupling yield the peptide synthesis conditions were 
optimized to stabilize the crown ether complex. Thus, the influence of solvent polarity and the 
counter anion on the complex stability were investigated. It was demonstrated that the 
complex stability between the N-terminal amino group of the peptide and the crown ether 35 
increases with decreasing solvent polarity and the presence of tosylate (Tos-) as counter ion 
and therefore, these conditions resulted in minimized side product formation during the 
coupling reaction. Moreover, the efficiency of the peptide bond formation increases 
significantly, when proline was chosen as the N-terminal amino acid of the immobilized 
peptide. As shown in Scheme 1.11, the same conditions were successfully applied for 
condensation of even larger peptide-fragments.21 The crown ether protected pentapeptide 42 
was reacted with immobilized tetrapeptide 43 in dichloromethane (DCM) resulting in 
immobilized nonapeptide complex 44. Deprotection of the α-amino group with 
di-isopropylethylamine (DIPEA) and cleavage of the peptide from the resin resulted in 










= resin tBu = tert-butylTos- = 
 
Scheme 1.11:  Solid-phase peptide fragment coupling employing crown ether 35 as non-covalent 
protective group for the N-terminus.21 
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To facilitate the amine deprotection, product isolation and the regeneration of the crown ether, 
Haswell et al. established a method for the regioselective modification of difunctional organic 
molecules using an immobilized crown ether as in-situ protection group in a flow reactor.22 
Hence, aminomethyl-18-crown-6 ether 46 was coupled to a carboxypolystyrene resin 47 to 
























Scheme 1.12:  Immobilization of methylamine crown ether 46.22 
 
As shown in Scheme 1.13, the immobilized crown ether 48 was successfully employed as 
SPG for the regioselective modification of tyramines 49a and 49b, exhibiting a hydroxy and 
amino group with similar reactivity. The subsequent complexation of 48 with compounds 49a 
and 49b resulted in complexes 50a and 50b, respectively. In the following step the exposed 
phenolic hydroxy group was converted applying acylation and alkylation reactions, while the 
protected amine was not reactive. Hence, reaction of 50a and 50b with acetic acid anhydride 
51 and methyliodide 52 resulted in formation of complexes 53, 54a and 54b, respectively. 
Deprotection of the amino group in presence of potassium chloride afforded tyramine 
derivatives 55, 56a and 56b reaching quantitative conversions. The immobilized crown ether 
48 was recycled in an additional washing step of potassium crown ether complex 57 with 
acetic acid in methanol.22 
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49a (n = 2)






50a (n = 2)








53   (n = 2) R = acetyl
54a (n = 2) R = methyl








55   (n = 2) R = acetyl
56a (n = 2) R = methyl




Scheme 1.13: Regioselective modification of tyramines 49a and 49b using immobilized crown ether 
48 as non-covalent protective group: Crown ether complex formation (1), chemical transformation (2), 
decomplexation (3) and regeneration of 48 (4).22 
 
1.4 Non-Covalent Protection of Active Sites in Enzymes from 
PEGylation 
After describing the utilization of non-covalent protective group approaches for peptide 
synthesis, this paragraph deals with SPGs for the derivatization of proteins. The introduction 
of poly(ethylene glycol), called PEGylation, in enzymes and proteins is a well established 
strategy in the development of new therapeutics.91-93 PEG conjugation reduces renal 
ultrafiltration of proteins, proteolytic degredation of enzymes and improves their solubility in 
organic solvents.92,93 Furthermore, masking of enzymatic surfaces by polymers reduces 
immunogenicity and antigenicity extending the residence time of enzymes in the body.94-97 
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However, PEGylation can result in dramatically decrease of the enzymatic or biological 
activity.23,24 The reason is that during the conjugation process PEG chains can be introduced 
in the active site of an enzyme erasing its activity. To overcome this limitation two strategies 
were developed preventing PEGylation of the active site.23,24  
For example, Veronese et al. applied the specific interaction between a substrate and the 
enzyme to block non-covalently the active site during PEGylation.23 This approach was 
demonstrated on the enzyme uricase E1 (urate oxidase) which catalyses the oxidation of uric 












Figure 1.2: a, Enzymatic reaction catalyzed by uricase E1. b, PEGylation of enzyme E1 in presence 
of substrate 57 acting as non-covalent protective group for the active site: PEGylation (1) and elution 
of substrate 57 (2).23 
As shown in Figure 1.2b, to prevent the modification of the active site the enzyme E1 was 
incubated with linear PEG-norleucin-N-hydroxysuccinimde ester (PEG-Nle-NHS) 59 in 
presence of substrate 57. The resulting PEGylated enzyme E1-PEG (Fig. 1.2b) was 
characterized and it turned out that an enzymatic activity of 40 % remains, while the enzyme 
PEGylated in absence of the substrate exhibited no activity at all.23 However, the relatively 
low enzymatic activity of conjugated protein E1-PEG can be explained by the fact that also 
PEG chains were introduced in the surrounding area of the active site. This gave rise to hinder 
the binding of substrate 57.23 
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To protect both, the active site and its proximity, from PEGylation the same group introduced 
a new method employing an inhibitor immobilized on an insoluble resin as non-covalent 
protection of serine protease trypsin E2 (Scheme 1.14).24 The inhibitor, benzamidine, had the 
function to protect the active site of the enzyme, while the resin (Sepharose) should inhibit the 
conjugation of the surrounding surface area of the protein. As shown in Scheme 1.14, the 
enzyme E2 was first immobilized on the inhibitor resin conjugate 60. In the next step, the 
enzyme was treated with monomethoxy-PEG -Nle-NHS 61 resulting in PEGylated protein 
E2-PEG. Investigation of the modified protein E2-PEG revealed that the enzymatic activity 
was maintained to a degree of 95 %, while the conjugation in absence of the inhibitor resulted 































Scheme 1.14: PEGylation of trypsin employing inhibitor resin conjugate 60 as non-covalent protective 
group for the active site and surrounding protein surface: Immobilization of enzyme E2 on resin (1), 
regioselective PEGylation of exposed enzymatic surface (2) and elution of modified enzyme E2-PEG 
(3).24   
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1.5 Nucleoprotein as Sequence-Specific Protective Group for DNA 
Molecules 
While protein can be functionalized avoiding modification of the active site with the help of 
supramolecular protection strategies, proteins itself can act as SPGs as will be detailed in the 
following paragraph.  
In order to develop nanometer-scale electronic devices in 1998 Braun and Ben-Yoseph 
introduced the formation of metallic conductive wires by coating DNA molecules with a 
metal, which can then be attached to macroscopic electrodes using their molecular recognition 
abilities.100,101 To allow more elaborate manipulations during the preparation of these 
microelectronic devices, in further studies Braun et al. established a sequence-specific 
molecular lithography technique.25 It was demonstrated that the enzyme RecA, a major 
protein responsible for genetic recombination in bacteria,102-104 can be applied in combination 
with a single stranded DNA (ssDNA) as sequence-specific non-covalent protective group 
during molecular lithography and subsequent metallization of double stranded DNA 
molecules (dsDNA) (Fig. 1.3).25           
AgNO3
Ag
KAuCl4 + KSCN 
+hydoquinone
gold wire gold wireexposed DNA







Figure 1.3: Sequence-specific lithography and metallization of dsDNA substrates employing 
RecA-ssDNA nucleoprotein filament as non-covalent protective group.25  
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As shown in Figure 1.3a, RecA was first polymerized on ssDNA resulting in a nucleoprotein 
complex, which could interact with aldehyde-derivatized dsDNA substrate. The sequence-
specific protection of this substrate was enabled by homologous recombination, the formation 
of a three-way junction of the nucleofilament and the corresponding sequence of dsDNA (Fig. 
1.3b and 1.4a). As shown in Figure 1.3c and Figure 1.4b, RecA was acting as protecting 
group hindering the reduction of silver on the recombined fragment during the molecular 
lithography process. The subsequent Gold metallization of dsDNA which is catalyzed by the 
silver aggregates (Fig. 1.3d) resulted in gab formation as proven by atomic force microscopy 





Figure 1.4: Sequence-specific lithography and metallization of dsDNA substrates. a, AFM image of 
recombined nucleoprotein filament. b, AFM image after silver aggregation. c, AFM image after gold 
metallization of silver coated dsDNA fragments. d, SEM image after gold metallization of silver 
aggregated dsDNA fragments.25 
 
Equally, in 2005 Yashima et al. also applied the sequence-specific gab formation during 
metallization of dsDNA using a RecA-ssDNA filament as protective group.26 In contrast to 
the work of Braun et al., two different RecA proteins were applied, one unmodified wild-type 
(WT) RecA and one RecA protein modified with a cysteine at the C-terminus (Cys-RecA). In 
previous studies it was demonstrated that both, WT- and Cys-RecA, exhibit the same activity 
regarding the formation of nucleoprotein filaments.105,106 But the genetically engineered 
Cys-RecA protein was expected to have higher labeling efficiency during gold deposition 
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using monomaleimido nanogold, while the function of WT-RecA was the non-covalent 
protection during the metallization process.26 As shown in Figure 1.5a, nucleoprotein filament 
existing of ssDNA and WT-RecA was applied as sequence-spceific protective group for a 
dsDNA substrate. In a second step, the WT-RecA-ss/dsDNA complex was incubated with 
Cys-RecA enabling nucleoprotein formation with dsDNA fragments which are not in contact 
with WT-RecA. As shown in Figure 1.5b, the following treatment of the filament with 
activated gold particles resulted in the introduction of gold only at Cys-RecA proteins, while 
the fragment complexed with WT-RecA showed no reactivity. Hence, the subsequent 
metallization resulted in a 25 µm long gold nanowire with a gab of 1 µm length.26  
gold-particles













Figure 1.5: a, Sequence-specific gab formation employing WT-RecA as protective group and 
Cys-RecA as a scaffold for metallization: Homologenous recombination (1), nucleoprotein filament 
formation with Cys-RecA (2), coupling of gold-nanoparticles to cystein residues of Cys-RecA protein 
(3) and gold metallization (4). b, SEM image after gold metallization.26 
Non-Covalent Protective Groups for the Modification of Synthetic and Natural Compounds  
23 | P a g e  
1.6 Motivation and Thesis Overview 
After describing several non-covalent protection strategies enabling the modification of 
multifunctionalized compounds, in the following the motivation and overview of my thesis 
are given. 
Modification of synthetic and natural compounds is a general tool to obtain molecular 
structures with different physical, chemical and biological properties. For example, 
transformation of organic dyes, which are widely applied in solar cells, changes their optical 
properties and electron-transfer abilities. The substitution of side groups of conductive 
polymers results in materials with different electrical and optical properties. And conjugation 
of diverse molecular architectures allows the combination of different properties resulting in 
new materials. Moreover, the modification of synthetic and natural product is especially a 
well established tool in the drug discovery and development process. For example, selective 
modifications of known therapeutics are utilized to overcome anti-drug resistance, increase 
their efficiency, decrease toxicity and find new indications. However, to obtain a compound 
with defined characteristics, often site-specific diversifications are necessary. But due to the 
fact that most molecules exhibit several functional groups with similar or equal chemical 
reactivity, these regioselective transformations are limited. The reaction of 
multifunctionalized compounds results often in a mixture of inseparable regioisomers. 
Therefore, selective modification of structurally complex molecules requires laborious and 
time consuming part- and total synthesis. That for example is an important reason why 
potential drug candidates exhibiting a complex molecular structure are excluded from the 
drug development process in pharmaceutical industries. To simplify the regioselective 
modification and facilitate the development of compounds with new properties, much effort 
has been devoted to the development of one-step derivatization methods on the level of the 
multifunctional molecules. Hence, in chapter 1 several strategies are described, which enable 
the regioselective transformation of many natural and synthetic compounds in only one 
reaction step. All the reported methods have the application of non-covalent protective groups 
in common. These protective groups, based on metal-chelate complexes, macrocycles, 
polymer conjugates and enzymes, allow site-specific protection of several functionalities of a 
molecule, while functional groups not in contact with the protective group can be transformed 
regioselectively. Another advantage of these introduced supramolecular protective groups 
(SPGs) is their easy introduction and removal due to the non-covalent interaction with the 
compound to be modified. Moreover, the application of this protection strategy facilitates the 
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synthesis of a broad spectrum of derivatives of a multifunctionalized compound. However, 
most of the introduced SPGs exhibit several limitations in order to be applied in industrial 
drug discovery process: Non-covalent protective groups based on macrocycles require 
extensive design and synthesis, and can bind only to small compounds exhibiting two 
functional groups; enzymes have a limited number of substrates they can interact with; and 
the application of metals in drug synthesis is often restricted and has to be minimized due to 
their toxicity.  
To overcome these limitations of existing non-covalent protective groups and at the same time 
benefit from their advantageous specific non-covalent interactions the work presented in this 
thesis is focused on the development of a new supramolecular protection strategy. In this 
work short ribonucleic acid sequences (RNA aptamers) are applied as non-covalent aptameric 
protective groups (APGs) for structurally complex aminoglycoside antibiotics. RNA aptamers 
are particularly very well suited as non-covalent protective groups, since nucleic acids can act 
as ligand (host) for a broad range of guest molecules of different structural complexity with 
high affinity and specificity. A further advantage is that they can be evolved through a well 
established selection process in few weeks and are produced by automated synthesis. In 
chapter 2, the applicability of three different RNA sequences as APGs is described for the 
regioselective modification of neamine antibiotic neomycin B exhibiting six amino- and seven 
hydroxy groups of similar reactivity. For modification of neomycin B acylation of amino 
groups was applied using N-hydroxy succinimide (NHS) esters of different size. Furthermore, 
it was investigated if an APG, which was generated for neomycin B, can also be utilized as 
non-covalent protective group for aminoglycosides with a related pharmacophore. Hence, an 
APG selected against neomycin B was tested for the regioselective modification of the 
antibiotic paromomycin. 
Since the presence of more than one binding site within one RNA aptamers (APG) can result 
in different protection modes for the guest molecule and therefore, can limit the 
regioselectivity of the modification reaction, the mode of action of APGs was elucidated in 
chapter 3. First, the number and the affinity of binding sites of different APGs for 
neomycin B were determined using Isothermal Titration Calorimetry (ITC). Afterwards, the 
mode of protection of each binding site was resolved by modification of neomycin B applying 
different conditions for the acylation reaction with NHS ester. Hence, the influence of the 
complex stability between antibiotic and APGs, reaction time and antibiotic/APG ratio on the 
regioselectivity was investigated. These parameters are particularly essential in order to 
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maximize the regioselectivity of the modification of the guest molecule and to verify the 
applicability of APGs under different conditions, such as various temperatures and varying 
salt concentration.  
After these proof-of-concept studies demonstrating the feasibility of the use of RNA aptamers 
as non-covalent protective groups, in chapter 4 the new concept is further exploited. To 
establish the introduced APG methodology as a general tool in organic synthesis different 
reactions are tested for the regioselective modification of the antibiotics neomycin B and 
paromomycin. First, different acylation reactions were tested using negatively charged 
activated esters, such as sulfo-NHS ester and 4-sulfo-tetra-fluorophenyl (STP) ester, to enable 
the introduction of more hydrophobic residues in the antibiotic neomycin B. This is 
particularly important, since the complex formation between APG and antibiotic is performed 
in aqueous buffer solution, which is a limiting factor regarding the utilization of hydrophobic 
reagents. Furthermore, the regioselective introduction of azide- and sulfhydryl groups was 
investigated using the azide-transfer reagent imidazoyl-1-sulfonyl azide and the thiolation 
reagent 2-iminothiolane, respectively. The regioselective diazotation and thiolation of the 
APG-protected compound have the advantage that they allow further modifications in an 
additional step without the use of APGs resulting in a broad spectrum of accessible 
derivatives. To exploit further the feasibility of the APG-methodology, modifications of 
different functionalities of neomycin B was investigated in presence of APG. Hence, urea 
bond formation using aliphatic and aromatic isocyanates was performed enabling a chemo- 
and regioselective modification of another amino group then described in previous chapters. 
Moreover, it was demonstrated that the APG strategy also allows chemo- and regioselective 
di-functionalization of neomycin B employing urea bond formation and azide introduction.  
Besides introducing the APG strategy for the regioselective modification of neamine 
antibiotics neomycin B and paromomycin, the work in chapter 5 describes the regioselective 
modification of neamine antibiotics in a single synthetic step without the use of non-covalent 
protective groups. It is well known that the neamine moiety of these antibiotics is essential for 
their antibacterial activity but at the same time this structural unit is also the main target of 
many resistance mechanisms in bacteria. Therefore, the modification of this part of the 
molecule is a very promising strategy to overcome antibacterial resistance and/or increase 
antibiotic activity. With this motivation in mind, a pH-dependent regioselective azide 
introduction at the 2-desoxystreptamine ring of diverse neamine antibiotics was demonstrated 
using the diazo-transfer reagent imidazoyl-1-sulfonyl azide in a buffered aqueous solution. 
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This strategy was testes employing neamine antibiotics neomycin B, paromomycin, 
ribostamycin, amikacin and apramycin and neamine as substrates. 
In the following chapters, a more detailed description of the above mentioned new strategies 
for the modification of neamine antibiotics will be given.         
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Emerging trends in drug discovery are prompting a renewed interest in natural 
products as source of chemical diversity and lead structures. However, due to the 
structural complexity of many natural compounds the synthesis of derivatives is not 
easily realized. Here, we demonstrate a conceptually new approach using 
oligonucleotides as aptameric protective groups (APGs). APGs block several 
functionalities by non-covalent interactions in a complex molecule and enable the highly 
chemo- and regioselective derivatization (98 %) of natural antibiotics in a single 
synthetic step with good conversions of up to 71 %. This technique should help to 
accelerate the discovery of new biologically active structures while avoiding costly and 
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2.1 Introduction 
Very recently, natural products have experienced a renaissance in drug discovery. This trend 
is rationalized by a growing number of new natural sources, improved separation methods and 
characterization techniques.1,2 Another reason for the high interest in natural products is the 
better chance of finding a desirable bioactivity due to their natural scaffolds.1,2 However, 
these frameworks are very often structurally complex exhibiting several chemical equivalent 
functionalities. Thus, regioselective modification of these molecular architectures is restricted 
to the application of genetically modified organisms1,2 and extensive semi- or total 
synthesis.3,4,5 The latter route is very often characterized by several protection and 
deprotection steps to modify specific functional groups or sites of the target molecule. A 
much simpler process to enable selective derivatization of complex natural products would be 
the introduction of macromolecular protective groups directly at the level of these 
compounds. Due to their extended size they can in parallel protect several functionalities of 
the natural product by non-covalent interactions while other groups not involved in binding 
can be specifically reacted.   
To test the feasibility of this approach, in the present study RNA aptamers were introduced as 
non-covalent aptameric protective groups (APGs). As a promising class of compounds with 
high affinity, specificity and stability, RNA and DNA molecules are particularly well suited 
as APGs, as they can act as ligands for a wide variety of low molecular weight compounds 
and macromolecular architectures,6,7 can be evolved through the well established in vitro 
evolution process SELEX8,9 (Systematic Evolution of Ligands by EXponential Enrichment) 
and can be produced by automated synthesis. Out of the aptamers that were generated against 
amino acids,10,11 nucleotides,12 organic dyes,8 porphyrin derivatives,13 proteins,14 hydrophobic 
lipids15 and aminoglycoside antibiotics,16,17,18 we chose aptamers for the latter class of 
compounds. Aminoglycosides offer a particularly attractive test for regioselective 
derivatization using APGs, since modification of antibiotics based on carbohydrates targeting 
prokaryotic 16S ribosomal RNA (rRNA)18,19,20 have become a powerful tool against drug-
resistant bacteria.21,22 Important examples based on the neamine scaffold are the neamine 
antibiotics neomycin B 1 and paromomycin 2 (Fig. 2.1a). 
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2.2 Results & Discussion 
2.2.1 Regioselective Acylation of Neomycin B Employing RNA as APG  
For a straightforward proof of concept that RNA can act as an APG, a well characterized 
aptamer-aminoglycoside complex was chosen: 23mer RNA aptamer (sequence: 5’-GGA CUG 
GGC GAG AAG UUU AGU CC-3’, apt1, Fig. 2.1b) and neomycin B (Fig. 2.1a)23. X-ray 
crystallography and nuclear magnetic resonance (NMR) measurements revealed that ring IV 
of guest molecule 1 is not involved in complex formation and extends into the solvent 
(Fig. 2.1c) .16  
 
a c
1 neomycin B   R = NH2




















Figure 2.1: a, Structure of representative aminoglycoside antibiotics. b, Stem-loop structure of APG 
apt1. c, Apt1 selectively protecting neomycin B16 (Color coding: white - hydrogen; green - carbon; 
red - oxygen; blue - nitrogen). 
 
 
As shown in Figure 2.2a, we choose the acetylation reaction employing 
N-hydroxysuccinimide (NHS) ester 3a-c to transform the amino groups of neomycin B in 
absence and presence of apt1.  According to mass spectrometric analysis reaction of acetic 
acid NHS ester 3a (10 equivalents) with the apt1-protected neomycin B resulted mainly in the 
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formation of mono-acetylated antibiotic derivatives (Fig. 2.2b). In stark contrast, the 
transformation of 1 under the same conditions but in absence of the APG yielded di-, tri-, 
tetra-, penta and hexa-acetylated aminoglycoside derivatives (Fig. 2.2c). These experiments 
clearly indicate the ability of apt1 to inhibit the reactivity of multiple amine groups within 

















































































3a R1 = methyl
3b R1 = isopropyl
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Figure 2.2: a, Reaction of amino groups (R = neomycin B) with NHS ester 3a-c in sodium phosphate 
buffer at room temperature (RT). b, Electrospray Ionisation (ESI) Mass Spectra (MS) of reaction 
mixture of neomycin B (1, NeoB) with 10 equiv. activated ester 3a in the presence of 1.5 equiv. apt1. 
c, ESI-MS spectra of reaction mixture of 1 with 10 equiv. NHS ester 3a in absence of APG.                
(i-vi = number of reacted amino groups of 1). 
 
 
To obtain further insight into the regioselectivity of transformations of neomycin B, reaction 
conditions were optimized to yield mono-acetylated antibiotic for the protected (Fig. 2.3a) and 
non-protected transformations (Fig. 2.3b). RNA-neomycin B complex was reacted with 30 
equivalents of the NHS ester 3a, while the unprotected antibiotic 1 was incubated with only 
one equivalent. After purification by High Performance Liquid Chromatography (HPLC, see 
experimental part Fig. 2.12), the mono-acetylated neomycin B derivatives were characterized 
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and regioselectivities were calculated using 1H-NMR spectroscopy (Fig. 2.3c). The RNA-
protected aminoglycoside 1 was proven to be acetylated at the amino group in C6 position at 
ring IV with an extremely high regioselectivity of 95 % resulting in neomycin B derivative 
4a, while in absence of APG the amino groups in C6 position of ring II and ring IV were 
highly reactive. Thus, the unprotected neomycin B was mainly converted into two inseparable 













































































Figure 2.3: a, Regioselective acetylation of 1 in presence of 1.5 equiv. of apt1 resulting in 4a. b, 
Unselective transformation of 1 in absence of APG results in a mixture of 4a and 4b. c, 1H-NMR 
(500 MHz, D2O) spectra of regioselectively mono-acetylated neomycin B 4a (upper) and mixture of 
regioisomers 4a and 4b (lower). 
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These results were confirmed by Heteronuclear Single Quantum Coherence (HSQC) spectra 
(Fig. 2.4) and Attached Proton Test (APT) measurements (see experimental part Fig. 2.11). 
As shown in Fig. 2.4a, spectrum of derivative 4a shows a remarkable chemical shift of the 
J(C6´´´-H) and J(C5´´´-H) coupling of ring IV in comparison to the 2D-spectrum of neomycin 







Figure 2.4 Sections of HSQC (500 MHz D2O) spectra of mono-acetylated neomycin B 4a (a) and 
neomycin B (b). Arrows indicate chemical shift of J(C6´´´-H) (red) and J(C5´´´-H) (black) coupling.  
 
 
To test whether apt1 can tolerate the introduction of larger residues than the acetyl group, 
neomycin B 1 was functionalized using the NHS esters 3b and 3c of isobutyric acid and 
4-pentynoic acid, respectively. Again, remarkable regioselectivities of 97 % and 98 % were 
achieved for obtained derivatives 5 and 6, respectively (Table 2.1). It is important to note 
here, that during the preparation of these derivatives, apt1 even tolarted the addition of 6.7 
volume % of the organic solvent dimethylformamide (DMF), which allowed easy 
solubilization of the hydrophobic activated esters 3b and 3c. In addition to these excellent 
regioselectivities, the APG-mediated modification exhibit conversions of neomycin B to 
antibiotic derivatives of up to 71 % (Table 2.1).    
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Table 2.1: Conversions and regioselectivities of acylation of neomycin B in presence of apt1.  
 
Compound APG DMF vol% R1       conv.^(%) r.s.*(%) 
    4a** apt1 0 methyl 48   95 
5 apt1 6.7 isopropyl 64   97 
6 apt1 6.7 3-butynyl 71   98 
 
All reactions were carried out according to the general procedure in presence of 1.5 equiv. apt1 (see 
experimental part 2.4.2.2). ^ Conversions of neomycin B to regioisomers 4a, 5 and 6 were calculated 
from HPLC- and 1H-NMR peak integrals assuming that only mono- and di-acylated derivatives were 
formed. ** Reaction was performed five times and the corresponding value of the regioselectivity and 
conversion is the calculated average. The error of the conversion was calculated to be 6 %. 
* Regioselectivities (r.s.) were calculated from 1H-NMR spectra. 
 
 
2.2.2 Regioselective Acylation of Neomycin B Employing Different APGs 
Two even shorter RNA sequences (apt2: 5’-CUG CAG UCC GAA AAG GGC CAG-3’, 
apt3: 5’-UGU AGG GCG AAA AGU UUU ACA-3’) (Fig. 2.5) were also employed as APGs 


























Figure 2.5 Stem-loop structures of APGs apt2 and apt3.9 
 
 
These aptamers were chosen from a pool of 21 sequences generated in the same SELEX 
experiment as apt1 performed by the group of Famulok.9Again, high regioselectivities were 
obtained in the formation of acetyl neomycin B 4a, reaching 94 % for apt2 and 93 % for 
apt3, respectively (Table 2.2). The conversions of 1 were comparable with apt1 (Table 2.2), 
reaching 49 % for apt2 and 55 % using apt3, assuming that only mono- and di-acetylated 
neomycin B derivatives were formed. As shown in Table 2.2, the application of apt2 as APG 
was also successful in the synthesis of 5 and 6 with high regioselectivities.  
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Table 2.2: Yield, conversions and regioselectivities of acylation of neomycin B in presence of     
                different APGs. 
Compound APG R2 conv.^(%)    yield^^(%) r.s.*(%) 
     4a** apt1 methyl 48 18†   95 
  4a apt1 methyl 48  45††   94 
     4a** apt2 methyl 49 29†   94 
  4a apt2 methyl 45  39††   93 
     4a** apt3 methyl 55  50††   93 
 5 apt2 isopropyl 53 23†   89 
 6 apt2 3-butynyl 63 19†   96 
 
All reactions were carried out according to the general procedure in presence of 1.5 equiv. APG (see 
experimental part 2.4.2.2). ^ Conversion (conv.) of 1 to antibiotic derivatives 4a, 5 and 6 were 
calculated from HPLC- and 1H-NMR peak integrals. ^^ Yields of mono-acylated derivatives (isomer 
mixture) were determined by HPLC. * Regioselectivity (r.s.) were calculated from 1H-NMR spectra. ** 
Reaction was performed three times and the corresponding values of the regioselectivities and 
conversions are the calculated averages. † Precipitation of RNA was employed as purification method. 
††
 Hydrolysis of RNA was employed as purification method. 
 
 
In contrast to the moderate conversions, the isolation of the antibiotic derivatives out of the 
RNA complex was still challenging. So far, the antibiotic 1 and its derivatives were extracted 
from the complex by melting the RNA aptamer complex at high temperatures (99 °C) and a 
precipitation of the APG with the positively charged surfactant didodecyldimethylammonium 
bromide (diC12DAB). While the resulting RNA surfactant complex was insoluble in the 
reaction buffer, the aminoglycoside 1 and its derivatives remained in solution. However, as 
shown in Table 2.2, antibiotic derivative 4a was obtained with a yield of only 18 % and 29 % 
for apt1 and apt2, respectively, applying this precipitation method. One reason for the low 
yield is most probably the co-precipitation of the aminoglycosides with the RNA. To improve 
the isolated yields of the aminoglycosides, the aptamer-complex was hydrolysed at 85 °C 
under basic conditions (pH = 14) instead. After destruction of the APGs, most amount of the 
neomycin B derivative 4a was recovered reaching 45 %, 39 % and 50 % for apt1, apt2 and 
apt3, respectively. (Table 2.2). 
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2.2.3 Regioselective Modification of a Related Antibiotic 
Likewise, the APGs presented here can be used to modify other aminoglycosides with a 
similar pharmacophore. For instance, the related antibiotic paromomycin 2 could be 
transformed to the corresponding N-acetyl derivative 7 employing apt1 as APG (Fig. 2.6a). 
Antibiotic derivative, 6´´´-N-acteyl paromomycin 7, was obtained with a yield of 22 % 
employing the precipitation of the RNA as purification method. Furthermore, the acetylation 
of paromomycin reached excellent regioselectivity of >90 %. As shown in Figure 2.6c, 
spectrum of derivative 7 shows a remarkable chemical shift of the J(C6´´´-H) and J(C5´´´-H) 
coupling in comparison to the 2D-spectrum of paromomycin 2 (Fig. 2.6b) proving the 
regioselective acetylation of amino group in C6 position of ring IV. This result demonstrates 
successfully that for the protection of the related antibiotics neomycin B 1 and paromomycin 
2 the interaction of the neamine moiety (ring I and II) is essential. Therefore, it can be 
concluded that the identified RNA aptamers against a particular structure can be applied as 
APGs for related molecules exhibiting a similar molecular shape. Furthermore, in light of 
many antibiotic derivatives presented in this studies, it should be apparent that the APG 
paradigm decreases the number of synthetic steps necessary for the modification of complex 
molecules to the extreme and is superior to previously reported non-covalent protective group 
approaches.24,25,26 Ring-IV-altered neomycin B derivatives have been previously described 
and were only obtained after extensive synthesis including more than 20 synthetic steps (see 
experimental part Scheme 2.2-2.6)3,29. Our newly developed technology allows the production 
of such antibiotic derivatives modified at the same positions in a single reaction.  
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Figure 2.6 a, Regioselective acetylation of paromomycin 2 using 30 equiv. of activated ester 3a in 
presence of 1.5 equiv. apt1. b, Sections of HSQC-spectra of antibiotic 2.  c, Sections of HSQC 
(500MHz, D2O) spectra of mono-acylated antibiotic derivative 7. Arrows indicate chemical shift of 




In this chapter, we have demonstrated the effective use of RNA sequences as non-covalent 
aptameric protective groups for the highly chemo- and regioselective derivatization of 
complex molecules bearing several functional groups with similar reactivity. This was 
successfully demonstrated for the structural complex aminoglycoside antibiotics neomycin B 
and paromomycin with three different aptamer sequences. These natural antibiotics were 
modified in a single step with substituents of variable size and hydrophobicities employing 
acylation that proceeds with excellent regioselectivities (89 % to 98 %) and good conversions 
of up to 71 %. However, at this point it has to be stressed that prior to the facile derivatization 
the generation of RNA aptamers by a SELEX experiment is necessary to obtain APGs. 
However, according to these results APGs merit consideration as a new synthetic strategy in 
organic synthesis as they can be evolved for a large variety of target molecules bearing 
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different structural features and their generation relies on a well-established in vitro evolution 
process. Moreover, APGs based on RNA aptamers can become an effective tool for the 
derivatization of complex natural products and vastly simplify drug development. 
 
2.4 Experimental Section 
2.4.1 Materials & Methods 
1H-NMR-, 13C-NMR-, heteronuclear single-quantum correlation (HSQC) spectra and attached 
proton test (ATP) were recorded on a Varian Unity Inova (500 MHz for 1H-NMR and HSQC, 
125 MHz for APT and 13C-NMR) and Oxford AS400 (400 MHz for 1H-NMR and 100.6 MHz 
for APT and 13C-NMR) NMR spectrometer at 25 °C using 3 mm NMR tubes (Sigma Aldrich). 
High resolution mass spectrometry (HRMS) was carried out on a LTQ ORBITRAP XL 
instrument (Thermo Scientific) employing electron impact ionization in positive ion mode 
(EI+). Chromatographic separations were carried out on a Shimadzu VP series HPLC modular 
system (DGU-14A3 Online Vacuum-Degasser, two LC-20 AT pumps, SIL-20A auto sampler, 
CTP-20 A column oven, RID-10 refractive detector, FRC-10 A fraction collector and 
Shimadzu LCsolution software). HPLC purification was performed with a Waters Spherisorb 
ODS-2 C18 analytical column (250 x 4.6 mm, spherical particles of 5 µm and 80 Å pore size) 
using isocratic elution at 40 °C. A pH-meter (Hanna Instruments pH 209) equipped with a 
glass combination electrode was used for pH adjustments of the reaction buffers. All 
chemicals and reagents were purchased from commercial suppliers and used without further 
purification, unless otherwise noted. Neomycin B trisulfate x hydrate (VETRANAL®), 
paromomycin sulfate salt (98 %), N,N-dimethylformamide (DMF, 99 %), N-
hydroxysuccinimide (NHS, 98 %), trifluoroacetic anhydride (99 %),  dichloromethane (DCM, 
99.5 %), tetrahydrofurane (THF, 99.9 %), pyridine (99 %), 4-pentynoic acid (95 %), acetic 
acid (99 %), isobutyric acid (99 %) and toluene (99.8 %) were purchased from Sigma Aldrich 
and used as received. For HPLC purification heptafluorobutyric acid (HFBA) (Fluka, puriss. 
p.a., for ion chromatography) and acetone (Sigma-Aldrich, HPLC grade) were used. Ultrapure 
water (specific resistance > 18.4 MΩ cm) was obtained by Milli-Q water purification system 
(Sartorius®). RNA aptamers (82 – 91 % purity) were purchased from BioSpring (Frankfurt 
am Main, Germany) and riboxx GmbH (Radebeul, Germany). Acetic acid 
N-hydroxysuccinimide esters 3a was synthesized according to a literature procedure.27 For the 
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regioselective transformation Milli-Q water was treated with diethylpyrocarbonate (DEPC) 
and sterilized using an autoclave (121 °C, 20 min). 
 
2.4.2 General Procedures 
2.4.2.1 Synthesis of Activated Ester for Antibiotic Modification28 
To  56.4 mL trifluoroacetic acid anhydride (0.47 mol) were added 20 g of 
N-hydroxysuccinimide  (0.196 mol) at 0 °C. The reaction was allowed to warm up to room 
temperature over 24 hours. Then 50 mL toluene were added and the volatile was removed in 
vacuo. The residue was taken up in 15 mL dichloromethane and the remaining solvent was 
removed in vacuo. The resulting product, N-trifluoroacetoxysuccinimde, was used without 
any further purification for the next step. To a solution of a carboxylic acid (17.5 mmol) in 15 
mL THF were added  5 g N-trifluoroacetoxysuccinimide (23.7 mmol) and 2.1 mL pyridine 
(26.4 mmol) at 0 °C. The reaction mixture was allowed to warm up to room temperature over 
24 h, before being quenched with 20 mL water. The aqueous phase was extracted twice with 
75 mL of a 1:1 mixture of diethyl ether and hexane. The combinated organic phases were 
washed with 100 mL sat. aq. NH4Cl solution, 100 mL sat. aq. NaHCO3 solution and 100 mL 
brine, dried over MgSO4, filtered and concentrated to yield activated ester 3b and 3c. 
 
2.4.2.2 Regioselective Acylation of Aminoglycoside Antibiotics 
3a R2 = methyl
3b R2 = isopropyl
3c R2 = 3-butynyl
1.) 1.5 equiv. APG (apt1-3)
2.) 30 equiv. ester (3a-c)  
10 mM sodium phosphate
buffer (pH ≈ 7), RT, 24 h  
4a R1 = NH2 R2 = methyl
5   R1 = NH2 R2 = isopropyl
6   R1 = NH2 R2 = 3-butynyl





2 paromomycin R1 = OH
7   R1 = OH R2 = methyl
Scheme 2.1: Regioselective transformation of amino group in C6 position of ring IV. 
 
A volume of 272 µL of a 6.1 mM RNA aptamer solution (sequences: 5’-GGA CUG GGC 
GAG AAG UUU AGU CC-3’ (apt1), 5’-CUG CAG UCC GAA AAG GGC CAG-3’ (apt2) 
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or 5’-UGU AGG GCG AAA AGU UUU ACA-3’ (apt3)) (1.66 µmol) in 10 mM sodium 
phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and was afterwards kept at room 
temperature for 15 min. Then 228 µL of a 4.8 mM solution of the aminoglycoside antibiotic 
(1.09 µmol) in 10 mM sodium phosphate buffer (pH 7.4) were added and the mixture was 
allowed to stand for 30 min at room temperature. Afterwards, 30 equiv. NHS ester (32.8 
µmol) dissolved in 500 µl sodium phosphate buffer (pH 7.4) (for activated ester 3a) or in 
36 µl DMF (for activated esters 3b and 3c) were added and the reaction mixture was allowed 
to react for 24 hours at room temperature. After addition of 60 µL of a 7 wt. % ethylamine 
water solution, the mixture was incubated for 30 min at room temperature and afterwards 
purified by following possible methods: 
a) Precipitation of RNA: The reaction mixture was heated to 99 °C for 10 min and to the 
hot solution 1 mL of a 53 mM aqueous solution of diC12DAB were added to 
precipitate the RNA. After incubation for 15 min at room temperature and 
centrifugation for 30 min at 6 °C (14k rpm) the supernatant was freeze-dried. To 
obtain sufficient amounts of antibiotic derivatives for 2D-NMR spectroscopy the 
synthetic step and the purification was performed three times. Thus, the resulting 
freeze dried samples from three runs were dissolved together in 400 µL water. Each 
30 µL fraction of this solution was purified by HPLC using a Waters Spherisorb ODS-
2C18 analytic column (water/acetone 1:0.9 containing 12.1 mM HFBA) at a flow rate 
of 1 ml/min at 40 °C to afford the antibiotic derivatives 4a, 5 and 6. After evaporation 
of acetone and freeze-drying the product was dissolved in 150 µL D2O for NMR 
studies. 
b) Hydrolysis of RNA: To the reaction mixture a volume of 160 µL of a aq. 2 M NaOH 
solution was added and allowed to incubate at 85 °C for 30 min. After cooling to room 
temperature each 50 µL fraction of this solution was purified by HPLC as described in 
method a) using water/acetone 1:0.81 containing 16.9 mM HFBA as eluent to obtain 
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2.4.3 Characterization of Activated Esters & Synthesized Antibiotic Derivatives 
 
2,5-dioxopyrrolidin-1-yl isobutyrate (3b). The title compound was prepared according to 
the general procedure described above. Product 3b was obtained as a white 
solid reaching a yield of 72 % (2.33 g, 12.6 mmol). 1H-NMR (CDCl3, 400 
MHz): δ[ppm] = 2.79 (septet, J  = 7.0 Hz, 1H, CH-(CH3)2); 2.72 (s, 4H, CH2-
CO); 1.22 (d, J = 7.6 Hz,  6H, CH(CH3)2). 13C-NMR (CDCl3, 100.6 MHz): δ 
(p.p.m.) = 172.06 (1C, CO-CH); 169.38 (2C, CO-CH2); 31.57 (1C, CH(CH3)2); 25.50 (2C, 
CO-CH2); 18.63(2C, CH(CH3)2). 
 
2,5-dioxopyrrolidin-1-yl pent-4-ynoate (3c). The title compound was prepared according to 
the general procedure described above. Product 3c was obtained as a 
white solid reaching a yield of 50 % (1.69 g, 8.7 mmol). 1H-NMR 
(CDCl3, 500 MHz): δ (p.p.m.) = 2.86 (t, J  = 7.5 Hz, 2H, CH2-CH2-
C CH); 2.82 (s, 4H, CH2); 2.59 (t, J  = 7.5 Hz, 2H, CH2-CH2-C CH);  2.04 (s, 1H, C CH). 
13C-NMR (CDCl3, 100.6 MHz): δ[ppm] = 169.05 (2C, CO); 167.12 (1C, CO); 80.98 (1C, 
C CH); 70.13 (1C, C CH); 30.37 (1C, CH2-CH2-C CH); 25.66 (2C, CH2), 14.16 (1C, 
CH2-CH2-C CH). 
 
6´´´-N-acetyl neomycin B x 5 HFBA (4a). The title compound was prepared according to the 
general procedure described above using NHS ester 3a. 
Derivative 4a was obtained as a white solid. For the measurement 
of regioselectivity and the characterization of the compound 
1H-NMR, HSQC as well as APT spectra were recorded and 
electrospray ionization (ESI)-MS was employed. The yield was 
calculated from 1H-NMR- and HPLC peak integrals: Rt = 7.6 
min, 45 % yield (apt1). TLC (CHCl3/MeOH/17 % NH4OH 2:1:1 
v/v/v) Rf = 0.52. 1H-NMR (D2O, 500 MHz) δ (p.p.m.) 6.06 (d, J 
= 4 Hz, 1H, 1-H´), 5.44 (d, J = 2 Hz, 1H, 1-H´´), 5.20 (d, J = 1.5 Hz, 1H, 1-H´´´), 4.44 (t, J = 
5.75 Hz, 1H, 3-H´´), 4.39 (dd, J = 5 Hz, J = 2 Hz, 1H, 2-H´´), 4.26 (t, J = 3 Hz, 1H, 3-H´´´), 
4.24 (m, 1H, 4-H´´), 4.09 (t, J = 6.75 Hz, 1H, 5-H´´´), 4.07 (m, 1H, 4-H),  4.01 (t, J = 10 Hz, 
1H, 5-H´), 3.98 – 3.92 (m, 3H, 5-Ha´´, 5-H, 3-H´), 3.76 (dd, 1H, J = 12.5 Hz, J = 5.5 Hz, 5-
Hb´´), 3.72- 3.68 (m, 2H, 4-H´´´, 6-H), 3.60 (dd, J = 14 Hz, J = 7.5 Hz, 1H, 6-Ha´´´), 3.56  (m, 
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(dd, J = 14 Hz, J = 6 Hz, 1H, 6-Hb´), 2.51 (dt, J = 12.5 Hz; J = 3.8 Hz, 1H, 2-Heq), 2.04 (s, 3H, 
CH3), 1.89 (dd, J = 12.7 Hz, 1H, 2-Hax). APT (D2O, 125.7 MHz) δ (p.p.m.) 174.49 (Carbonyl-
C), 110.00 (C-1´´), 95.51 (C-1´´´), 95.49 (C-1´), 84.62 (C-5), 81.66 (C-4´´), 75.39 (C-3´´), 
75.29 (C-4), 73.58 (C-2´´), 72.45 (C-5´´´), 72.42 (C-6), 70.35 (C-4´), 69.22 (C-3´), 67.88 (C-
5´), 67.56 (C-3´´´), 66.10 (C-4´´´), 60.00 (C-5´´), 53.15 (C-2´), 50.90 (C-2´´´), 49.65 (C-1), 
48.16 (C-3), 39.85 (C-6´), 39.33 (C-6´´´), 27.88 (C-2), 21.74 (CH3). MS (EI+) (m/z): found 
657.33008 [M+H]+, 679.31226 [M+Na]+; calculated 657.33013 [M+H]+, 679.31207 
[M+Na]+. 
 
6´´´-N-2-methylpropanoyl neomycin B x 5 HFBA (5). The title compound was prepared 
according to the general procedure described above using NHS 
ester 3b. Derivative 5 was obtained as a white solid. For the 
measurement of regioselectivity and the characterization of the 
compound 1H-NMR and HSQC spectra were recorded and ESI-
MS was employed. The yield was calculated from 1H-NMR- and 
HPLC peak integrals: Rt = 9.65 min, 30 % yield (apt1). TLC 
(CHCl3/MeOH/17 % NH4OH 2:1:1 v/v/v) Rf = 0.50. 1H-NMR 
(D2O, 500 MHz) δ (p.p.m.) 5.98 (s, 1H, 1-H´), 5.38 (s, 1H, 1-
H´´), 5.15 (s, 1H, 1-H´´´), 4.39 (d, J = 6.0 Hz, 1H, 3-H´´), 4.37 (m, 1H, 2-H´´), 4.21 (m, 1H, 
3-H´´´), 4.17 (m, 1H, 4-H´´), 4.06-4.01 (m, 2H, 5-H´´´, 4-H),  3.96 (t, J = 10.3 Hz, 1H, 5-H´), 
3.92 – 3.88 (m, 3H, 5-Ha´´, 5-H, 3-H´), 3.70 (dd, 1H, J = 14 Hz, J = 5.8 Hz, 5-Hb´´), 3.65- 
3.61 (m, 2H, 4-H´´´, 6-H), 3.54-3.50 (m, 3H, 6-Ha´´´, 3-H, 2-H´´´), 3.46 (m, 1H, 4-H´),  3.44-
3.38 (m, 3H, 6-Ha´, 2-H´, 6-Hb´´´), 3.36-3.33 (m, 1H, 1-H), 3.28  (dd, J = 13.5 Hz, J = 6 Hz, 
1H, 6-Hb´), 2.47 (m, 2H, CH(CH3)2, 2-Heq), 1.86 (dd, J = 12.2 Hz, 1H, 2-Hax), 1.09 (s, J = 6.5 
Hz, 6H, CH3). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 110.3 (C-1´´), 95.5 (C-
1´), 95.2 (C-1´´´), 84.7 (C-5), 81.5 (C-4´´), 75.2 (C-4), 74.9 (C-3´´), 73.5 (C-2´´), 72.5 (C-
5´´´), 72.4 (C-6), 70.4 (C-4´), 69.2 (C-3´), 67.9 (C-5´), 67.5 (C-3´´´), 66.1 (C-4´´´), 60.0 (C-
5´´), 53.3 (C-2´), 50.9 (C-2´´´), 49.6 (C-1), 48.2 (C-3), 39.9 (C-6´), 39.0 (C-6´´´), 34.9 
(CH(CH3)2), 28.0 (2C, CH(CH3)2),  27.9 (C-2); signal of quaternary carbon (CO) is missing 
due to the fact that it is not detectable by HSQC spectroscopy. MS (EI+) (m/z): found 
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6´´´-N-4-pentinoyl neomycin B x 5 HFBA (6). The title compound was prepared according 
to the general procedure described above using NHS ester 3c. 
Derivative 6 was obtained as a white solid. For the measurement 
of regioselectivity and the characterization of the compound 
1H-NMR and HSQC spectra were recorded and ESI-MS was 
employed. The yield was calculated from 1H-NMR- and HPLC 
peak integrals: Rt = 9.8 min, 41 % yield (apt1). TLC 
(CHCl3/MeOH/17 % NH4OH 2:1:1 v/v/v) Rf = 0.60. 1H-NMR 
(D2O, 500 MHz) δ (p.p.m.) 6.06 (d, J = 4 Hz, 1H, 1-H´), 5.43 (s, 
1H, 1-H´´), 5.19 (s, 1H, 1-H´´´), 4.47 (d, J = 5.75 Hz, 1H, 3-H´´), 4.41 (m, 1H, 2-H´´), 4.26 
(m, 1H, 3-H´´´), 4.22 (m, 1H, 4-H´´), 4.11 - 4.06 (m, 2H, 5-H´´´, 4-H),  4.01 (t, J = 10 Hz, 1H, 
5-H´), 3.97 – 3.94 (m, 3H, 5-Ha´´, 5-H, 3-H´), 3.77 (dd, J = 13 Hz, J = 5 Hz, 1H, 5-Hb´´), 
3.75- 3.68 (m, 2H, 4-H´´´, 6-H), 3.61 (dd, J = 14 Hz, J = 7.5 Hz, 1H, 6-Ha´´´), 3.56-3.53 (m, 
2H, 3-H, 2-H´´´), 3.52 – 3.45 (m, 4H, 4-H´, 6-Ha´, 2-H´, 6-Hb´´´), 3.36 (m, 1H, 1-H), 3.33  
(dd, J = 14 Hz, J = 6 Hz, 1H, 6-Hb´), 2.56 – 2.43 (m, 6H, (CH2)2, 2-Heq, C C-H), 1.90 (dd, J 
= 12.3 Hz, 1H, 2-Hax). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 110.1 (C-1´´), 
95.5 (C-1´), 95.3 (C-1´´´), 84.7 (C-5), 81.6 (C-4´´), 75.2 (C-3´´), 75.1 (C-4), 73.5 (C-2´´), 72.7 
(C-5´´´), 72.4 (C-6), 70.5 (C-4´), 70.4 (C CH), 69.2 (C-3´), 67.9 (C-5´), 67.5 (C-3´´´), 66.1 
(C-4´´´), 60.1 (C-5´´), 53.3 (C-2´), 50.9 (C-2´´´), 49.5 (C-1), 48.2 (C-3), 39.9 (C-6´), 39.3 (C-
6´´´), 34.2 (CO-CH2-CH2), 27.8 (C-2), 14.5 (CO-CH2-CH2); signals of quaternary carbons 
(CO, C CH) is missing due to the fact that they are not detectable by HSQC spectroscopy.  
MS (EI+) (m/z): found 695.34564 [M+H]+, 717.32770 [M+Na]+; calculated 695.34578 
[M+H]+, 717.32772 [M+Na]+. 
 
6´´´-N-acetyl paromomycin x 4 HFBA (7). The title compound was prepared according to 
the general procedure describe above using NHS ester 3a. 
Derivative 7 was obtained as white solid. For the measurement 
of regioselectivity and the characterization of the compound 
1H-NMR, HSQC as well as APT spectra were recorded and ESI-
MS was employed. The yield was calculated from 1H-NMR- and 
HPLC peak integrals: Rt = 4.78 min, 22 % yield (apt1). 1H-NMR 
(D2O, 500MHz): δ (p.p.m.) = 5.81 (d, J = 3.5Hz, 1H, 1-H´); 5.39 
(s, 1H, 1-H´´); 5.20 (s, 1H, 1-H´´´); 4.44 (t, J = 5.5Hz, 1H, 3-
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5-H´´´); 4.04 (t, J = 7.8 Hz, 1H, 4-H); 3.97 – 3.89 (m, 4H, 6-Ha´,  5-Ha´´, 3-H´, 5-H); 3.81-
3.75 (m, 3H, 6-Hb´,  5-Hb´´, 5-H´); 3.73 - 3.67 (m, 2H, 4-H´´´, 6-H); 3.62 – 3.57 (m, 2H, 6-
Ha´´´, 3-H); 3.55 (m, 1H, 2-H´´´); 3.51 (t, J = 9.3 Hz, 1H, 4-H´); 3.43 (m, 1H, 2-H´); 3.42 (dd, 
J = 15 Hz, J = 6 Hz, 1H, 6-Hb´´´); 3.38 - 3.35 (m, 1H, 1-H); 2.51 (dt, J = 12,5 Hz, J = 2.5 Hz, 
1H, 2-Heq); 2.04 (s, 3H, CH3); 1.86 (dd, J = 12.5 Hz, 1H, 2-Hax). APT (D2O, 125.7 MHz): δ 
(p.p.m.) = 174.93 (CO); 109.78 (C-1´´); 95.98 (C-1´); 95.56 (C-1´´´); 84.11 (C-5); 81.53 (C-
4´´); 77.23 (C-4); 75.53 (C-3´´); 73.73 (C-5´); 73.44 (C-2´´); 72.51 (C-5´´´); 72.16 (C-6); 
69.08 (C-4´); 68.63 (C-3´); 67.56 (C-3´´´); 66.13 (C-4´´´); 60.11 (C-6´, C-5´´); 53.161 (C-2´); 
50.88 (C-2´´´); 49.48 (C-1); 48.63 (C-3); 39.38 (C-6´´´); 27.87 (C-2); 21.71 (CH3). found 
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2.4.4 NMR-Spectra of Antibiotics & Synthesized Antibiotic Derivatives 
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Figure 2.9b: 1H-NMR (500 MHz, D2O) spectrum of 6´´´-N-acetyl paromomycin x 4 HFBA 7. 
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6´´´-N-acetyl neomycin B 4a





















Figure 2.10: HSQC (500 MHz, D2O) spectra of the isomeric mixture of mono-acetylated neomycin B 
derivatives obtained without APG (a) and of 6´´´-N-acetyl neomycin B x 5 HFBA 4a produced in the 
presence of APG apt1 (b). Duplication of signals proves the formation of mainly two mono-acetylated 
neomycin B isomers, i.e. the 6´´´-N-acetyl neomycin B 4a and 6´-N-acetyl neomycin B 4b, when no 
APG was employed. In contrast, utilization of apt1 as APG resulted in only one detectable regioisomer 
4a.  
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1   R1 = R2 = H
4a R1 = H, R2 = COCH3





Figure 2.11: Attached Proton Tests (APT, 500 MHz, D2O) of mono-acetylated derivatives after 
transformation of neomycin B (1) in presence of apt1 (a) and in absence of APG (b) using NHS ester 
3a. APT of Neomycin B (c). Spectrum a) proves regioselective transformation of the amino group in 
C6 position at ring IV of neomycin B 1 resulting in derivative 4a, while the spectrum b) shows the 
presence of two mono-acetylated Neomycin B derivatives, 6´´´-N-acetyl neomycin B 4a and 6´-N-
acetyl neomycin B 4b. 
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Figure 2.12: HPLC elugrams of reaction mixture after transformation of neomycin B (1, NeoB) using 
30 equiv. of activated ester 3a in presence of 1.5 equiv. APG apt1 (a), apt2 (b) and apt3 (c) (i-ii = 
number of reacted amino groups of 1). APGs apt1 and apt2 were precipitated, while apt3 was 
hydrolyzed. 
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Figure 2.13: HPLC elugram of reaction mixture after transformation of paromomycin (2, Paro) using 
30 equiv. of activated ester 3a in presence of 1.5 equiv. APG apt1 (i = one amino group is acetylated). 
Hydrolysis of the RNA was employed. 
 
 
2.4.7 Conventional Synthesis of Neomycin B Modified at Ring IV 
 
The synthesis of neomycin B derivatized at ring IV (Scheme 2.2-2.6) was performed by 

















R1 = H, R2 = acetonitril
R1 = allyl, R2 = acetonitril




 Scheme 2.3: Synthesis of building block II 
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R1 = Ac, R2 = pNBz,
R3 = allyl, α:β = 1:3.5
R1 = H, R2 = H, R3 = allyl
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In the previous chapter, aptameric protective groups (APGs) have been utilized for 
regioselective derivatization of natural products. The application of different RNA 
sequences as APGs was proven to be highly efficient in regioselective one-step-
modifications of the multifunctional aminoglycoside antibiotics neomycin B and 
paromomycin carrying several chemically equivalent amino- and hydroxy groups. 
However, since RNA aptamers are known to have more than one binding site for these 
antibiotics, the mode of action needs to be elucidated in more detail. Herein, a model was 
developed that explains the regioselective outcome of these transformations. In 
particular we demonstrate that some aptamers bind the antibiotics in such a way that 
different protection modes are realized. With the help of our studies the reaction 
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1. Introduction 
In 2009 supramolecular protective groups (SPGs) based on macrocycles were applied for the 
regioselective derivatization of small molecules.1,2 Non-covalent interactions between the 
SPG (host) and the guest molecule exhibiting multi functional groups allowed the protection 
of several of these, while functionalities not in contact with the host could be transformed 
regioselectively. However, SPGs based on macrocycles exhibit serious limitations. The small 
cavity size for the host allows so far only complexation of small, di- or tri-functional 
molecules, such as 7-hydroxy naphthol1 and N-(2-aminoethyl)propane-1,3-diamine.2 
Furthermore, these SPGs require elaborate design and synthesis for each guest molecule.1,2 To 
overcome these limitations, in the first chapter we have introduced a novel class of non-
covalent protective groups based on RNA sequences, so called aptameric protective groups 
(APGs), allowing highly regioselective derivatization of the structurally complex antibiotics 
neomycin B 1 and paromomycin 2 (Fig. 3.1a). APGs were successfully applied to protect 
several functional groups within guest molecules 1 and 2 allowing chemo- and regioselective 
transformations of antibiotic´s ring IV. RNA molecules are well suited as APGs as they can 
be generated via the well established in vitro evolution process SELEX (Systematic Evolution 
of Ligands by EXponential Enrichment). Moreover, RNA aptamers have been selected 
against a broad range of multiply functionalized guest molecules, such as carbohydrates,3,4,5,6 
unpolar lipids,7 enzymes,8 amino acids,9,10,11,12 steroids,13 and aromatic molecules, such as 
catecholamines,14 machalit green and tetramethylrosamine.15 Their specific host-guest 
recognition abilities were already successfully used in bioanalytic,16 diagnostic and 
therapeutic17,18,19 applications. However, in contrast to SPGs based on macrocycles,1,2 APGs 
can exhibit more than one recognition site for guest molecules, as demonstrated for 
aminoglycosides.20,21,22 As a result, different protection modes for guest molecule can be 
expected resulting in a mixture of regioisomers after transformation. During the last years the 
recognition mode between a 23mer RNA aptamer apt1 (5´-GGA CUG GGC GAG AAG 
UUU UGA CC-3´) and neomycin B were investigated in detail. After the structure of the 1 - 
apt1 complex (Fig. 3.1b) was solved by NMR spectroscopy,4 Stampfl et al. demonstrated that 
the sequence of apt1 exhibits three binding pockets for 1, of which two exhibit high affinity 
to neomycin B.20 Despite the presence of several binding sites, high regioselectivities in 
derivatization of the amino group in C6 position of ring IV of 1 and 2 were achieved using N-
hydroxysuccinimide (NHS) esters (chapter 2). However, the formation of other regioisomers 
under certain reaction conditions could not be avoided limiting the regioselectivity of the 
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modification. Therefore, the mode of action of APGs exhibiting more than one recognition 
site for 1 needed to be elucidated. 
a b
1 neomycin B    R = NH2









Figure 3.1: a, Structure of representative aminoglycoside antibiotics. b, APG apt1 selectively 
protecting neomycin B4 (Color coding: white – hydrogen, green – carbon, red – oxygen, blue – 
nitrogen). Blue arrow indicates the amino group accessible for regioselective acylation (chapter 2). 
 
3.2 Results & Discussion 
3.2.1 RNA Aptamers as APGs & Their Binding Sites.   
In this study we applied the RNA sequences apt1 (23mer), apt2 (21mer) and apt3 (36mer) as 
APGs for neomycin B (Fig. 3.2). All these sequences were selected by SELEX by Wallis and 
coworkers.23 It has to be mentioned that during the selection of the aptamers 
aminoglycoside 1 was randomly immobilized on solid support using its amino groups in C6 
position at ring II and IV.23 Therefore, at least two interaction modes were expected between 
the antibiotic 1 and chosen RNA sequences: In one binding mode rings I, II and III are 
shielded allowing reactions on ring IV while in the other mode rings I, III and IV are 































                             
Figure 3.2:  Stem-loop structures and sequences of applied APGs apt1, apt2 and apt3.23 
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To determine number and affinities of binding sites for antibiotic 1 of sequences apt1, apt2 
and apt3 Isothermal Titration Calorimetry (ITC) experiments were performed (see 
experimental part 3.5.6). These, ITC experiments indicated the presence of two binding sites 
within all sequences exhibiting high affinity for neomycin B (see additional experimental part 
Table 3.4). The results show that the affinity difference between the two present binding sites 
within apt1 (Ka,1 = 1.542x109 M-1, Ka,2 = 3.3x106 M-1) and  apt2 (Ka,1 = 2.33x108 M-1; Ka,2 = 
1.9x106 M-1) is more than two orders of magnitude. In contrast, the difference of affinity for 
the antibiotic 1 within apt3 is only one order of magnitude (Ka,1 = 62x106 M-1, 
Ka,2 = 1.2x106 M-1) assuming that this sequence also exhibits two high-affinity binding sites. 
However, from these ITC measurements it can be concluded that two antibiotic molecules can 
bind to a single aptamer (apt1, apt2 and apt3) with high affinities. 
 
3.2.2 Dependence of Regioselectivity on APG/Antibiotic Ratio 
After proving the presence of two binding sites for neomycin B within sequences apt1, apt2 
and apt3, the protection mode of 1 by these APGs was investigated. Therefore, antibiotic 1 
was complexed with sequences apt1, apt2 and apt3 and reacted subsequently with a large 
excess of NHS ester 3 (10-30 equiv.) to indentify reactive, unprotected amine groups of 1 
(Scheme 3.1). After transformation the resulting products were purified by High Performance 
Liquid Chromatography (HPLC) and characterized using mass spectrometry and NMR 
spectroscopy. As shown in Scheme 3.1, in presence of the aptamers the transformation of 1 
with acetyl activated ester 3 resulted in the formation of mainly mono-acylated neomycin B 
derivatives 4a, 4b and diacetylated antibiotic 5. In absence of APGs aminoglycoside 1 is 
transformed into tetra- up to hexa-acetylated neomycin B derivatives (chapter 2, Fig. 2.2). Its 
needs to be noted that besides the di-acetyl neomycin B 5 other regioisomers exhibiting two 
acetyl groups were formed in minor amounts (see experimental part Fig. 3.8). Moreover, 
based on the result obtained in chapter 2 and 4, in the following experiments it is assumed that 
exclusively mono- and di-acetylated derivatives are formed in presence of an APG.  However, 
due to the fact that 4a (acetylation product at ring IV, desired product) and 4b (acetylation 
product at ring II) cannot be separated by HPLC, the ratios of mono-acetylated regioisomers 
4a and 4b were determined by NMR spectroscopy. From the NMR spectra the 
regioselectivities of the formation of 4a were calculated. 
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Scheme 3.1: Transformation of neomycin B in presence of APG (apt1, apt2 and apt3) applying an 
excess of NHS ester 3 in 10mM sodium phosphate buffer solution (pH ≈ 7) at room temperature. 
 
To investigate the influence of the different binding sites of apt1 and apt2 on the 
regioselectivity different APG/1 ratios were applied for the transformation using activated 
ester 3, i.e. 0.5, 1.0 and 1.5. Applying a ratio of 1.5 one can assume that neomycin B is 
exclusively present within the binding site with higher affinity whereas at a ratio of 0.5 both 
binding sites are occupied by the antibiotic 1. In Figure 3.3 sections of the 1H-NMR spectra of 
the isolated mono-acetylated products for these reactions are given. From these spectra the 
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corresponding regioselectivities for the transformations were calculated. As shown in Figure 
3.3, with increasing APG/neomycin B ratios the reaction seemed to proceed with higher 
regioselectivities (for apt1: from 88 % to 96 % and for apt2: from 88 % to 93 %). This also 
means, that when both binding sites of apt1 and apt2 are occupied, (APG/1 ratio = 0.5) more 
side product 4b is formed. Moreover, with lower amounts of APG the conversion of 
neomycin B to diacetylated antibiotic 5 increased from 5 % to 28 %, using 1.5 and 0.5 equiv. 
apt1, respectively (Table 3.1). Similar results were obtained applying apt2 as APG 
(Table 3.1). This is a strong hint that di-acetylation of neomycin B resulting in formation of 5 
is happening predominantly in the low affinity binding site whereas 4a originates from 
transformation of 1 in the high affinity binding site. The fact that both aptamers, apt1 and 
apt2, show a similar behavior can be explained by similar protection of neomycin B by these 
two sequences, which is supported by comparable binding affinities as determined by the ITC 
























Figure 3.3: Section of 1H-NMR (500 MHz, D2O) spectra of mono-acetylated isomer mixtures (4a, 4b) 
in dependence of the APG/1 ratio (apt1 (a) and apt2 (b)). The NMR signal of the anomeric proton of 
ring IV of regioisomer 4a is splitting into two (5.20 ppm, β-anomer; 5.30 ppm, α-anomer) due to 
anomerisation. Regioselectivities (r.s.) were calculated from the integrals of the anomeric protons of 
ring II of the regioisomers 4a and 4b.  
 
In contrast, the transformation of 1 in presence of apt3 results mainly in a mixture of 4a, 4b 
and 5 in similar amounts (Table 3.1).  This result suggests that both binding sites exhibiting 
similar affinities have a different protection mode for neomycin B, or antibiotic 1 can interact 
differently with each binding site. However, it seems that lower affinity differences between 
the binding sites (Ka,1 and Ka,2) within one RNA aptamer cause lower ratios of yielded 
regioisomers 4a and 4b during acetylation. This gave rise to lower regioselectivities in order 
to form 4a (Table 3.1).  
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Table 3.1: Dependence of the formation of 4a, 4b and 5 on the APG/neomycin B ratio. 
APG equiv. APG 1^ (%) 4a* (%) 4b* (%) 5^ (%) 
   apt1** 0.5 25 41 6 28 
apt1 1.0 39 51 3 7 
   apt1** 1.5 44 48 3 5 
   apt2** 0.5 27 33 5 35 
apt2 1.0 53 36 4 7 
   apt2** 1.5 49 42 3 6 
   apt3** 1.5 9 29 37 25 
 
Reactions were performed according to the general procedure using 30 equiv. activated ester 3 
(experimental part 3.5.2). ^ Conversions of 1 to di-acetyl neomycin B 5 and the unconverted amounts 
of 1 were determined by analytical HPLC (see experimental part Fig. 3.11). * Conversions of 1 to 4a 
and 4b were calculated from the mixture of mono-acetyl derivatives (4a and 4b) applying integrals of 
HPLC and corresponding 1H-NMR peaks (Fig. 3.3). ** Experiments were repeated up to five times and 
an error of the conversion was calculated to be of up to 6 %; it is assumed that only mono- and di- 
acetylated derivatives were formed and the error of all experiments are in the same range.   
 
3.2.3 Dependence of Regioselectivity on Reaction Time 
To get a better understanding of the protection mode of the individual binding sites within 
apt1 and apt2, the evolution of formation of 4a, 4b and 5 was investigated over time in 
presence of 0.5 equivalents of APG. As shown in Table 3.2, regioisomers 4a and 4b are 
formed immediately after one minute reaction time, while the formation of the di-acetyl 
neomycin B 5 is considerably slower. Furthermore, with longer reaction time the formation of 
the mono-acetyl regioisomer 4a and the di-acetyl derivative 5 was increased, while the 
amount of isomer 4b was reduced significantly (Table 3.2). As demonstrated in Figure 3.4, the 
1H-NMR spectra show a significant increase of the regioisomer 4a/4b ratio with increased 
reaction time.  It has to be mentioned that a slightly reduced amount of derivative 5 was 
observed for apt2 after long reaction time (24 hours). This can be explained by the formation 
of higher acetylated products using apt2 as APG (see experimental part Fig. 3.10). However, 
from these observations two conclusions can be drawn: (1) During the reaction a significant 
amount of 4b is formed (see short reaction times); (2) a major part of mono-acetylated 
neomycin B 4b is further converted to antibiotic derivative 5 exhibiting two acetyl groups. 
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Taking into account that 4a is mainly formed in the high affinity binding site (vide supra) one 
can conclude that 4b predominantly originates from the low affinity binding site of apt1 and 
apt2. These conclusions are also supported by the result reported in Table 3.1. The higher the 
APG/antibiotic 1 ratio is, the less of 1 is present in the low affinity binding site resulting in 
minimized formation of 4b and 5 during modification of neomycin B.  
 
Table 3.2: Dependence of the formation of 4a, 4b and 5 on the reaction time. 
APG equiv. APG 1^ (%) 4a* (%) 4b* (%) 5^ (%) 
apt1 1 min 69 15 10 6 
apt1 20 min 38 29 10 23 
apt1 2 h 30 37 7 26 
apt1 24 h 23 45 4 28 
apt2 1 min 44 22 19 15 
apt2 20 min 24 25 13 38 
apt2 2 h 21 30 8 41 
apt2 24 h 24 35 4 37 
 
Reactions were performed according the general procedure using 10 equiv. activated ester 4 (see 
experimental part 3.5.2). ^ Conversions of 1 to di-acetyl neomycin B 5 and the unconverted amounts 
of 1 were determined by analytical HPLC (see experimental part Fig. 3.12). * Conversions of 1 to 4a 
and 4b were calculated from the mixture of mono-acetyl derivatives (4a and 4b) applying integrals of 
HPLC and corresponding 1H-NMR peaks (Fig. 3.4). It is assumed that only mono- and di-acetylated 
derivatives were formed and the conversion error is expected to be in the range of 6 % (based on 
similarity to the results shown in Table 3.1). For each aptamer one reaction was carried out, from 
which aliquots were taken after 1min, 20 min, 2 h and 24 h for HPLC- and 1H-NMR studies.  
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Figure 3.4: Section of 1H-NMR (500 MHz, D2O) spectra of mono-acetylated isomer mixtures (4a, 4b) 
dependent on reaction times using apt1 (a) and apt2 (b) as APG. Regioselectivities (r.s.) were 
calculated from 1H-NMR peak integrals of regioisomers 4a and 4b.  
 
3.2.4 Dependence of Regioselectivity on Salt Concentration & Temperature 
Finally, it needs to be investigated why 4b and 5 are formed even when an excess of APG is 
employed. Therefore, we studied whether the amine group in C6 position of ring II is also 
reactive in the high affinity binding site as indicated by the low amounts of 4b and 5 formed 
at a high APG/1 ratio (Table 3.1). The apt1-antibiotic 1 complex (ratio APG/1 = 1.5) was 
formed as for the reactions above at a sodium ion concentration of 10 mM. Since the complex 
stability is reduced with the increase of salinity20, concentrated aqueous NaCl solution 
(231 mM and 578 mM) was added subsequently to reach a final sodium concentration of 30 
and 60 mM. Then, the complex was again reacted with 30 equivalent of activated ester 3 and 
the regioselectivities of the monoacetylation of antibiotic´s ring IV in presence of 10, 30 and 
60 mM sodium concentration were calculated from NMR spectra (Fig. 3.5). Employing 
1H-NMR spectroscopy the antibiotic derivatives 4a and 4b were the only mono-acetylated 
neomycin B regioisomers which were detected. Moreover, the spectra presented in Figure 3.5 
show an increase of the portion of 4b with higher salt concentration resulting in a decrease of 
regioselectivities to 85 % and 81 % for 30 mM and 60 mM concentration, respectively (at 
10 mM regioselectivity = 94 %). This result indicates that the amino group in C6 position at 
ring II is also reactive in the high affinity binding site of apt1 resulting in 4b as side product. 
Therefore, it can be concluded that the minor reactivity of ring II is limiting the 
regioselectivity of the acetylation reaction of ring IV to 94 % at a salinity of 10 mM. This 
result is also in agreement with previous findings that the regioselectivity is dependent on the 
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size of the residue introduced at the amine group of ring IV (chapter 2). It was observed that 
sterically more demanding residues result in higher regioselectivities (isopropyl and 3-butynyl 
gave 97 % and 98 % regioselectivities, respectively) indicating the minor reactivity of ring II 












Figure 3.5: Section of 1H-NMR (500 MHz, D2O) spectra of mono-acetylated isomer mixtures (4a, 4b) 
dependent on sodium concentration using apt1 as APG. Regioselectivities (r.s.) were calculated from 
the integrals of the anomeric protons of ring II of the regioisomers 4a and 4b. 
 
However, in contrast to mono-acetylated derivative 4b the formation of 
di-acetyl neomycin B 5 was not increasing significantly with higher salinity (8 % at 60 mM 
[Na]+). Therefore, to test whether derivative 5 can also be formed in the high affinity binding 
site the reaction was performed again using 1.5 equivalents of APG apt1 but applying higher 
reaction temperatures to destabilize more the complex (Table 3.3).  
 
Table 3.3: Dependence of the formation of 4a, 4b and 5 on the reaction temperature. 
temp. (°C) 1^ (%) 4a* (%) 4b* (%) 5^ (%) r.s. (%) 
20 59 35 2 3   94 
40 43 42 5 10   90 
50 24 55 5 16   92 
 
Reactions were performed according the general procedure using 30 equiv. activated ester 3 (see 
experimental part 3.5.2). ^ Conversions of 1 to di-acetyl neomycin B 5 and the unconverted amounts 
of 1 were determined by analytical HPLC (see experimental part Fig. 3.13). * Conversions of 1 to 4a 
and 4b were calculated from the mixture of mono-acetyl derivatives (4a and 4b) applying integrals of 
HPLC and corresponding 1H-NMR peaks. It is assumed that only mono- and di- acetylated derivatives 
were formed.   
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As shown in Table 3.3, employing a reaction temperature of 40 °C and 50 °C the conversion 
of neomycin B to di-acetyl neomycin B 5 is increasing to 10 % and 16 %, respectively. From 
these observations we can concluded that 5 can also be formed in minor amounts in the high 
affinity binding site.    
 
3.3 Mode of Action of Aptameric Protective Groups 
Based on all presented results the suggested mode of action of APGs (apt1 and apt2) can be 
summarized as followed: As shown in Scheme 3.2, neomycin B occupying the high affinity 
binding site is transformed predominantly into the 6´´´-N-acetyl neomycin B derivative 4a, 
while in the low affinity site the mono-acetylated derivative 4b is mainly formed. During the 
course of the reaction, derivative 4b is further converted to the di-acetyl neomycin B 5 while 
regioisomer 4a shows no or very little reactivity in the high affinity binding site. Therefore, 
6´´´-N-acetyl neomycin B 4a is formed as main mono-acetylated derivative applying apt1 and 
apt2 as APGs. Moreover, our data suggest that higher affinity difference between both 


































Scheme 3.2: Suggested mode of action of RNA aptamers apt1 and apt2 as APG exhibiting two 
binding sites for aminoglycoside neomycin B. 
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3.4 Conclusion 
In this work, a model for the mode of action of APGs has been developed inducing high 
regioselectivities for the acylation of neomycin B. This was of particular importance since 
these APGs exhibit two binding sites for the antibiotic. Our studies demonstrated that 
different binding sites in these aptamers give rise to different protection modes of the 
aminoglycoside that result in two different mono-acylated neomycin B derivatives. Based on 
these findings the reaction conditions especially the aptamer/antibiotic ratio and the reaction 
time can be adjusted in order to obtain one of these isomers in excellent regioselectivity. 
Finally, our studies demonstrated that ITC measurement is a useful tool to estimate the 
applicability of RNA aptamers as APGs. This holds especially true when in the future SELEX 
will be employed for APG generation to new targets from which the structure of the RNA-
target complex is unknown. 
 
3.5 Experimental Section  
3.5.1 Materials & Methods  
NMR spectra were recorded on a Varian Unity Inova Varian Unity Inova (500 MHz for 1H-
NMR and HSQC, 125 MHz for APT) NMR spectrometer at 25 °C using 3 mm NMR tubes 
(Sigma-Aldrich). High resolution mass spectrometry (HRMS) was carried out on a LTQ 
ORBITRAP XL instrument (Thermo scientific) employing electron impact ionization in 
positive ion mode (EI+).  Chromatographic separations were carried out on a Shimadzu VP 
series HPLC modular system (DGU-14A3 Online Vacuum-Degasser, two LC-20 AT pumps, 
SIL-20A auto sampler, CTP-20 A column oven, RID-10 refractive detector, FRC-10 A 
fraction collector and Shimadzu LCsolution software). High performance liquid 
chromatography (HPLC) purification was carried out with a Waters Spherisorb ODS-2 C18 
analytical column (250 x 4.6 mm, spherical particles of 5 µm and 80 Å pore size) using 
isocratic elution at 40 °C. A pH-meter (Hanna Instruments pH 209) equipped with a glass 
combination electrode was used for pH adjustments of the reaction buffers. All chemicals and 
reagents were purchased from commercial suppliers and used without further purification, 
unless otherwise noted. Neomycin B trisulfate x hydrate (VETRANAL®), 
N-hydroxysuccinimide (NHS, 98 %), trifluoroacetic anhydride (99 %), dichloromethane 
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(DCM, 99.5 %), tetrahydrofurane (THF, 99.9 %), pyridine (99 %), acetic acid (99 %), 
isobutyric acid (99 %) and toluene (99.8 %) were purchased from Sigma Aldrich and used as 
received. For HPLC purification heptafluorobutyric acid (HFBA) (Fluka, puriss. p.a., for ion 
chromatography), acetone (Sigma-Aldrich, HPLC grade) were used. Ultrapure water (specific 
resistance > 18.4 MΩ cm) was obtained by Milli-Q water purification system (Sartorius®). 
RNA aptamers (82 – 91 % of purity) were purchased from BioSpring (Frankfurt am Main, 
Germany) and riboxx GmbH (Radebeul, Germany). Acetic acid N-hydroxysuccinimide 
ester 3 was prepared according to standard literature procedures24. For the preparation of the 
sodium phosphate buffer (10 mM, pH 6.8 and 7.4) Milli-Q water was treated with 
diethylpyrocarbonate (DEPC) and sterilized using an autoclave (121 °C, 20 min). 
 
3.5.2 General Procedures for Regioselective Acylation of Neomycin B  
3
1.) 1.5 equiv. APG (apt1-3)
2.) 10-30 equiv. ester 3
10 mM sodium phosphate


























Scheme 3.3: Regioselective transformation of neomycin B 1 
 
a) Procedure using 0.5, 1 and 1.5 equiv. RNA aptamer.  
A volume of 272 µL of a 6.1 mM (1.66 µmol, 1.5 equiv.), 4.07 mM (1.10 µmol, 1.0 equiv.) or 
2.03 mM (0.55 µmol, 0.5 equiv.) RNA solution in 10 mM sodium phosphate buffer (pH 6.8) 
was heated to 85 °C for 10 min and afterwards stored for 15 min at room temperature.  
228 µL of a 4.8 mM solution of neomycin B sulfate (1.09 µmol) in 10 mM sodium phosphate 
buffer (pH 7.4) were added and the mixture was allowed to stand for 30 min at room 
temperature. Then 30 equiv. activated ester 3 (32.4 µmol) dissolved in 500 µL sodium 
phosphate buffer (pH 7.4) were added and the reaction mixture was allowed to react 24 hours 
at room temperature. After addition of 60 µL of a 7 wt. % ethylamine water solution and 
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further incubation for 30 min at room temperature the crude mixture was heated to 99 °C for 
10 min. To the hot solution 1 mL of a 53 mM aqueous solution of diC12DAB was added to 
precipitate the RNA. After incubation for 15 min at room temperature and centrifugation for 
30 min at 6 °C (14k rpm) the supernatant was freeze dried. To obtain a sufficient amount of 
antibiotic derivative for NMR studies, this entire procedure was repeated twice and the 
resulting freeze dried samples were dissolved together in 400 µL water. Each 30 µL fraction 
was purified by HPLC using a Waters Spherisorb ODS-2C18 analytic column (water/acetone 
1:0.9 containing 12.1 mM HFBA) and a flow rate of 1 ml/min at 40 °C to determine the 
conversion of neomycin B to mono- and di-acetylated neomycin B derivatives and for 
investigation of the regioselectivity of the monoacetylation by NMR studies. 
b) Procedure using 0.5 equiv. RNA and different reaction time.  
A volume of 3.26 mL of a 6.1 mM (19.9 µmol, 1.5 equiv.) RNA solution in 10 mM sodium 
phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and afterwards stored for 15 min at 
room temperature.  Then 2.74 mL of a 4.8 mM solution of neomycin B sulfate (13.2 µmol) in 
10 mM sodium phosphate buffer (pH 7.4) were added and the mixture was allowed to stand 
for 30 min at room temperature before 10 equiv. activated ester 3 (132 µmol) dissolved in 
6.0 mL sodium phosphate buffer (pH 7.4) were added. After 1 min, 20 min, 2 h and 24 h an 
aliquot of 3 mL was taken out of the reaction mixture and incubated with 180 µL of a 7 wt. % 
ethylamine water solution for 30 min at room temperature. The purification, analysis and 
characterization was performed according to procedure (a). 
c) Procedure using a 10, 30 and 60 mM sodium ion concentration.  
A volume of 300 µL of a 5.54 mM (1.66 µmol, 1.5 equiv.) RNA solution in 10 mM sodium 
phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and afterwards stored for 15 min at 
room temperature. Then a volume of 228 µL of a 4.8 mM solution of neomycin B sulfate 
(1.09 µmol) in 10 mM sodium phosphate buffer (pH 7.4) was added and the mixture was 
allowed to stand for 30 min at room temperature. Additionally, a volume of 50 µL of 10, 231 
or 578 mM sodium chloride solution was added to reach a final salinity of 10, 30 or 60 mM 
Na+ concentration, respectively. To each reaction mixture 30 equiv. of NHS ester 3 
(32.8 µmol) dissolved in 36 DMF were added. After a reaction time of 24 h at room 
temperature a volume of 60 µL of 7 wt. % ethylamine water solution was added and 
incubated for 30 min at room temperature. Finally, 100 µL of aq. 2 M NaOH solution were 
added and heated to 85 °C for 30 min and cooled down to room temperature. Each 50 µL 
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fraction was purified by HPLC using a Waters Spherisorb ODS-2C18 analytic column 
(water/acetone 1.0:0.81 containing 16.9 mM HFBA) and a flow rate of 1 ml/min at 40 °C to 
determine the conversion of neomycin B to mono- and di-acetylated neomycin B derivatives 
and for investigation of the regioselectivity of the monoacetylation by NMR studies. 
d) Procedure using different reaction temperature.  
A volume of 300 µL of a 6.1 mM (1.66 µmol, 1.5 equiv.) RNA solution in 10 mM sodium 
phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and afterwards stored for 15 min at 
room temperature. Then 228 µL of a 4.8 mM solution of neomycin B sulfate (1.09 µmol) in 
10 mM sodium phosphate buffer (pH 7.4) were added and the mixture was allowed to stand 
for 30 min at room temperature before 30 equiv. activated ester 3 (32.8 µmol) dissolved in 
500 µL sodium phosphate buffer (pH 7.4) were added. The reaction mixture was allowed to 
incubate for 24 h at 20, 40 or 50 °C and the antibiotic derivatives were purified according to 
procedure (b) using 93 µL aq. 2M NaOH solution for the hydrolysis of RNA. 
 
3.5.3 Characterization of Synthesized Neomycin B Derivative 
 6´´´-N-acetyl neomycin B x 5 HFBA (4a). The title compound was prepared according to 
the general procedure described above using NHS ester 3. 
Derivative 4a was obtained as a white solid. For the measurement 
of regioselectivity and the characterization of the compound 
1H-NMR, HSQC as well as APT spectra were recorded and 
electrospray ionization (ESI)-MS was employed. The yield was 
calculated from 1H-NMR- and HPLC peak integrals by: Rt = 7.5 
min, 45 % yield (apt1). TLC (Chloroform/MeOH/17 % aq. 
NH4OH 2:1:1 v/v/v) Rf = 0.52. 1H-NMR (D2O, 500 MHz) δ 
(p.p.m.) 6.06 (d, J = 4 Hz, 1H, 1-H´), 5.44 (d, J = 2 Hz, 1H, 1-H´´), 5.20 (d, J = 1.5 Hz, 1H, 1-
H´´´), 4.44 (t, J = 5.75 Hz, 1H, 3-H´´), 4.39 (dd, J = 5 Hz, J = 2 Hz, 1H, 2-H´´), 4.26 (t, J = 3 
Hz, 1H, 3-H´´´), 4.24 (m, 1H, 4-H´´), 4.09 (t, J = 6.75 Hz, 1H, 5-H´´´), 4.07 (m, 1H, 4-H),  
4.01 (t, J = 10 Hz, 1H, 5-H´), 3.98 – 3.92 (m, 3H, 5-Ha´´, 5-H, 3-H´), 3.76 (dd, 1H, J = 12.5 
Hz, J = 5.5 Hz, 5-Hb´´), 3.72- 3.68 (m, 2H, 4-H´´´, 6-H), 3.60 (dd, J = 14 Hz, J = 7.5 Hz, 1H, 
6-Ha´´´), 3.56  (m, 2H, 3-H, 2-H´´´),  3.53-3.41 (m, 4H, 6-Ha´, 2-H´, 6-Hb´´´, 4-H´), 3.38 (m, 
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Heq), 2.04 (s, 3H, CH3), 1.89 (dd, J = 12.7 Hz, 1H, 2-Hax). APT (D2O, 125.7 MHz) δ (p.p.m.) 
174.49 (Carbonyl-C), 110.00 (C-1´´), 95.51 (C-1´´´), 95.49 (C-1´), 84.62 (C-5), 81.66 (C-4´´), 
75.39 (C-3´´), 75.29 (C-4), 73.58 (C-2´´), 72.45 (C-5´´´), 72.42 (C-6), 70.35 (C-4´), 69.22 (C-
3´), 67.88 (C-5´), 67.56 (C-3´´´), 66.10 (C-4´´´), 60.00 (C-5´´), 53.15 (C-2´), 50.90 (C-2´´´), 
49.65 (C-1), 48.16 (C-3), 39.85 (C-6´), 39.33 (C-6´´´), 27.88 (C-2), 21.74 (CH3). MS (EI+) 
(m/z): found 657.33008 [M+H]+, 679.31226 [M+Na]+; calculated 657.33013 [M+H]+, 
679.31207 [M+Na]+. 
 
3.5.4 NMR-Spectra of Synthesized Neomycin B Derivatives 
 























Figure 3.6b: HSQC (500 MHz, D2O) spectrum of 6´´´-N-acetyl neomycin B x 5 HFBA 4a. 
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Figure 3.7a: 1H-NMR (500 MHz, D2O) spectrum  of 1:1 mixture of acetyl neomycin B x 5 HFBA 4a and 
4b. The mixture was synthesized applying the general procedure (3.5.2 a) but in absence of APG and 






6´´´-N-acetyl neomycin B 4a










Figure 3.7b: HSQC (500 MHz, D2O) spectrum of a 1:1 mixture of acetyl neomycin B x 5 HFBA 4a and 
4b. The mixture was synthesized applying the general procedure (3.5.2 a) but without APG using only 
1 equiv. of activated ester 3. 
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Figure 3.8: 1H-NMR (500 MHz, D2O) spectrum of 6´,6´´´-N-diacetyl neomycin B x 4 HFBA 5 
synthesized without APG using 2 equiv. of activated ester 3 (a) and synthesized in presence of APGs 



































Figure 3.9: HSQC (500 MHz, D2O) spectrum of 6´,6´´´-N-diacetyl neomycin B x 4 HFBA 5. Arrows 
indicate the chemical shift of J(C6-H)- (red), J(C5-H)- (blue) and J(C1-H) coupling (black) of ring II and 
IV.   
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3.5.5 High Resolution Mass Spectrometric & High Performance Liquid 
Chromatography Analyses 











































































Figure 3.10: ESI-MS spectra of reaction mixture of neomycin B 1 (NeoB) reacted with 10 equiv. 
NHS ester 3 in presence of 1.5 equiv. APG apt1 (a) and apt2 (b) (i-vi = number of reacted amino 































Figure 3.11: HPLC elugrams after transformation of neomycin B 1 (NeoB) with 30 equiv. of NHS 
ester 3 in presence of 0.5 equiv. (1), 1.0 equiv. (2) and 1.5 equiv. (3) APG apt1 (a) and apt2 (b)         
(i-ii = number of reacted amino groups of 1).          
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Figure 3.12: HPLC elugrams of neomycin B 1 (NeoB) reacted with 10 equiv. of NHS ester 3 in 
presence of 0.5 equiv APGs apt1 (a) and apt2 (b) applying different reaction times (i-ii = number of 




















Figure 3.13: HPLC elugram of neomycin B 1 (NeoB) reacted with 30 equiv. of NHS ester 3 in 
presence of 1.5 equiv. APGs apt1 at 20 °C (1), 40 °C (2) and 50 °C (3) (i-ii = numb er of reacted amino 
groups of 1). 
 
3.5.6 Isothermal Titration Calorimetry 
ITC was employed to determine the binding constants between neomycin B and the aptameric 
APG apt1, apt2 and apt3. Microcalorimetric titrations of antibiotic 1 to RNA aptamers were 
performed by using a MicroCal ITC 200 Microcalorimeter (Northampton, MA). A 200 µM 
neomycin B solution was injected from a 40 µL rotating syringe into an isothermal sample 
chamber containing 200 µL of 7 µM aptamer solution. A 10 mM sodium phosphate buffer 
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(pH 6.8) was used to prepare both solutions, as well as to load the reference cell. The 
experiments were carried out at 25 °C and with a stirring speed of 1000 rpm. Typically, 
injections of 1.2 µL of titrant were added into the cell with a delay between injections of 100 
seconds, up to a aptamer/antibiotic 1 ratio of 1:5. The effective heat of the antibiotic-aptamer 
interaction upon each titration step was corrected for dilution effect by subtracting the values 
obtained in the titration of 1 into buffer solution. Each injection generated a point for point 
heat curve (microcalories per second vs. time) which was conveniently integrated in order to 
obtain the heats of the bimolecular interactions associated with those injections. Then the 
normalized heat signals were analyzed by using the ITC non-linear curve fitting functions for 
two binding sites from MicroCal Origin 7.0 software (MicroCal, Inc.; Northampton, MA). 
The satisfactorily fitted curve was used to determine the molar enthalpy change for binding 
(∆H°) and the corresponding binding constant (Ka). Fundamental thermodynamic equations 
were used to determine the molar free energy of binding, ∆G°, and the molar entropy change 
(∆S°). Each neomycin B-aptamer titration was repeated at least three times in order to 
increase the accuracy of the thermodynamic parameters. 
Figure 3.14 (paragraph 3.2.1) on top shows the heats resulting from each injection of 
neomycin B into one of the aptamer solutions studied. On the bottom are the integrated heats 
after correcting for the heat of dilution, as well as, the best-fitted function. All the 
thermodynamic parameters were summarized in the Table 3.4. An inspection of the Figure 
3.14 or the data in Table 3.4 reveals that each interaction between 1 with the APG (apt1, apt2 
and apt3) was enthalpy driven and resulted in exothermic reactions confirming that the 
specific RNA-aptamer interaction contributes strongly to the high complex stability. Although 
the three aptamers show the spontaneous formation of complexes, the natures of these were 
different. The titrations of 1 into apt1 and apt2 solutions showed similar profiles with two 
apparent phases, suggestive of two distinct binding sites (Fig.3.14a and Fig. 3.14b). In both 
aptamer-neomycin B complexes, the steepness of the first of the two phases resulted in 
association constants Ka,1 higher than 108 M-1, indicating a tight binding interaction between 1 
and the aptamers, apt1 and apt2. In contrast, the titration of 1 into solution of apt3 showed 
different profile. However, in agreement with the NMR results obtained in our studies 
applying all three aptamers, it is assumed that also apt3 exhibits two different binding sites. In 
fact the profile can be fit to two-sites model with similar association constants (Fig. 3.14c). 
This model explains the creation of 4a and 4b at approximately equimolar ratio as main 
products from apt3, as compared with apt1 and apt2. Thus, ITC results confirm the presence 
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of two binding sites of different affinity within apt1 and apt2, and similar affinity within apt3 
for neomycin B. 
 
Figure 3.14: ITC profiles (top) and corresponding integrated injection heats (bottom) at 25.0 °C for the 
titration of 7 µM RNA aptamer solution (apt1 (a), apt2 (b) and apt3 (c)) with 200 µM neomycin B 
solution (Neomycin B/RNA aptamer molar ratio). The integrated injection heats were corrected with 
the heat of dilution (derived from control titrations of aminoglycoside 1 into buffer alone), and then 
fitted by using a two binding site model (solid line). Applied buffer: 10 mM sodium phosphate, pH = 
6.8. The blue arrows indicate the high affinity binding site and the red arrows the low affinity binding 
site. 
 
Table 3.4: Association constants (Ka), molar entropy (∆H°) and molar enthalpy ( ∆S°) for      




Ka / 106 M-1 ∆H° / kcal mol-1 ∆S° / cal mol-1 deg-1 
apt1 1 1542 - 14.9 - 7.9 
 2 3.3 - 5.7 10.7 
apt2 1 233 - 18.6 - 24.1 
 2 1.9 - 7.2 4.6 
apt3 1 62 - 9.1 5.1 
 2 1.2 - 6.4 6.3 
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Aptameric Protective Groups Enable Various 
Transformations in Different Positions of Neamine 
Antibiotics 
(Part of this chapter is published online:  
A. A. Bastian, A. Marcozzi, A. Herrmann. Nature Chemistry 4, 1-5 (2012)) 
 (Based on this chapter a European patent is filed: A. Bastian, A. Marcozzi, A. Herrmann 2011) 
In the first chapter, RNA sequences have been introduced as efficient non-covalent 
protective groups for the regioselective modification of structurally complex natural 
products. Their application as aptameric protective groups (APGs) allowed the 
transformation of a single functional group out of several present in neamine antibiotics, 
namely neomycin B and paromomycin, with high regioselectivities. So far, modifications 
were introduced successfully using N-hydroxysuccinimide esters as acyl-transfer reagent 
resulting in novel antibiotic derivatives.  Here, we demonstrate that APGs allow the 
application of different reactions and conditions for regioselective modifications of 
neamine antibiotics. Furthermore, we prove that the application of same RNA sequences 
as APG enables the synthesis of a broad spectrum of aminoglycosides derivatives 
modified at different positions with excellent regioselectivities of >99 %. The 
introduction of new functional groups in neamine antibiotics will accelerate the 
synthesis of new promising antibiotic derivatives. Moreover, this work emphasized the 
applicability of oligonucleotides as APGs allowing facile access to novel derivatives of 
structurally complex natural products.  
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4.1 Introduction 
The application of non-covalent protective groups based on host-guest interactions has 
recently emerged as a promising and simpler alternative to standard covalent protection and 
deprotection protocols in derivatization of multifunctionalized compounds.1,2 Reinaud et al. 
applied a zinc(II)-complex based on a functionalized calix[6]arene as supramolecular 
protective group (SPG) for the chemo- and  regioselective carbamoylation of the 
unsymmetrical triamine N-(2-aminoethyl)propane-1,3-diamine.1 Similarly, Kohnke et al. 
utilized a calix[4]pyrrole derivative as SPG in the selective O-alkylation of 6-hydroxy-1-
naphthol.2 However, these host systems exhibit serious limitations as non-covalent protective 
groups. Due to the small cavity size their application as SPG is limited to small guest 
molecules. Moreover, the generalization of the concept on the basis of macrocyclic cavities is 
prohibitively difficult due to the painstaking design and synthesis of the host system required 
for the guest molecule.  
To overcome these limitations, ribonucleic acids were introduced as aptameric protective 
groups (APGs) for the regioselective derivatization of more complex structures (chapter 2). It 
is well known that strong binders consisting of RNA and DNA aptamers can be evolved 
through the straightforward Systematic Evolution of Ligands by EXponential Enrichment 
(SELEX) process.3,4 The resulting sequences can be produced by automated synthesis in large 
scale and they can act as ligands for a wide variety of low molecular weight compounds5,6,7,8,9 
as well as biomacromolecules, especially proteins.10,11,12  
Facing these advantages, the applicability of APGs for the regioselective modification of 
neamine antibiotics neomycin B 1 and paromomycin 2 (Fig. 4.1a) were investigated. It was 
demonstrated that the APG apt1 protects non-covalently ring I, II and III of antibiotic 1, while 
ring IV is available for chemical transformation (Fig. 4.1b). Moreover, in our previous study 
two more aptameric sequences, i.e. apt2 and apt3 (Fig. 4.1c), that were chosen randomly 
from a pool of published RNA sequences,13 were applied successfully as APGs (chapter 2). 
Furthermore, it was demonstrated that the utilization of these aptamers as non-covalent 
protective group for antibiotic 1 and 2 enabled regioselective acylation of the amino group in 
C6 position at ring IV of antibiotics 1 and 2. 
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Figure 4.1: a, Aminoglycoside antibiotics used for regioselective modification protected by APGs. 
b, Neomycin B 1 – apt1 complex;14 color code: white – hydrogen, green – carbon, blue – nitrogen, red 
– oxygen, grey – APG apt1. Arrows indicate the amino groups in C2 position (red) and C6 position 
(blue) at ring IV of antibiotic 1. c, RNA sequences applied as APGs for neamine antibiotics 1 and 2.  
 
However, the APG strategy is limited so far to one chemical transformation. Neomycin B and 
paromomycin were so far only acylated using N-hydroxysuccinimide (NHS) esters as shown 
in Scheme 4.1 for acetyl-NHS ester 3. Furthermore, the modification of neamine antibiotics 1 
and 2 is restricted to the transformation of the amino group in C6 position at ring IV applying 
APGs (blue arrow in Fig. 4.1a and b). To establish the APG technology as a general tool in 
organic synthesis its scope needs to be extended. For that reason, in this chapter we 
demonstrate that APGs enable also modifications in another position than the 6C position of 
antibiotic´s ring IV (red arrow in Fig. 4.1a and b). In particular, we applied successfully 
diverse reagents enabling modifications, namely acylation, azide introduction and urea 
derivative formation, at the C6 and C2 position at ring IV of aminoglycosides 1 and 2 
(Scheme 4.1). 
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Scheme 4.1: Reactions for the regioselective transformations of amino groups at the neamine 
antibiotic´s ring IV in presence of APGs: acylation (1), thiolation (2), urea bond formation (3) and azide 
introduction (4). 
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4.2 Results & Discussion 
4.2.1 Regioselective Modification of Antibiotic´s Ring IV in C6 Position  
4.2.1.1 Modification Using Negatively Charged Activated Ester 
Since the transformation of the neamine antibiotics 1 and 2 protected by APG takes place in 
an aqueous buffer solution, the introduction of hydrophobic residues via acylation reaction is 
limited by the low solubility of NHS-esters in water. Therefore, negatively charged activated 
esters, sulfo-N-hydroxysuccinimide (sulfo-NHS) ester 4 and 4-sulfo-tetra-fluorophenyl (STP) 
ester 5, were employed as acyl-transfer reagents in this study (Fig. 4.2). Due to their negative 
charge at the sulfo group these activated ester show higher solubility in aqueous solution and 
therefore, they have been already applied successfully as acyl-transfer reagents under such 
conditions.15,16 
To test the applicability of negatively charged activated NHS ester 4 for modification of the 
amino group in C6 position at ring IV of antibiotic 1 we used the 23mer RNA aptamer apt1 
as APG. The apt1-aminoglycoside 1 complex was reacted with 10 equivalents of sulfo-NHS 
ester 4 (Fig. 4.2a). To determine the reactivity of ester 4 with neomycin B protected by apt1 
High Performance Liquid Chromatography (HPLC) analysis was performed. As shown in 
Figure 4.2b, after a reaction time of 24 hours a conversion of 7 % of 1 to mono-acetylated 
neomycin B derivatives was determined. In contrast, using a non-charged NHS ester a 
conversion of the neomycin B up to 71 % was detected (chapter 2). The low reactivity can be 
explained by repulsion of negative charges located at the APG and reagent 4. Since the RNA 
sequence apt1 exhibits a negatively charged phosphate backbone, we assume that the attack 
of ester 4 at ring IV of neomycin B is hindered by the APG. 
However, to test whether a different negative charged acetyl-transfer reagent can be applied 
for the transformation, we utilized acyl-transfer reagent 5 which also carries a sulfo group 
(Fig 4.2a). In contrast to the NHS ester 4, STP ester 5 was reactive under same conditions. As 
shown in Figure 4.2c, neomycin B was converted mainly to mono-acetylated products with 
conversions of 31 % and a yield of approx. 30 %, while di-acetylated derivatives were formed 
reaching a conversion of only 4 %. Performing the reaction at higher temperature (40 °C) to 
increase the conversion gave the same result.  
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Figure 4.2: a, Regioselective transformation of antibiotic 1 (NeoB) using 15 equiv. of activated esters 
4 and 5 in presence of 1.5 equiv. of apt1. Reactions were performed in 10 mM sodium phosphate 
buffer (pH ≈ 7) at room temperature and 24 hours reaction time. b, HPLC elugram of reaction mixture 
after transformation of 1 employing sulfo-NHS ester 4. c, HPLC elugram of reaction mixture after 
transformation of 1 using STP-ester 5 (i-ii = number of reacted amino groups of 1). Conversions of 1 to 
mono- and di-substituted derivatives are given below the corresponding peaks. It is assumed that only 
mono- and di-acetylated derivatives were formed. 
 
However, SPT ester 5 showed increased reactivity compared to activated ester 4. This 
behavior can be explained by their different molecular structures. As shown in Figure 4.3, 
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computer models of both compounds suggest that the sulfo-NHS ester 4 exhibits a sterically 
more demanding structure due to the presence of sp3-hybridized carbon atoms. In comparison, 
activated ester 5 has predominantly sp2-hybridized carbon atoms resulting in a planar 
structure. Due to the fact that the sulfo group is located in the para-position to the ester group, 
we assume that the flat structure of the aromatic STP ester 5 enables a reaction with the 
protected antibiotic 1 despite the negative charge. Another possible explanation for the higher 
reactivity of 5 is the occurrence of π-π-interactions of 5 with the aromatic nucleobases of the 
APG compensating the electrostatic repulsion. 
4 5
Figure 4.3: Simulated 3D-structures (ChemDraw) of activated esters 4 and 5. Color code: white – 
hydrogen, grey – carbon, blue – nitrogen, red – oxygen, orange – sulfur, yellow – fluorine. The black 
arrows indicate the electrophiles for a nucleophilic attack. 
 
To determine the regioselectivity of the transformation using STP-ester 5, the fraction of 
mono-acetylated neomycin B derivatives was purified and 1H-NMR- and HSQC spectra were 
recorded (see experimental part Fig. 4.11a and 4.11b).  This analysis showed that 1 was 
acetylated at the amino group in C6 position of ring IV resulting in antibiotic derivative 10 
with a regioselectivity of 83 %. However, the regioselectivity is considerable lower in 
comparison to the utilization of acetyl NHS-ester 3, which reached a selectivity of 95 % 
(chapter 2). This difference can be explained by the increased salt concentration in the 
reaction mixture. Due to the fact that the activated ester 5 is applied as sodium salt, a final salt 
concentration of approx. 26 mM is reached in the reaction mixture. In chapter 3.2.4 it was 
demonstrated that the regioselectivity of the acetylation reaction is decreasing with higher 
salinity due to the destabilization of the apt1-aminoglycoside 1 complex.17 Therefore, with 
the increase of sodium concentration the amine group in C6 position of ring II of neomycin B 
becomes also available for transformations resulting in lower regioselectivities for the 
acylation reaction. 
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4.2.1.2 Introduction of a Sulfhydryl Group Using Traut´s Reagent  
After we demonstrated that the negatively charged reagent, STP-ester 5, can be applied in the 
regioselective transformation of neomycin B, we investigated whether an APG also allows the 
application of positively charged reagents. As a straightforward proof we applied 
2-iminothiolane hydrochloride 6 (Scheme 4.2) as an acyl-transfer reagent. Named after its 
inventor Traut´s, reagent 6 is fully water soluble, stable and reacts preferably with primary 
amino groups.18 Moreover, after transformation with 6, a sulfhydryl group is available for 
further coupling reactions (Scheme 4.2). Due to the scope of further derivatization this cyclic 
imidothioester 6 has been successfully applied for thiolation of biomacromolecules such as 
proteins and enzymes19,29 and oligosaccharides.21,22 As shown in Scheme 4.2, in an additional 
synthetic step the thiolated product 11 can undergo an oxidative dimerization resulting in 
product 12 or be coupled in the same manner to different thiolated substrates giving 







Scheme 4.2: Possible scenario for the downstream reactions after thiolation of an amino group of 
antibiotic 1 with Traut´s reagent: Thiolation of an amine with 2-iminothiolane 6 (1), oxidative 
dimerization (2), conjugation of iminium chloride 11 (3) and acidic hydrolysis of 11 to acylated product 
14 (4). 
 
However, the formed iminium ion 11 is not stable against hydrolysis under acidic conditions 
(pH < 3) (Scheme 4.2).23 Due to the fact that the synthesized antibiotic derivatives were 
purified by HPLC using an acidic eluent (pH 2), the hydrolyzed product 14 was obtained. 
Nevertheless, applying excess of Traut´s reagent 6 and apt1 as APG neomycin B was 
modified regioselectively in C6 position at ring IV resulting in thiolated derivative 14 (Fig. 
4.4a). This was proven employing 2D-NMR spectroscopic measurements as demonstrated in 
Figure 4.4b. 
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Figure 4.4: a, Regioselective thiolation of neomycin B in presence of 1.5 equiv. APG apt1 using 
Traut´s reagent 6. Reaction was performed in 10 mM sodium phosphate buffer (pH ≈ 7) at room 
temperature and 24 hours reaction time. b, HSQC-section of antibiotic derivative 14. Chemical shifts of 
the J(C6´´´-H) couplings (red arrows) and the J(C5´´´-H) coupling (blue arrow) indicate regioselective 
acylation of the amino group in C6 position at ring IV.  
 
Furthermore, using an excess of 30 equivalents of reagent 6 resulted in a regioselectivity of 
only 74 % in order to form thiolated derivative 14 as calculated from 1H-NMR data (Table 
4.1, see experimental part Fig. 4.12a). However, using 30 equivalents of Traut´s reagent the 
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mono-thiolated derivatives were obtained with a yield of 57 %, while the utilization of 
reduced amounts of 6 gave lower yields reaching 43 % and 40 % using 15 and 5 equivalents, 
respectively (Table 4.1). As demonstrated by HPLC analysis, in all cases neomycin B was 
mainly converted to mono-acylated derivatives using Traut´s reagent (see experimental part 
Fig. 4.23). In contrast to the decreasing yields, the regioselectivity of the acylation reaction 
increased up to 91 % using reduced amounts of 6 (Table 4.1).  
 
Table 4.1: Yields and regioselectivities of the transformation of neomycin B using different 




14 30 57 74 
14 15 43 89 
14 5 40 91 
 
All reactions were carried out according to the general procedure (see experimental part 4.4.2.3.1). 
^ Isolated yields of mono-thiolated derivative 14 (isomer mixture). Yields were determined by HPLC. 
* Regioselectivities (r.s.) were calculated using 1H-NMR spectroscopy. 
 
The low regioselectivity and enhanced formation of more side products using 30 equivalents 
of 6 can be explained by destabilization of the apt1-aminoglycoside 1 complex by the excess 
of the charged reagent 6. As demonstrated in previous studies, the complex stability is mainly 
determined by the charge-charge interactions of neomycin B and the aptamer apt1.17 
Furthermore, it was shown that the complex stability was reduced with the increase of 
positively charged counter ions (chapter 3). Therefore, we assume that the positively charged 
iminium group of the Traut´s reagent 6 weakens the apt1-antibiotic 1 interaction leading to 
side reactions. Therefore, optimization of stoichiometric ratio of reagent 6 and APG protected 
neomycin B was necessary to reduce the formation of side products and obtain high 
regioselectivity (91 %). 
This result demonstrates that the APG methodology allows not only the application of neutral 
NHS esters and negatively charged STP esters, but also the utilization of the positively 
charged acyl-transfer reagent 2-iminothiolane hydrochloride 6. A further advantage of the 
APGs Enable Various Transformations in Different Positions of Neamine Antibiotics 
95 | P a g e  
 
presented thiolation strategy is that neomycin B can be conjugated to other entities in only one 
additional synthetic step without the use of APGs. This gives a facile access to a broad range 
of antibiotic derivatives modified at ring IV.   
 
4.2.2 Regioselective Modification of Antibiotic´s Ring IV in C2 Position 
Employing Urea Bond Formation. 
So far, we successfully demonstrated that the APG-strategy facilitates regioselective 
transformation of two neamine antibiotics, namely neomycin B 1 and paromomycin 2, using 
various types of acylation reagents. For this approach three different aptameric sequences 
were successfully utilized as APGs (chapter 2). However, these aptamers enabled so far the 
modification of the amino group in C6 position at ring IV of these aminoglycosides. In 
contrast, here we present the application of the same APGs enabling chemoselective 
transformations of the amino group in C2 position at ring IV reaching high regioselectivities. 
For this approach urea bond formation was applied for transformation of antibiotics 1 and 2 
using apt1 and apt2 as APGs.  
For the straightforward proof of the chemo- and regioselective transformation, neomycin B 
was reacted with 15 equivalents of p-methoxyphenyl isocyanate 7a in absence and presence 
of apt1 and the reaction mixtures were analyzed using High Resolution Mass Spectrometry 
(HRMS) and HPLC. As demonstrated by mass spectrometric and HPLC analyses, in absence 
of apt1 antibiotic 1 was transformed to an inseparable mixture of derivatives exhibiting up to 
four urea groups (Fig. 4.5a and Fig. 4.5c), whereas in presence of apt1 only one amino group 
was transformed (Fig. 4.5b and 4.5d). Also the application of APG apt2 resulted only in the 
formation of a single urea derivative as demonstrated by HPLC analysis (see experimental 
part Fig. 4.24).  
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Figure 4.5: HRMS spectra of reaction mixture after transformation of neomycin B 1 using 15 
equivalents of p-methoxyphenyl isocyanate 7a in absence (a) and presence (b) of 1.5 equivalent APG 
apt1. HPLC elugram of reaction mixture after transformation of 1 in absence (c) and presence (d) of 
apt1. (i-iv = number of reacted amino groups of 1). 
 
Further characterization of the mono-urea derivative by NMR experiments proved that 
antibiotic 1 was transformed exclusively at a single position in presence of APGs resulting in 
aminoglycoside derivative 15a (Fig. 4.6a, Table 4.2). As demonstrated in Figure 4.6b, the 
HSQC spectrum proves the regioselective transformation of the amino group in C2 position at 
ring IV resulting in antibiotic derivative 15a. Moreover, 1H-NMR spectroscopic 
measurements (see experimental part Fig. 4.13a) showed exclusively the presence of 
regioisomer 15a, when employing apt1 and apt2 as APG (Table 4.2). Furthermore, similar 
results were achieved using isocyanates 7b and 7c as reagents (Fig. 4.6a). As shown in Table 
4.2, the transformation of antibiotic 1 using 7b resulted also exclusively in regioisomer 15b, 
while the utilization of isocyanate 7c yielded derivative 15c with slightly lower 
regioselectivity. Furthermore, all reactions show moderate conversions (Table 4.2) of 
neomycin B and resulting the mono-urea derivatives were isolated by HPLC reaching yields 
of up to 51 % using urea bond formation (Fig. 4.6a).  
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1 R1 = NH2
2 R1 = OH
15a R1 = NH2 R2 = OMe
15b R1 = NH2 R2 = H
15c R1 = NH2 R2 = NMe2
16   R1 = OH R2 = OMe
7a R2 = OMe
7b R2 = H
















Figure 4.6: a, Regioselective transformation of the amino group in C2 position at ring IV of antibiotic 1 
and 2 in presence of 1.5 equivalents APG apt1 or apt2 using 15 equivalents of aromatic isocyanates 
7a-c. Reactions were performed in 10 mM sodium phosphate buffer (pH ≈ 7) containing 6.4 volume % 
DMF at room temperature and 24 hours reaction time. Yields of mono-urea derivatives (isomer 
mixture) were determined by HPLC. b, HSQC spectrum of neomycin B derivative 15a. Chemical shifts 
of the J(C1´´´-H) coupling (black arrow), J(C2´´´-H) coupling (red arrow) and J(C3´´´-H) coupling (blue 
arrow) indicate the regioselective urea bond formation in C2 position at ring IV.  
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Furthermore, we demonstrated that the urea group can be also introduced regioselectively in 
related antibiotic paromomycin 2 in presence of APGs apt1 and apt2. Thus, antibiotic 2 was 
transformed successfully with isocyanate 7a to the corresponding urea derivative 16 in 
presence of an APG (Fig. 4.6a, Table 4.2). It was found that 2 was also preferably 
transformed at the C2 position of ring IV with good conversions of 53 % and 52 % and 
excellent regioselectivities of 97 % and 92 % applying apt1 and apt2, respectively (Table 
4.2). 
Table 4.2: Conversions and regioselectivities of urea bond formation in C2 position of 
antibiotic´s ring IV. 
Compound APG R1 R2 conv.^(%) r.s.*(%) 
   15a** apt1 NH2 OMe 49 >99 
   15a** apt2 NH2 OMe 44 >99 
   15b** apt1 NH2 H 44 >99 
15b apt2 NH2 H 37 >99 
   15c** apt1 NH2 N(Me)2 51 92 
 15c apt2 NH2 N(Me)2 57 93 
  16** apt1 OH OMe 53 97 
16 apt2 OH OMe 52 92 
 
All reactions were carried out according to the general procedure using 15 equiv. of aromatic 
isocyanates 7a-c (see experimental part 4.4.2.3.2). ^ Conversions of neomycin B to corresponding 
derivatives were calculated from HPLC- and 1H-NMR peak integrals. * Regioselectivities (r.s.) were 
calculated using 1H-NMR spectroscopy. ** Reaction was performed up to four times and average of 
conversion and regioselectivity is given. An error of the conversion is calculated to be up to 6 %.  
 
The preferential modification of two different amino group at ring IV using urea formation 
and acylation reaction can be explained as a combination of two factors: as shown in Figure 
4.7, the aromatic isocyanates 7a exhibits a planar structure, while acetyl NHS ester 3 is a 
more sterically hindered molecule due to the presence of sp3-hydridized carbon atoms. 
Furthermore, in comparison to ester 3 the reactive unit of the isocyanates 7a is smaller and 
additionally, not sterically hindered by a methyl group as it is the case for 3. This enables the 
attack of the amino group in C2 position of ring IV protected partly by the APG. Additionally, 
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it seems that in aqueous medium isocyanates exhibit higher reactivity towards amines with 
lower pKa value, i.e. amino groups attached to secondary carbon atoms in neomycin B. 
3 7a
Figure 4.7: Simulated 3D-structures (ChemDraw) of acetyl NHS ester 3 and p-methoxyphenyl 
isocyanate 7a. Color code: white – hydrogen, grey – carbon, blue – nitrogen, red – oxygen. Black 
arrows indicate the electrophiles for a nucleophilic attack. 
 
This result showed that a detailed understanding of the interaction between APG and guest 
molecule together with careful choice of reagent and conditions enables a modification at 
different amino groups of antibiotic 1 and 2 using the same APG sequence. 
 
4.2.3 Regioselective Mono- & Di-Functionalization of Neomycin B 
After we applied successfully different reactions to enable region- and chemoselective 
modifications of two different positions at ring IV of neomycin B 1 and paromomycin 2 in 
presence of APGs, we investigate the selective mono- and di-functionalization of antibiotic 1 
in presence of APG apt1. Therefore, we used a diazo-transfer reagent 8 to perform azide 
introduction and aliphatic isocyanates 9a-c to enable urea formation at two amino groups of 
antibiotic´s ring IV.  
4.2.3.1 Regioselective Azide Introduction at Antibiotic´s Ring IV   
To introduce an azide group at ring IV of neomycin B, we utilized imidazole-1-sulfonyl azide 
hydrochloride 8 as diazo-transfer reagent (Fig. 4.8). “Diazo donor” 8 was introduced by 
Goddard-Borger and Stick in 2007 as an efficient, shelf-stable and water soluble reagent.24 
Moreover, investigation of 8 showed its convenient applicability in aqueous media using mild 
conditions and without the use of transition metal catalysts, such as copper(II), nickel(II), and 
zinc(II).25 Furthermore, reagent 8 was applied successfully for the regioselective azide 
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introduction in structurally complex natural products, namely peptides25 and neamine 
antibiotics (chapter 5), in aqueous solution. Here, we demonstrate a regioselective azide 
introduction in neomycin B employing 8 in presence of theAPG apt1. We performed the 
transformation applying basic conditions (pH 8), copper(II) sulfate as catalyst and eight 
equivalents of reagent 8 in presence and absence of apt1. Under these conditions the reaction 
of neomycin B in presence of apt1 resulted in a mixture of antibiotic derivatives exhibiting 
one and two azide groups (see experimental part Fig. 4.26), while in absence of the APG 
mainly hexa-azido derivatives were detected (see experimental part Fig. 4.19). The mono- and 
di-functionalized antibiotic derivatives formed in presence of the APG could be separated by 
HPLC purification and were obtained with a yield of 46 % and 16 %, respectively. Their 
characterization by NMR spectroscopic measurements showed that reagent 8 reacted 
exclusively with the amino groups at ring IV of the antibiotic 1 resulting in mono-azide 17 




































Figure 4.8: a, Regioselective azide introduction in neomycin B in presence of 1.5 equivalents APG 
apt1 using 8 equiv. of diazo-transfer reagent 8. Reaction was performed in 10 mM sodium phosphate 
buffer (pH ≈ 8) at room temperature and 24 hours reaction time. b, HSQC-section of mono-azido 
neomycin B derivative 17. Chemical shifts of the J(C6´´´-H) couplings (black arrows) indicate the 
regioselective azide introduction in C6 position at ring IV. c, HSQC-section of di-azido neomycin B 
derivative 18. Chemical shifts of the J(C6´´´-H) couplings (black arrows) and J(C2´´´-H) coupling (red 
arrow) indicate the regioselective azide introduction in C6 and C2 position at ring IV, respectively.    
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As proven by 2D-NMR spectra, mono-azido derivative 17 exhibits the azide group in C6 
position and the di-azido derivative 18 in C2 and C6 position of ring IV (Fig. 4.8b and 4.8c). 
Employing 1D-NMR spectroscopy, regioselectivities up to 93 % were determined for the 
azide introduction (see experimental part Fig. 4.15a and 4.16a). 
However, neomycin B was transformed to derivatives 17 and 18 with conversions of approx. 
48 % and 17 %, respectively. From this result we can conclude that the amino group in C6 
position is more reactive than the one in C2 position of ring IV, since the amine in C6 position 
of 1 is transformed in both antibiotic derivatives to an azide. The additional minor conversion 
of the amino group in C2 position resulting in di-azido derivative 18 can be explained in two 
ways. On the one hand, the reactive azide function of the reagent 8 is not sterically hindered, 
enabling an attack of the amine in C2 position of ring IV, as described previously for 
isocyanates (paragraph 4.2.2). On the other hand, the sodium concentration was increased to 
approx. 21 mM as an effect of pH adjustment using sodium hydroxide and sodium carbonate. 
Since the binding constant between aptamer apt1 and antibiotic 1 is lower with the increase of 
salinity (chapter 3),17 it can be assumed that the destabilization of the complex enables also 
the transformation of the amino group in C2 position.  
It can be summarized that, despite of basic conditions, presence of copper(II) as catalyst and 
increased sodium concentration, excellent regioselectivities were achieved employing 
imidazole-1-sulfonyl azide hydrochloride 8 as diazo-transfer reagent. This result demonstrates 
the robustness of the RNA aptamers as APGs for the modification of aminoglycoside 
antibiotics. Furthermore, the regioselective introduction of azide groups has several 
advantages. On the one hand, an azide group can be applied as a protective group enabling 
selective modification of other amino groups of neomycin B. On the other hand, azides can be 
further transformed in a single step into 1,2,3-triazoles via “click-chemistry” employing 
Huisgen reaction26 and into amides and carbamates using Staudinger reaction27 that could 
result in a broad spectrum of new antibiotic derivatives. 
 
4.2.3.2 Regioselective Urea Bond Formation at Antibiotic´s Ring IV 
In the previous paragraph, we described a successful regioselective azide introduction in C2- 
and C6 position at ring IV of neomycin B in presence of APG apt1. Our studies demonstrated 
that at first place the amino group in C6 position was transformed regioselectively resulting in 
6´´´-azido neomycin B 17, while in further course of the reaction the amino group in C2 
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position of 17 was transformed yielding 6´´´, 2´´´-diazido neomycin B 18. In contrast, here we 
present a different reaction sequence of both amines at ring IV of the antibiotic 1 in presence 
of apt1. For this purpose we utilized the introduction of urea groups employing aliphatic 
isocyanates 9a-c. As shown in Figure 4.9a, neomycin B was reacted with 30 equivalents of 
propyl isocyanates 9a in presence of APG apt1. With HPLC analysis (experimental part 
Fig. 4.27) of the reaction mixture it was demonstrated that the transformation of 1 resulted 
mainly in mono- and di-substituted derivatives reaching yields of 21 % and 31 %, respectively 
(Table 4.3). After separation of neomycin B derivatives exhibiting one and two urea groups 
by HPLC purification, the obtained derivatives were characterized by NMR spectrometric 
measurements. As show in Figure 4.9a, neomycin B was transformed to the mono-urea 
derivative 19a and di-urea derivative 20a.  
a
1







6´´´2´´´9a R = propyl
9b R = isopropyl
9c R = tert-butyl
19a R = propyl
19b R = isopropyl
19c R = tert-butyl
20a R = propyl
20b R = isopropyl




































Figure 4.9: a, Regioselective transformation of neomycin B in presence of 1.5 equivalents apt1 using 
30 equiv. of aliphatic isocyanates 9a-c. Reactions were performed in 10 mM sodium phosphate buffer 
(pH ≈ 7) containing 6.4 volume % DMF at room temperature and 24 hours reaction time. b, HSQC-
section of neomycin B derivative 19a. Chemical shifts of the J(C2´´´-H)- and J(C3´´´-H) coupling (black 
arrows) indicate the selective reaction of the amino group in C2 position at ring IV. c, HSQC-section of 
neomycin B derivative 20a. Chemical shifts of the J(C2´´´-H)- and J(C3´´´-H) coupling (black arrows) 
and of the J(C5´´´-H)- and J(C6´´´-H) coupling (red arrows) indicate the transformation of amines in C2 
and C6 position at ring IV, respectively. 
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Employing 2D-NMR spectroscopy it was proven that the derivative 19a exhibits the urea 
group in C2 position at ring IV (Fig. 4.9b), while derivative 20a has two urea functionalities 
in C2- and C6 position at ring IV (Fig. 4.9c).  As calculated from 1H-NMR spectra, the mono-
functionalization and di-functionalization of antibiotic 1 reached excellent regioselectivities of 
90 % and >99 % for 19a and 20a, respectively (Table 4.3, experimental part Fig. 4.17a and 
Fig. 4.18a).  
In comparison to the azide introduction (reaction in C6 position, then in C2 position), 
applying aliphatic isocyanates an opposite order of reaction of amino groups at antibiotic´s 
ring IV was determined (first C2 position, then C6 position). This difference can be explained 
as follows. On the one hand, isocyanates react preferably with amino groups located at the 
secondary carbon atoms (C2 position) under the applied conditions, as demonstrated in 
paragraph 4.2.2 for aromatic isocyanates. Thus, neomycin B is first converted to mono-urea 
derivative 19a (Fig. 4.9a). On the other hand, aliphatic isocyanates show reactivity with all 
amines of antibiotic 1 resulting in derivatives containing five and six urea group in absence of 
APG (see experimental part Fig. 4.20, 4.21 and 4.22). As a consequence, the additional 
reactivity of the amino group in C6 position at ring IV leads finally to the regioselective 
formation of di-urea derivative 20a in presence of apt1 (Fig. 4.9a). 
To test whether sterically more demanding aliphatic isocyanates are applicable, antibiotic 1 
was reacted with isopropyl- (9b) and tert-butyl- (9c) isocyanate (Fig. 4.9a). The application of 
30 equivalents of reagents 9b resulted in the corresponding mono-urea regioisomer 19b and 
di-urea derivative 20b, while employing 9c the transformation occurred only in a single 
position at the antibiotic 1 resulting in derivative 19c (Fig. 4.9a, Table 4.3). Furthermore, it 
turned out that the conversion of neomycin B to di-urea derivative 20b was decreased to 21 % 
employing isocyanates 9b in comparison with the less sterically demanding isocyanate 9a 
reaching 35 % for derivative 20a (Table 4.3). In contrast, the conversions of neomycin B to 
the mono-urea regioisomers 19b and 19c increased to 35 % and 42 % using sterically more 
demanding isocyanates 9b and 9c, respectively. The reduced formation of di-substituted 
isomers 20b and absence of di-urea derivative 20c applying more sterically demanding 
isocyanates can be explained by the size of the introduced residues at the amine in C2 position 
in the first place. After transformation of the amine in C2 position the introduced urea group 
is hindering the reaction of the amino group in C6 position, resulting in decreased or 
prevented formation of di-substituted derivatives. However, all derivatives were formed with 
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extremely high regioselectivities ranging from 90 % to 95 % employing isocyanates 9b and 
9c (Table 4.3). 
 
Table 4.3: Conversions and regioselectivities of mono- and di-functionalization of neomycin B. 
Product    R   conv.^(%)  yield*(%)     r.s.**(%) 
19a propyl 24 21 91 
19b isopropyl 35 32 90 
19c tert-butyl 42 38 95 
20a propyl 35 31      >99 
20b isopropyl 21 17 95 
  20b^^ isopropyl n.d. - - 
 
All reactions were carried out according to the general procedure using 30 equiv. of aliphatic 
isocyanates 9a-c in presence of 1.5 equiv. apt1 (see experimental part 4.4.2.3.2). ^ Conversions of 1 
to antibiotic derivatives were calculated from HPLC- and 1H-NMR peak integrals. ^^ Derivative was not 
detectable (n.d.) by HPLC analysis. * Yields of mono- and di-urea derivatives (isomer mixture) were 
determined by HPLC. ** Regioselectivities (r.s.) were calculated using 1H-NMR spectroscopy.  
 
Summarized, this result demonstrates that the order of transformation of the amino groups at 
ring IV of neomycin B is determined by the choice of chemical transformation. Employing 
urea bond formation, the amine in C2 position was reacted first and then the created mono-
urea derivatives 19a-c were transformed to di-urea derivatives 20a-b. Reaction of neomycin B 
with diazo-transfer reagent 8 resulted first in the antibiotic derivative 17 modified in 
C6 position and then in di-azido derivative 18 transformed in C6 and C2 position (paragraph 
4.2.3.1).  
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4.3 Conclusion 
In this chapter, we investigated six different reagents and four different reactions regarding 
their applicability for the modification of two antibiotics, namely neomycin B and 
paromomycin, in presence of two different APGs. We successfully employed acylation, 
thiolation, urea bond formation and azide introduction as reactions in presence of APG apt1 
reaching moderate yields and excellent regioselectivities. At this point it has to be emphasized 
that the APG-technology allows not only the application of neutral reagents but also 
positively and negatively charged ones for modification.  Moreover, it was shown that the 
application of the same RNA aptamers as APGs allows the transformation of different 
positions at ring IV of the aminoglycosides. Using apt1 as APG the amino group in C6 
position at ring IV of neomycin B was acylated using a STP ester and 2-iminothiolane 
hydrochloride with regioselectivities of 83 % and 91 %, respectively. In the same position an 
azide group was introduced regioselectively applying imidazole-1-sulfonyl azide 
hydrochloride reaching a regioselectivity of 93 %. In contrast, the amino group in C2 position 
at ring IV of neomycin B and paromomycin was converted to urea groups using aliphatic and 
aromatic isocyanates in presence of APGs apt1 and apt2 reaching regioselectivities up to >99 
%.  Furthermore, it was successfully demonstrated that by choosing reagents and conditions 
properly, azide- and urea groups could be introduced regioselectively in both positions at ring 
IV of neomycin B resulting in di-azido- and di-urea antibiotic derivatives using imidazole-1-
sulfonyl azide hydrochloride and aliphatic isocyanates as reagents, respectively. Summarized, 
these results show the wide applicability of APGs allowing a broad range of chemo- and 
regioselective modifications of aminoglycoside antibiotics. Employing various reactions for 
the transformation in different positions, this study helps to accelerate the search for new 
active compounds based on neamine antibiotics using RNA aptamers as APGs. The 
aminoglycoside derivatives described in this chapter are particularly suited as starting point 
for the generation of libraries of this class of antibiotics, because they can be reacted further 
by a large variety of organic reactions. 
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4.4 Experimental Section 
4.4.1 Materials & Methods 
1H-NMR-, heteronuclear single-quantum correlation (HSQC) spectra and Attached Proton 
Test (ATP) were recorded on a Varian Unity Inova (500 MHz for 1H-NMR and HSQC, 125 
MHz for APT and 13C-NMR), Oxford AS400 (400 MHz for 1H-NMR and 100.6 MHz for 
APT and 13C-NMR) and Oxford 600 (600 MHz for 1H-NMR and HSQC) NMR spectrometer 
at 25 °C. High resolution mass spectrometry (HRMS) was carried out on a LTQ ORBITRAP 
XL instrument (Thermo Scientific) employing electron impact ionization in positive ion mode 
(EI+). Chromatographic separations were carried out on a Shimadzu VP series high 
performance liquid chromatography (HPLC) modular system (DGU-14A3 Online Vacuum-
Degasser, two LC-20 AT pumps, SIL-20A auto sampler, CTP-20 A column oven, RID-10 
refractive detector, FRC-10 A fraction collector and Shimadzu LCsolution software). HPLC 
purification was performed with a Waters Spherisorb ODS-2 C18 analytical column (250 x 4.6 
mm, spherical particles of 5 µm and 80 Å pore size) using isocratic elution at 40 °C. A pH-
meter (Hanna Instruments pH 209) equipped with a glass combination electrode was used for 
pH adjustments of the reaction buffers. All chemicals and reagents were purchased from 
commercial suppliers and used without further purification, unless otherwise noted. 
Neomycin B trisulfate x hydrate (VETRANAL®), paromomycin sulfate salt (98 %), N,N-
dimethylformamide (DMF, 99 %), N-hydroxysuccinimide (NHS, 98 %), trifluoroacetic acid 
anhydride (99 %),  dichloromethane (DCM, 99.5 %), tetrahydrofurane (THF, 99.9 %), 
pyridine (99 %), 4-pentynoic acid (95 %), acetic acid (99 %), 4-methoxyophenyl isocyanate 
(99 %), phenyl isocyanate (98 %), 4-(dimethylamino)-phenyl isocyanate (97 %), propyl 
isocyanate (99 %), isopropyl isocyanates (98 %), tert-butyl isocyanate (97 %), 
2-iminothiolane hydrochloride (98 %), and toluene (99.8 %), sulfuryl chloride (97 %), sodium 
azide (95 %), acetonitril (99.8 %), imodazole (99 %), methanolic 3N HCl solution, sulfuric 
acid (30 % SO3) and di-cyclohexylcarbodiimde (99 %) were purchased from Sigma Aldrich 
and used as received. 2,3,5,6-tetra-fluoro phenol (98 %) was purchased from Acros Organics. 
For HPLC purification heptafluorobutyric acid (HFBA) (Fluka, puriss. p.a., for ion 
chromatography) and acetone (Sigma-Aldrich, HPLC grade) were used. Ultrapure water 
(specific resistance > 18.4 MΩ cm) was obtained by Milli-Q water purification system 
(Sartorius®). RNA aptamers (82 – 91 % purity) were purchased from BioSpring (Frankfurt 
am Main, Germany) and riboxx GmbH (Radebeul, Germany). For the regioselective 
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transformation Milli-Q water was treated with diethylpyrocarbonate (DEPC) and sterilized 
using an autoclave (121 °C, 20 min). 
 
4.4.2 General Procedures 
4.4.2.1 Synthesis & and Characterization of Reagents for Antibiotic Modifications 
Synthesis of Diazo-Transfer Reagent Imidazole-1-sulfonyl Azide Hydrochloride (8)24 
A volume of 1.6 mL of sulfuryl chloride (20 mmol) was added drop wise to an 
ice-cooled suspension of 1.3 g sodium azide (20 mmol) in 20 mL acetonitril 
and the mixture was stirred overnight at room temperature. Then 2.6 g of 
imidazole (38 mmol) were added portion-wise to the ice-cooled mixture and the resulting 
slurry was stirred for additional 3h at room temperature. The reaction mixture was diluted 
with ethyl acetate 40 mL, washed twice with 40 mL water and then twice with 40 mL sat. aq. 
NaHCO3 solution, dried over MgSO4 and filtered. The filtrate was cooled in an ice-batch and 
a 10 mL of a 3M HCl methanolic solution were added drop wise to precipitate the product. 
Finally, the filter cake was washed three times with 10 mL ethyl acetate to obtain 7 as 
colorless hydrochloride salt. Yield: 1.9 g (9.1 mmol, 45% yield). 1H-NMR (D2O, 400 MHz) 
δ (p.p.m.) 9.53 (s, 1H, H-2), 8.07 (s, 1H, H-5), 7.67 (s, 1H, H-4). 13C-NMR (D2O, 100.6 
MHz) δ (p.p.m.) 137.6, 122.6, 120.18. HRMS (EI+) (m/z): found 174.0078 [M-Cl]+, calc. 
174.0080 [M-Cl]+. 
 
Synthesis of Acetyl Sulfo-Succinimde Ester (4)15 
A volume of 136 µL (2.31 mmol) acetic acid and 500 mg (2.56 mmol) 
sulfo-N-hydroxysuccinimide were dissolved into 6.25 ml DMF. To 
this solution 600 mg (2.8 mmol) of 1,3-dicyclohexylcarbodiimide 
(DCC) were added and the solution was stirred for 24 hours. This 
solution was cooled to 4 °C and the precipitate (urea) is filtered. To this filtrate were added 
200 ml of a ethyl acetate – hexane (1:1) mixture and this mixture was stirred for 30 min and 
stored at 4 – 8 °C over weekend. The precipitate is collected though filtration and then dried 
in a desiccators to obtain 4 as a white solid. Yield: 353 mg (1.36 mmol, 59%). 1H-NMR (D2O, 
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(dd, 1H, J = 19.2 Hz, J =  3.2 Hz, CH2b); 2.45 (s, 3H, CH3-CO). 13C-NMR (D2O, 100.6 MHz): 
δ (p.p.m.) = 170.11, 168.90, 167.40 (3C, CO); 56.25 (1C, C-SO2); 29.50 (1C, CH2); 16.85 
(1C, CH3-CO). 
 
Synthesis of Sodium 4-(acetoxy)-2,3,5,6-tetra-fluorobenzenesulfonate (5)16 
A amount of 10.1 g of 2,3,5,6-tetrafluorophenol (61.4 mmol) were 
taken up in 22 mL fuming sulphuric acid (30 % SO3) and stirred at 
ambient temperature for 18 hours before pouring the mixture into 
200 mL iced brine. The product was precipitated by adding 6 g of 
NaCl and stirred until no further precipitate was formed. This mixture was filtered through a 
sintered glass disc and the collected solids were taken up in 330 mL boiling acetonitril, 
filtered while hot, and allowed to cool slowly to ambient temperature. The colourless 
crystalline product was collected by filtration and dried in vacuum yielding 5.42 g (20.2 
mmol, 33 % yield) of 4-sulfo-tetrafluorophenol sodium salt. 270 mg of this salt (1.0 mmol) 
and 53.8 µL of acetic acid (0.94 mmol) were dissolved in 30 mL acetone. After 230 mg DCC 
(1.1 mmol) were added, the mixture was stirred at room temperature for 20 hour. The 
resulting precipitate was removed by filtration and the filtrate was concentrated under reduced 
pressure. The crude mixture was purified by column chromatography using a 4:1 
acetone/chloroform mixture to yield 5 as a white solid: Yield 163 mg (0.53 mmol, 56 % 
yield). Rf (acetone/chloroform 4:1) = 0.55. 1H-NMR (D2O, 400 MHz) δ (p.p.m.) 2.46 (s, 3H, 
CH3-CO). 13C-NMR (D2O, 50.43 MHz): δ (p.p.m.) = 170.07 (1C, CO); 147.01 (dq), 144.09 
(ddd) (2C, 3-C-Ar, 5-C-Ar); 145.03 (dq), 142.10 (ddd) (2C, 2-C-Ar, 6-C-Ar),  131.14 (1C, C-
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4.4.2.2 Regioselective Transformation of Antibiotic´s Ring IV 
4.4.2.2.1 Acylation in C6 Position of Neomycin B 
1.) 1.5 equiv. APG apt1
2.) 15 equiv. ester 4 or 5
or 5 equiv. 6
10 mM sodium phosphate
buffer (pH ≈ 7), RT, 24 h  
10  R = methyl






Scheme 4.3: Regioselective transformation of amino group in C6 position of ring IV. 
A volume of 300 µL of a 5.54 mM RNA aptamer solution (1.66 µmol) in 10 mM sodium 
phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and was afterwards kept at room 
temperature for 15 min. Then, 228 µL of a 4.8 mM solution of neomycin B sulphate 
(1.09 µmol) in 10 mM sodium phosphate buffer (pH 7.4) were added and the mixture was 
allowed to stand for 30 min at room temperature. Then, 15 equiv. of activated ester, acetyl 
sulfo-NHS ester 4 or STP-ester 5 (16.4 µmol) in 500 µl of 10 mM sodium phosphate buffer 
(pH 7.4), or 5 equiv. of 2-iminothiolane hydrochloride (16.4 µmol) dissolved in 42 µL of 
10 mM sodium phosphate buffer (pH 7.4) were added and the reaction mixture was allowed 
to react for 24 hours at room temperature. After addition of 60 µL of aq. 7 wt. % ethylamine 
solution and further incubation for 30 min at room temperature, 162 µl (acylation with 
activated ester) or 90 µl (thiolation with 2-iminothiolane HCl) of 2M NaOH solution were 
added, heated to 85 °C for 30 min and cooled to room temperature. To obtain sufficient 
amount of aminoglycoside derivatives, this entire procedure was repeated twice and the three 
resulting reaction mixtures were combined before each 50 µL fraction was purified by HPLC 
using a Waters Spherisorb ODS-2C18 analytic column (water/acetone 1:0.81 containing 16.9 
mM HFBA) at a flow rate of 1 ml/min at 40 °C to afford the antibiotic derivatives 10 and 14. 
After evaporation of acetone and freeze drying of collected fractions the product was 
dissolved in 150 µL of D2O for NMR studies. 
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1.) 1.5 equiv. APG
2.) 15 equiv. isocyanate 7a-c
10 mM sodium phosphate
buffer (pH ≈ 7), RT, 24 h  
15a R1 = NH2, R2 = OMe
15b R1 = NH2, R2 = H
15c R1 = NH2, R2 = N(Me)2
16   R1 = OH,  R2 = OMe
1 neomycin B    R1 = NH2





7a  R2 = OMe
7b  R2 = H
7c  R2 = N(Me)2
1.) 1.5 equiv. APG




(pH ≈ 7), 
RT, 24 h  
9a  R3 = propyl
9b  R3 = isopropyl
9c  R3 = tert-butyl
19a R1 = NH2, R3 = propyl
19b R1 = NH2, R3 = isopropyl
19c R1 = NH2, R3 = tert-butyl
20a R1 = NH2, R3 = propyl
20b R1 = NH2, R3 = isopropyl
 
Scheme 4.4: Mono- and di-functionalization at ring IV of antibiotics 1 and 2. 
A volume of 300 µL of a 5.54 mM RNA aptamer solution (1.66 µmol) in 10 mM sodium 
phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and was afterwards kept at room 
temperature for 15 min.  Then, 228 µL of a 4.8 mM solution of the aminoglycoside antibiotic 
(1.09 µmol) in 10 mM sodium phosphate buffer (pH 7.4) were added and the mixture was 
allowed to stand for 30 min at room temperature. Afterwards, 15 equiv. (16.4 µmol) of 
aromatic isocyanate 7a-c or 30 equiv. (49.2 µmol) of aliphatic isocyanates 9a-c dissolved in 
36 µL DMF were added and the reaction mixture was allowed to react for 24 hours at room 
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temperature. After addition of 60 µL of aq. 7 wt. % ethylamine solution and further 
incubation for 30 min at room temperature, 93 µl of aq. 2 M NaOH solution were added and 
the crude mixture was heated to 85 °C for 30 min and cooled to room temperature. To obtain 
sufficient amount of aminoglycoside derivatives, this procedure was repeated twice and the 
three resulting reaction mixtures were combined before each 50 µL fraction was purified by 
HPLC using a Waters Spherisorb ODS-2C18 analytic column (water/acetone 1.0:0.81 
containing 16.9 mM HFBA) at a flow rate of 1 ml/min at 40 °C to afford the antibiotic 
derivatives 15a-c, 16, 19a-c and 20a-b. After evaporation of acetone and freeze drying the 
product was dissolved in 150 µL of D2O for NMR studies. 
 
4.4.2.2.3 Azide Introduction in C2 and C6 Position of Neomycin B 
1.) 1.5 equiv. APG (apt1)
2.) 8. equiv. 8 in water (pH = 8)
3.) CuSO4, Na2CO3
10 mM sodium phosphate
buffer (pH ≈ 8), RT, 24 h  






Scheme 4.5: Regioselective transformation of amino group in C2 and C6 position of ring IV. 
A volume of 300 µL of a 5.54 mM RNA aptamer solution (1.66 µmol) in 10 mM sodium 
phosphate buffer (pH 6.8) was heated to 85 °C for 10 min and was afterwards kept at room 
temperature for 15 min.  Then, 228 µL of a 4.8 mM solution of neomycin B sulphate (1.09 
µmol) in 10 mM sodium phosphate buffer (pH 7.4) were added and the mixture was allowed 
to stand for 30 min at room temperature. Afterwards, 180 µL of an aqueous solution of diazo-
transfer reagent 8 (10 mg/mL, adjusted to pH 8 by adding of approx. 25 µL aq. 2 M NaOH 
solution), were added into the solution of the aptamer complex solution. Finally, a volume of 
59 µL of an aqueous solution of sodium carbonate (10 mg/mL) and 50 µL of an aqueous 
solution of copper sulfate (2 mg/mL) were added and the mixture was allowed to react for 24 
hours at room temperature. After addition of 60 µL of aq. 7 wt. % ethylamine solution and 
further incubation for 30 min at room temperature, 125 µl of aq. 2 M NaOH solution were 
added and the crude mixture was heated to 85 °C for 30 min and cooled to room tempertaure. 
To obtain sufficient amount of aminoglycoside derivatives, this entire procedure was repeated 
twice and the three resulting reaction mixtures were combined before each 50 µL fraction was 
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purified by HPLC using a Waters Spherisorb ODS-2C18 analytic column (water/acetone 
1.0:0.81 containing 16.9 mM HFBA) at a flow rate of 1 ml/min at 40 °C to afford the 
antibiotic derivatives 17 and 18. After evaporation of acetone and freeze drying of collected 
fractions the product was dissolved in 150 µL of D2O for NMR studies. 
 
4.4.3 Characterization of Synthesized Antibiotic Derivatives 
6´´´-N-acetyl neomycin B x 5 HFBA (10). The title compound was prepared according to the 
general procedure described above. Derivative 10 was obtained as 
a white solid. For the measurement of regioselectivity and the 
characterization of the compound 1H-NMR, HSQC as well as 
APT spectra were recorded and electro spray ionization (ESI) MS 
was employed. The yield was calculated from 1H-NMR- and 
HPLC peak integrals: Rt = 7.5 min, 30 % yield (apt1). TLC 
(CHCl3/MeOH/17% NH4OH 2:1:1 v/v/v) Rf = 0.52. 1H-NMR 
(D2O, 500 MHz) δ (p.p.m.) 6.06 p.p.m. (d, J = 4 Hz, 1H, 1-H´), 
5.44 (d, J = 2 Hz, 1H, 1-H´´), 5.20 (d, J = 1.5 Hz, 1H, 1-H´´´), 4.44 (t, J = 5.75 Hz, 1H, 3-H´´), 
4.39 (dd, J = 5 Hz, J = 2 Hz, 1H, 2-H´´), 4.26 (t, J = 3 Hz, 1H, 3-H´´´), 4.24 (m, 1H, 4-H´´), 
4.09 (t, J = 6.75 Hz, 1H, 5-H´´´), 4.07 (m, 1H, 4-H),  4.01 (t, J = 10 Hz, 1H, 5-H´), 3.98 – 3.92 
(m, 3H, 5-Ha´´, 5-H, 3-H´), 3.76 (dd, 1H, J = 12.5 Hz, J = 5.5 Hz, 5-Hb´´), 3.72- 3.68 (m, 2H, 
4-H´´´, 6-H), 3.60 (dd, J = 14 Hz, J = 7.5 Hz, 1H, 6-Ha´´´), 3.56  (m, 2H, 3-H, 2-H´´´),  3.53-
3.41 (m, 4H, 6-Ha´, 2-H´, 6-Hb´´´, 4-H´), 3.38 (m, 1H, 1-H),  3.32  (dd, J = 14 Hz, J = 6 Hz, 
1H, 6-Hb´), 2.51 (dt, J = 12.5 Hz; J = 3.8 Hz, 1H, 2-Heq), 2.04 (s, 3H, CH3), 1.89 (dd, J = 12.7 
Hz, 1H, 2-Hax). APT (D2O, 125.7 MHz) δ (p.p.m.) 174.49 (Carbonyl-C), 110.00 (C-1´´), 
95.51 (C-1´´´), 95.49 (C-1´), 84.62 (C-5), 81.66 (C-4´´), 75.39 (C-3´´), 75.29 (C-4), 73.58 (C-
2´´), 72.45 (C-5´´´), 72.42 (C-6), 70.35 (C-4´), 69.22 (C-3´), 67.88 (C-5´), 67.56 (C-3´´´), 
66.10 (C-4´´´), 60.00 (C-5´´), 53.15 (C-2´), 50.90 (C-2´´´), 49.65 (C-1), 48.16 (C-3), 39.85 
(C-6´), 39.33 (C-6´´´), 27.88 (C-2), 21.74 (CH3). MS (EI+) (m/z): found 657.33008 [M+H]+, 
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6´´´-N-γ-sulfhydryl-propionyl neomycin B x 5 HFBA (14). The title compound was 
prepared according to the general procedure described above. 
Derivative 14 was obtained as a white solid. For the measurement 
of regioselectivity and the characterization of the compound 1H-
NMR and HSQC spectra were recorded and electro spray 
ionization (ESI)-MS was employed. The yield was calculated 
from 1H-NMR- and HPLC peak integrals: Rt = 16.3 min, 30 % 
yield (apt1). 1H-NMR (D2O, 500 MHz) δ (p.p.m.) 6.03 (s, 1H, 1-
H´), 5.42 (s, 1H, 1-H´´), 5.18 (s, 1H, 1-H´´´), 4.44-4.35 (m, 2H, 3-
H´´, 2-H´´), 4.26-4.12 (m, 2H, 3-H´´´, 4-H´´), 4.11-4.04 (m, 2H, 4-H, 5-H´´´), 4.00 (t, J = 10.3 
Hz, 1H, 3-H´), 3.96-3.89 (m, 3H, 5-H, 5-H´, 5-Ha´´), 3.77-3.67 (m, 3H, 5-Hb´´, 6-H, 4-H´´´), 
3.58-3.43 (m, 7H, 3-H, 2-H´´´, 6-Ha´´´, 6-Hb´´´, 6-Ha´, 4-H´, 2-H´), 3.37 (dt, J = 10.5 Hz, J = 
4.5 Hz, 1H, 1-H), 3.28 (dd, J = 14 Hz, J = 6 Hz, 1H, 6-Hb´), 2.75 (q, J = 7 Hz, 2H, γ-CH2), 
2.50 (dt, J = 12.5 Hz, J = 3.5 Hz, 1H, 2-Heq), 2.38 (t, J = 7.3 Hz, 2H, α-CH2), 2.02-1.87 (m, 
3H, β-CH2, 2-Hax). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 110.3 (C-1´´), 
95.9 (C-1´´´), 95.6 (C-1´), 84.9 (C-5), 81.8 (C-4´´), 76.1 (C-3´´), 75.4 (C-4), 74.1 (C-2´´), 72.8 
(C-5´´´), 72.5 (C-6), 70.8 (C-4´), 69.5 (C-3´), 68.2 (C-5´), 67.7 (C-3´´´), 66.4 (C-4´´´), 60.5 
(C-5´´), 53.6 (C-2´), 51.1 (C-2´´´), 49.9 (C-1), 48.5 (C-3), 40.2 (C-6´), 39.5 (C-6´´´), 37.0 (γ-
CH2), 34.2 (α-CH2), 28.0 (C-2), 24.6 (β-CH2). MS (EI+) (m/z): found 717.32732 [M+H]+, 
739.30863 [M+Na]+; calculated 717.33350 [M+H]+, 739.31544 [M+Na]+. 
2´´´-N-[(4-methoxyphenyl)amino]carbonyl neomycin B x 5 HFBA (15a). The title 
compound was prepared according to the general 
procedure described above. Derivative 15a was 
obtained as a white solid. For the measurement of 
regioselectivity and the characterization of the 
compound 1H-NMR and HSQC spectra were recorded 
and ESI-MS was employed. The yield was calculated 
from 1H-NMR- and HPLC peak integrals: Rt = 15.0 
min, 44 % yield (apt1). TLC (CHCl3/MeOH/17% NH4OH 2:1:1 v/v/v) Rf = 0.45. 1H-NMR 
(D2O, 500 MHz) δ (p.p.m.) 7.23 (d, J = 9 Hz, 2H, Ar-H3, Ar-H5), 7.00 (d, J = 9 Hz, 2H, 
Ar-H2, Ar-H6),  6.05 (d, J = 3.5 Hz, 1H, 1-H´), 5.42 (d, J = 1.5 Hz, 1H, 1-H´´), 5.11 (s, 1H, 
1-H´´´), 4.43 (t, J = 5.25 Hz, 1H, 3-H´´), 4.33 (m, 1H, 2-H´´), 4.26-4.19 (m, 2H, 5-H´´´, 
4-H´´), 4.12-4.07 (m, 2H, 4-H, 2-H´´´), 4.04 (m, 1H, 3-H´´´),  4.00 (t, J = 14.5 Hz, 1H, 5-H´), 









































114 | P a g e  
 
4-H´´´), 3.55 (dt, J = 3 Hz, J = 9.5 Hz, 1H, 3-H), 3.51-3.41 (m, 3H, 2-H´, 4-H´, 6-Ha´),  
3.38-3.28 (m, 4H, 1-H, 6-Ha´´´, 6-Hb´´´, 6-Hb´), 2.50 (dt, J = 11.5 Hz; J = 3 Hz, 1H, 2-Heq), 
1.90 (dd, J = 12.7 Hz, 1H, 2-Hax). APT (D2O, 125.7 MHz) δ (p.p.m.) 158.47 (Carbonyl-C), 
156.10 (Ar-C4), 130.32 (Ar-C1), 125.11 (2C, Ar-C2,C6), 114.93 (2C, Ar-C3,C5), 110.12 
(C-1´´), 98.72 (C-1´´´), 95.64 (C-1´), 84.75 (C-5), 82.05 (C-4´´), 75.82 (C-3´´), 74.95 (C-4), 
74.31 (C-2´´), 72.79 (C-6), 70.61 (C-4´), 70.18 (C-5´´´), 69.78 (C-3´´´), 69.41 (C-3´), 68.07 
(C-4´´´), 67.93 (C-5´), 60.00 (C-5´´), 55.58 (CH3), 53.36 (C-2´), 51.13 (C-2´´´), 49.75 (C-1), 
48.42 (C-3), 40.61 (C-6´´´), 39.95 (C-6´), 27.93 (C-2). MS (EI+) (m/z): found 764.36742 
[M+H]+, 786.34508 [M+Na]+; calculated 764.36724 [M+H]+, 786.34918 [M+Na]+. 
2´´´-N-(phenylamino)carbonyl neomycin B x 5 HFBA (15b). The title compound was 
prepared according to the general procedure described 
above. Derivative 15b was obtained as a white solid. For 
the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC 
spectra were recorded and ESI-MS was employed. The 
yield was calculated from 1H-NMR- and HPLC peak 
integrals: Rt = 18.2 min, 51 % yield (apt1). TLC 
(CHCl3/MeOH/17% NH4OH 2:1:1 v/v/v) Rf = 0.48.  1H-NMR (D2O, 500 MHz) 1H-NMR 
(D2O, 500 MHz) δ (p.p.m.)  7.38 (t, J = 7.75 Hz, 2H, Ar-H3, Ar-H5), 7.30 (d, J = 8.0 Hz, 2H, 
Ar-H2, Ar-H6), 7.18 (t, J = 7.25 Hz, 1H, Ar-H4),  6.03 (d, J = 3.5 Hz, 1H, 1-H´), 5.40 (s, 1H, 
1-H´´), 5.16 (s, 1H, 1-H´´´), 4.43 (t, J = 5.25 Hz, 1H, 3-H´´), 4.34 (m, 1H, 2-H´´), 4.24 (t, 
J = 4.5 Hz, 1H, 5-H´´´), 4.18 (m, 1H, 4-H´´), 4.11-4.03 (m, 3H, 4-H, 2-H´´´, 3-H´´´),  3.99 (t, 
J = 10.00 Hz, 1H, 5-H´), 3.95 – 3.85 (m, 3H, 5-Ha´´, 5-H, 3-H´), 3.72-3.67 (m, 3H, 5-Hb´´, 
6-H, 4-H´´´), 3.54 (dt, J = 10Hz, J = 3 Hz, 1H, 3-H),  3.49-3.39 (m, 3H, 2-H´, 4-H´, 6-Ha´), 
3.36-3.31 (m, 3H, 1-H, 6a-H´´´, 6-Hb´´´),  3.27 (dd, J = 14 Hz, J = 7 Hz, 1H, 6-Hb´), 2.49 (dt, J 
= 12 Hz; J = 4 Hz, 1H, 2-Heq), 1.90 (dd, J = 12.5 Hz, 1H, 2-Hax). 13C-signals based on HSQC 
spectrum (D2O, 500 MHz) δ (p.p.m.) 129.5 (2C, Ar-C3,C5), 124.7 (Ar-C4), 121.9 (2C, Ar-
C2,C6), 110.1 (C-1´´), 98.6 (C-1´´´), 95.3 (C-1´), 84.9 (C-5), 81.8 (C-4´´), 75.6 (C-3´´), 74.3 
(C-4), 74.1 (C-2´´), 72.4 (C-6), 70.8 (C-4´), 70.4 (C-5´´´), 70.0 (C-3´´´), 69.5 (C-3´), 68.2 (C-
4´´´), 68.1 (C-5´), 60.2 (C-5´´), 53.5 (C-2´), 50.9 (C-2´´´), 49.8 (C-1), 48.5 (C-3), 40.7 (C-
6´´´), 40.2 (C-6´), 27.9 (C-2); signals of quaternary carbons (CO, Ar-C1) are missing due to 
the fact that they are not detectable by HSQC spectroscopy. MS (EI+) (m/z): found 734.35551 
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2´´´-N-[4-(N,N-dimethylamino)phenyl]carbonyl neomycin B x 6 HFBA (15c). The title 
compound was prepared according to the general 
procedure described above. Derivative 15c was 
obtained as a white solid. For the measurement of 
regioselectivity and the characterization of the 
compound 1H-NMR and HSQC spectra were 
recorded and ESI-MS was employed. The yield was 
calculated from 1H-NMR- and HPLC peak integrals: 
Rt = 16.9 min, 48 % yield (apt1). TLC (CHCl3/MeOH/17% NH4OH 2:1:1 v/v/v) Rf = 0.53. 
1H-NMR (D2O, 500 MHz) 1H-NMR (D2O, 500 MHz) δ (p.p.m.) 7.50 (m, 4H, Ar-H2, Ar-H3, 
Ar-H5, Ar-H6),  6.01 (d, J = 3.5 Hz, 1H, 1-H´), 5.39 (d, J = 2 Hz, 1H, 1-H´´), 5.12 (d, J = 1.5 
Hz, 1H, 1-H´´´), 4.44 (t, J = 5.0 Hz, 1H, 3-H´´), 4.36 (m, 1H, 2-H´´), 4.25 (t, J = 4.25 Hz, 1H, 
5-H´´´), 4.14 (m, 1H, 4-H´´), 4.11-4.08 (m, 3H, 4-H, 2-H´´´, 3-H´´´),  3.99 (m, 1H, 5-H´), 3.92 
– 3.87 (m, 3H, 5-Ha´´, 5-H, 3-H´), 3.77 (s,br, 1H, 4-H´´´),  3.73-3.66 (m, 2H, 5-Hb´´, 6-H), 
3.53 (td, J = 11.5 Hz, J = 3.5 Hz, 1H, 3-H), 3.48-3.42 (m, 3H, 2-H´, 6-Ha´, 4-H´),  3.41-3.31 
(m, 3H, 6-Ha´´´, 6-Hb´´´, 1-H) , 3.27 (dd, J = 13.5 Hz, J = 6.5 Hz, 1H, 6-Hb´),  3.24 (s, 6H, 
N(CH3)2), 2.48 (dt, J = 12.5 Hz; J = 2.5 Hz, 1H, 2-Heq), 1.90 (dd, J = 12.5 Hz, 1H, 2-Hax). 13C-
signals based on HSQC spectrum (D2O, 500 MHz) δ (p.p.m.) 121.1, 121.2 (4C, Ar-C2,Ar-C3, 
Ar-C5,Ar-C6), 110.1 (C-1´´), 98.3 (C-1´´´), 95.4 (C-1´), 84.7 (C-5), 81.3 (C-4´´), 75.4 (C-3´´), 
75.1 (C-4), 74.0 (C-2´´), 72.3 (C-6), 70.4 (C-4´), 70.2 (C-5´´´), 69.7 (C-3´´´), 69.2 (C-3´), 68.0 
(C-4´´´), 67.8 (C-5´), 59.9 (C-5´´), 53.3 (C-2´), 50.6 (C-2´´´), 49.6 (C-1), 48.2 (C-3), 46.2 (2C, 
N(CH3)2), 40.4 (C-6´´´), 39.9 (C-6´), 27.7 (C-2); signals of quaternary carbons (CO, Ar-C1, 
Ar-C4) are missing due to the fact that they are not detectable by HSQC spectroscopy. MS 
(EI+) (m/z): found 777.39821 [M+H]+, 799.37998 [M+Na]+; calculated 777.39887 [M+H]+, 
799.38082 [M+Na]+. 
2´´´-N-[(4-methoxyphenyl)amino]carbonyl paromomycin x 4 HFBA (16). The title 
compound was prepared according to the general 
procedure described above. Derivative 16 was 
obtained as a white solid. For the measurement of 
regioselectivity and the characterization of the 
compound 1H-NMR and HSQC spectra were recorded 
and ESI-MS was employed. The yield was calculated 
from 1H-NMR- and HPLC peak integrals: Rt = 7.4 
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(D2O, 600 MHz) δ (p.p.m.) 7.24 (d, J = 9 Hz, 2H, Ar-H2), 7.01 (d, J = 9 Hz, 2H, Ar-H3),  
5.81 (d, J = 3.5 Hz, 1H, 1-H´), 5.37 (d, J = 1.5 Hz, 1H, 1-H´´), 5.12 (s, 1H, 1-H´´´), 4.46 (t, 
J = 5.5 Hz, 1H, 3-H´´), 4.33 (m, 1H, 2-H´´), 4.23 (t, J = 5.5 Hz, 1H, 5-H´´´), 4.18 (m, 1H, 
4-H´´), 4.09-4.01 (m, 3H, 4-H, 2-H´´´, 3-H´´´), 3.93-3.85 (m, 4H, 5-Ha´´, 6-Ha´, 3-H´, 5-H), 
3.83 (s, 3H, OCH3), 3.80-3.68 (m, 4H, 5-H´, 5-Hb´´, 6-Hb´, 4-H´´´), 3.71 (t, J = 9.5 Hz, 1H, 6-
H), 3.56 (t, J = 9.75 Hz, 1H, 3-H), 3.51 (t, J = 7.75 Hz, 1H, 4-H´), 3.44 (dd,  J = 11.0 Hz, J =  
4.0 Hz,  m, 1H, 2-H´), 3.38-3.30  (m, 3H, 6-Ha´´´, 6b-Hb´´´, 1-H), 2.50 (dt, J = 13.0 Hz; J = 
4.0 Hz, 1H, 2-Heq), 1.86 (dd, J = 12.0 Hz, 1H, 2-Hax). 13C-signals based on HSQC (D2O, 600 
MHz) δ (p.p.m.) 125.3 (2C, Ar-C2, C6), 114.9 (2C, Ar-C3, C5), 110.1 (C-1´´), 98.7 (C-1´´´), 
96.2 (C-1´), 84.5 (C-5), 81.9 (C-4´´), 77.4 (C-4), 75.7 (C-3´´), 74.2 (C-2´´), 74.1 (C-5´), 72.4 
(C-6), 70.5 (C-5´´´), 70.0 (C-3´´´), 69.4 (C-4´), 69.0 (C-3´), 68.3 (C-4´´´), 60.4, 60.3  (2C, C-
5´´, C-6´), 55.8 (CH3), 53.9 (C-2´), 51.1 (C-2´´´), 49.8 (C-1), 49.1 (C-3), 40.8 (C-6´´´), 28.2 
(C-2); signals of quaternary carbons (CO, Ar-C1, Ar-C4) are missing due to the fact that they 
are not detectable by HSQC spectroscopy.  MS (EI+) (m/z): found 765.35071 [M+H]+, 
787.33215 [M+Na]+; calculated 765.35126 [M+H]+, 787.33320 [M+Na]+. 
6´´´-azido neomycin B x 5 HFBA (17). The title compound was prepared according to the 
general procedure described above. Derivative 17 was obtained as 
a white solid. For the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC spectra 
were recorded and electros pray ionization (ESI)-MS was 
employed. The yield was calculated from 1H-NMR- and HPLC 
peak integrals: Rt = 13.0 min, 46 % yield (apt1). 1H-NMR (D2O, 
500 MHz) δ (p.p.m.) 6.00 (d, J = 3.5 Hz, 1H, 1-H´), 5.43 (s, 1H, 
1-H´´), 5.26 (s, 1H, 1-H´´´), 4.49 (dd, J = 7 Hz, J = 5 Hz, 1H , 3-H´´), 4.44 (d, J = 4.5 Hz, 1H, 
2-H´´), 4.26-4.20 (m, 3H, 3-H´´´, 4-H´´, 5-H´´´), 4.06 (t, J = 9.5 Hz, 1H, 4-H), 4.01-3.92 (m, 
4H, 3-H´, 5-Ha´´, 5-H, 5-H´), 3.78-3.66 (m, 4H, 5-Hb´´, 6-Ha´´´, 4-H´´´, 6-H), 3.52-3.36 (m, 
2H, 2-H´´´, 3-H), 3.51-3.43 (m, 4H, 4-H´, 6-Ha´, 6-Hb´´´, 2-H´), 3.37 (dt, J = 11.8 Hz, J = 4.5 
Hz, 1H, 1-H), 3.30 (dd, J = 14 Hz, J = 6.5 Hz, 1H, 6-Hb´), 2.50 (dt, J = 12.5 Hz, J = 4.3 Hz, 
1H , 2-Heq), 1.90 (dd, J = 12.5 Hz, 1H, 2-Hax). 13C-signals based on HSQC (D2O, 500 MHz) δ 
(p.p.m.) 110.2 (C-1´´), 95.6 (C-1´), 95.2 (C-1´´´), 84.6 (C-5), 81.4 (C-4´´), 75.3 (C-4), 75.1 
(C-3´´), 73.7 (C-5´´´), 73.4 (C-2´´), 72.5 (C-6), 70.5 (C-4´), 69.3 (C-3´), 67.9 (C-5´), 67.7 (C-
3´´´), 66.5 (C-4´´´), 60.2 (C-5´´), 53.4 (C-2´), 50.9 (C-6´´´), 50.8 (C-2´´´), 49.6 (C-1), 48.2 (C-
3), 39.9 (C-6´), 27.9 (C-2). MS (EI+) (m/z): found 641.30845 [M+H]+,  663.28839 [M+Na]+; 
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3´´´,6´´´-di-azido neomycin B x 4 HFBA (18). The title compound was prepared according to 
the general procedure described above. Derivative 18 was 
obtained as a white solid. For the measurement of regioselectivity 
and the characterization of the compound 1H-NMR and HSQC 
spectra were recorded and electro spray ionization (ESI)-MS was 
employed. The yield was calculated from 1H-NMR- and HPLC 
peak integrals:  Rt = 8.9 min, 16 % yield (apt1). 1H-NMR (D2O, 
500 MHz) δ (p.p.m.) 6.04 (d, J = 3 Hz, 1H, 1-H´), 5.47 (s, 1H, 1-
H´´), 5.17 (d, J = 1 Hz, 1H , 1-H´´´), 4.49 (dd, J = 5.5 Hz, J = 4 Hz, 1H, 3-H´´), 4.45 (dd, J = 4 
Hz, J = 2 Hz, 1H, 2-H´´), 4.28 (dt, J = 5.3 Hz, J = 2 Hz, 1H, 4-H´´), 4.16-4.13 (m, 2H, 3-H´´´, 
5-H´´´), 4.08 (t, J = 8.3 Hz, 1H, 4-H), 4.03-3.94 (m, 4H, 5-H´, 3-H´, 5-Ha´´, 5-H), 3.90 (m, 
1H, 2-H´´´), 3.78 (dd, J = 10.5 Hz, J = 4.5 Hz, 1H, 5-Hb´´), 3.72-3.67 (m, 2H, 6-Ha´´´, 6-H), 
3.62 (m, 1H, 4-H´´´), 3.56 (dt, J = 9.3 Hz, J = 3.5 Hz, 1H, 3-H), 3.53-3.44 (m, 4H, 6-Ha´, 6-
Hb´´´, 2-H´, 4-H´), 3.39 (dt, J = 9.5 Hz, J = 3.5 Hz, 1H, 1-H), 3.32 (dd, J = 11.5 Hz, J = 5 Hz, 
1H, 6-Hb´), 2.52 (dt, J = 10.5 Hz, J = 3.5 Hz, 1H, 2-Heq), 1.92 (dd, J = 10.5 Hz, 1H, 2-Hax). 
13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 110.2 (C-1´´), 98.1 (C-1´´´), 95.7 (C-
1´), 84.6 (C-5), 81.5 (C-4´´), 75.3 (C-4), 74.7 (C-3´´), 74.3 (C-5´´´), 73.2 (C-2´´), 72.4 (C-6), 
70.3 (C-4´), 69.2 (C-3´´´), 69.0 (C-3´), 67.8 (C-5´), 67.2 (C-4´´´), 60.3 (C-5´´), 59.6 (C-2´´´), 
53.2 (C-2´), 50.8 (C-6´´´), 49.8 (C-1), 48.2 (C-3), 39.8 (C-6´), 28.1 (C-2). MS (EI+) (m/z): 
found 667.29664 [M+H]+, 689.27895 [M+Na]+; calculated 667.30056 [M+H]+, 689.28250 
[M+Na]+. 
2´´´-N-(propylamino)carbonyl neomycin B x 5 HFBA (19a). The title compound was 
prepared according to the general procedure described 
above. Derivative 19a was obtained as a white solid. 
For the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC 
spectra were recorded and electros pray ionization 
(ESI)-MS was employed. The yield was calculated 
from 1H-NMR- and HPLC peak integrals: Rt = 11.6 
min, 21 % yield (apt1). 1H-NMR (D2O, 500 MHz) δ (p.p.m.) 6.03 (d, J =4 Hz, 1H, 1-H´), 5.40 
(s, 1H, 1-H´´), 5.07 (s, 1H, 1-H´´´), 4.40 (t, J = 5.5 Hz, 1H, 3-H´´), 4.32 (dd, J = 4 Hz, J = 2 
Hz, 1H, 2-H´´), 4.22 (t, J = 4.3 Hz, 1H, 5-H´´´), 4.15 (dt, J = 6.8 Hz, J = 3 Hz, 1H, 4-H´´), 
4.08 (t, J = 9.8 Hz, 1H, 4-H), 4.01-3.97 (m, 3H, 5-H´, 3-H´´´, 2-H´´´), 3.95-3.88 (m, 3H, 3-H´, 
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3.49-3.41 (m, 3H, 4-H´, 6-Ha´, 2-H´), 3.39-3.22 (m, 3H, 6-Ha´´´, 6-Hb´´´, 1-H), 3.29 (dd, J = 
13.5 Hz, J = 6.5 Hz, 1H, 6-Hb´), 3.04 (q, J = 6.6 Hz, 2H, α-CH2), 2.49 (dt, J = 12.5 Hz, J = 3.8 
Hz, 1H, 2-Heq), 1.89 (dd, J = 12.5 Hz, 1H, 2-Hax), 1.45 (q, J = 7.2 Hz, 2H, β-CH2), 0.85 (t, J = 
7.3 Hz, 3H, CH3). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 110.0 (C-1´´), 98.8 
(C-1´´´), 95.4 (C-1´), 84.8 (C-5), 81.7 (C-4´´), 75.8 (C-3´´), 75.1 (C-4), 74.1 (C-2´´), 72.5 (C-
6), 70.5 (C-4´), 70.3 (C-5´´´), 70.0 (C-3´´´), 69.4 (C-3´), 68.1 (C-4´´´), 68.0 (C-5´), 60.1 
(C-5´´), 53.4 (C-2´), 50.9 (C-2´´´), 49.6 (C-1), 48.3 (C-3), 41.6 (α-CH2), 40.5 (C-6´´´), 39.9 
(C-6´), 27.9 (C-2), 22.4 (β-CH2), 10.3 (CH3); signal of quaternary carbon (CO) is missing due 
to the fact that it is not detectable by HSQC spectroscopy.  MS (EI+) (m/z): found 700.36911 
[M+H]+, 722.34964 [M+Na]+; calculated 700.37233 [M+H]+, 722.35427 [M+Na]+. 
2´´´-N-(isopropylamino)carbonyl neomycin B x 5 HFBA (19b). The title compound was 
prepared according to the general procedure described 
above. Derivative 19b was obtained as a white solid. For 
the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC 
spectra were recorded and electro spray ionization (ESI)-
MS was employed. The yield was calculated from 1H-
NMR- and HPLC peak integrals: Rt = 12.1 min, 32 % 
yield (apt1). 1H-NMR (D2O, 500 MHz) δ (p.p.m.) 6.03 (d, J = 3.5 Hz, 1H, 1-H´), 5.40 (s, 1H, 
1-H´´), 5.06 (s, 1H, 1-H´´´), 4.41 (t, J = 5.3 Hz, 1H 3-H´´), 4.33 (dd, J = 5 Hz, J = 2.5 Hz, 1H, 
2-H´´), 4.22 (t,  J = 5.3 Hz, 1H, 5-H´´´), 4.15 (t, J = 5 Hz, 1H, 4-H´´), 4.09 (t, J = 9.8 Hz, 1H, 
4-H), 4.02-3.98 (m, 3H, 5-H´, 3-H´´´, 2-H´´´), 3.95-3.89 (m, 3H, 3-H´, 5-H, 5-Ha´´), 3.75-3.66 
(m, 4H, 4-H´´´, 6-H, 5-Hb´´, CH(CH3)2), 3.55 (dt, J = 11.3 Hz, J = 4 Hz, 1H, 3-H), 3.50-3.42 
(m, 3H, 4-H´, 6-Ha´, 2-H´), 3.37-3.33 (m, 3H, 6-Ha´´´, 6-Hb´´´, 1-H), 3.29 (dd, J = 13.5 Hz, J 
= 6 Hz, 1H, 6-Hb´), 2.50 (dt, J = 12 Hz, J = 3.5 Hz, 1H, 2-Heq), 1.90 (dd, J = 12 Hz, 1H, 2-
Hax), 1.09 (d, J = 6.5 Hz, 6H, CH3). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 
110.0 (C-1´´), 98.72 (C-1´´´), 95.4 (C-1´), 84.9 (C-5), 81.8 (C-4´´), 75.7 (C-3´´), 75.1 (C-4), 
74.2 (C-2´´), 72.4 (C-6), 70.6 (C-4´), 70.3 (C-5´´´), 70.0 (C-3´´´), 69.4 (C-3´), 68.1 (C-4´´´), 
68.0 (C-5´), 60.1 (C-5´´), 53.4 (C-2´), 50.9 (C-2´´´), 49.7 (C-1), 48.4 (C-3), 42.2 (CH(CH3)2), 
40.6 (C-6´´´), 40.0 (C-6´), 27.9 (C-2), 22.0 (2C, CH(CH3)2); signal of quaternary carbon (CO) 
is missing due to the fact that it is not detectable by HSQC spectroscopy.  MS (EI+) (m/z): 
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2´´´-N-(tert-butylamino)carbonyl neomycin B x 5 HFBA (19c). The title compound was 
prepared according to the general procedure described 
above. Derivative 19c was obtained as a white solid. For 
the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC 
spectra were recorded and electro spray ionization (ESI)-
MS was employed. The yield was calculated from 1H-
NMR- and HPLC peak integrals: Rt = 13.2 min, 38 % 
yield (apt1). 1H-NMR (D2O, 500 MHz) δ (p.p.m.) 5.98 (d, J = 4 Hz, 1H, 1-H´), 5.38 (s, 1H, 1-
H´´), 4.91 (d, J = 2.5 Hz, 1H, 1-H´´´), 4.35 (m, 2H, 2-H´´, 3-H´´), 4.22-4.16 (m, 2H, 4-H´´, 5-
H´´´), 4.03 (t, J = 9.8 Hz, 1H, 4-H), 3.97-3.92 (m, 3H, 5-H´, 2-H´´´, 3-H´´´), 3.92-3.87 (m, 
3H, 3-H´, 5-H, 5-Ha´´), 3.70-3.56 (m, 3H, 6-H, 5-Hb´´, 4-H´´´), 3.53 (dt, J = 11.3 Hz, J = 4 Hz, 
1H, 3-H), 3.47-3.37 (m, 3H, 4-H´, 6-Ha´, 2-H´), 3.35-3.30 (m, 3H, 6-Ha´´´, 6-Hb´´´, 1-H), 3.26 
(dd, J = 15 Hz, J = 5.5 Hz, 1H, 6-Hb´), 2.48 (dt, J = 12.5 Hz, J = 3 Hz, 1H, 2-Heq), 1.88 (dd, J 
= 11.5 Hz, 1H, 2-Hax), 1.16 (s, 9H, CH3). 13C-signals based on HSQC (D2O, 500 MHz) δ 
(p.p.m.) 110.9 (C-1´´), 97.91 (C-1´´´), 95.7 (C-1´), 85.0 (C-5), 81.4 (C-4´´), 74.3 (C-3´´), 74.0 
(C-4), 73.7 (2C, C-2´´, C-5´´´), 72.4 (C-6), 70.4 (C-4´), 70.4 (C-3´´´), 69.4 (C-3´), 68.1 (C-5´), 
68.7 (C-4´´´), 60.8 (C-5´´), 53.4 (C-2´), 51.4 (C-2´´´), 49.7 (C-1), 48.4 (C-3), 40.4 (C-6´), 40.0 
(C-6´´´), 27.9 (C-2), 24.3 (3C, CH3); signals of quaternary carbons (CO, C(CH3)3) are missing 
due to the fact that they are not detectable by HSQC spectroscopy. MS (EI+) (m/z): found 
714.38522 [M+H]+, 736.36821 [M+Na]+; calculated 714.38798 [M+H]+, 736.36992 
[M+Na]+. 
2´´´,6´´´-bis-N-(propylamino)carbonyl neomycin B x 4 HFBA (20a). The title compound 
was prepared according to the general procedure 
described above. Derivative 20a was obtained as a 
white solid. For the measurement of regioselectivity 
and the characterization of the compound 1H-NMR 
and HSQC spectra were recorded and electro spray 
ionization (ESI)-MS was employed. The yield was 
calculated from 1H-NMR- and HPLC peak integrals: 
Rt = 9.6 min, 31 % yield (apt1). 1H-NMR (D2O, 500 
MHz) δ (p.p.m.) 6.05 (d, J = 4 Hz, 1H, 1-H´), 5.39 (s, 1H, 1-H´´), 4.98 (s, 1H, 1-H´´´), 4.37-
4.32 (m, 2H, 3-H´´, 2-H´´), 4.16 (dt, J = 5.5 Hz, J = 2.5 Hz, 1H, 4-H´´), 4.09 (t, J = 9.8 Hz, 
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Ha´´), 3.73-3.68 (m, 2H, 5-Hb´´, 6-H), 3.65 (m, 1H, 4-H´´´), 3.56 (dt, J = 11.3 Hz, 3.5 Hz, 1H, 
3-H), 3.50 (t, J = 9.5 Hz, 1H, 4-H´), 3.48-3.35 (m, 5H, 6-Ha´, 2-H´, 6-Ha´´´, 6-Hb´´´, 1-H), 
3.31 (dd, J = 14 Hz, J = 6.5 Hz, 1H, 6-Hb´), 3.06 (2xq, J = 6.5 Hz, 4H, α-CH2), 2.50 (dt, J = 12 
Hz, J = 3.8 Hz, 1H, 2-Heq), 1.90 (dd, J = 12.5 Hz, 1H, 2-Hax), 1.47 (2xq, J = 7 Hz, 4H, β-CH2), 
0.87 (2xt, J = 7.5 Hz, 6H, CH3).13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 110.2 
(C-1´´), 99.3 (C-1´´´), 95.8 (C-1´), 85.0 (C-5), 82.2 (C-4´´), 76.1 (C-3´´), 75.4 (C-4), 74.4 (C-
2´´), 73.6 (C-5´´´), 72.7 (C-6), 70.7 (C-4´), 70.3 (C-3´´´), 69.5 (C-3´), 68.2 (C-5´), 67.1 (C-
4´´´), 60.5 (C-5´´), 53.7 (C-2´), 51.4 (C-2´´´), 50.0 (C-1), 48.6 (C-3), 41.9 (2C, α-CH2), 40.2 
(C-6´), 40.0 (C-6´´´), 28.0 (C-2), 22.6 (2C, β-CH2), 10.6 (2C, CH3); signals of quaternary 
carbons (2x CO) are missing due to the fact that they are not detectable by HSQC 
spectroscopy.  MS (EI+) (m/z): found 785.42184 [M+H]+, 807.40231 [M+Na]+; calculated 
807.40703 [M+H]+, 679.31207 [M+Na]+. 
2´´´,6´´´-bis-N-(isopropylamino)carbonyl neomycin B x 4 HFBA (20b). The title 
compound was prepared according to the general 
procedure described above. Derivative 20b was obtained 
as a white solid. For the measurement of regioselectivity 
and the characterization of the compound 1H-NMR and 
HSQC spectra were recorded and electro spray ionization 
(ESI)-MS was employed. The yield was calculated from 
1H-NMR- and HPLC peak integrals: Rt = 9.8 min, 17 % 
yield (apt1). 1H-NMR (D2O, 500 MHz) δ (p.p.m.) 6.04 
(d, J = 3 Hz, 1H, 1-H´), 5.39 (s, 1H, 1-H´´), 4.98 (s, 1H, 1-H´´´), 4.35 (t, J = 5 Hz, 1H, 3-H´´), 
4.33 (dd, J = 4.5 Hz, J = 2.5 Hz, 1H, 2-H´´), 4.15 (dt, J = 5.5 Hz, J = 3 Hz, 1H, 4-H´´), 4.08 (t, 
J = 9.5 Hz, 1H, 4-H), 4.01-3.97 (m, 3H, 3-H´´´, 5-H´, 5-H´´´), 3.95-3.89 (m, 4H, 2-H´´´, 3-H´, 
5-H, 5-Ha´´), 3.73-3.67 (m, 4H, CH(CH3)2, 5-Hb´´, 6-H), 3.64 (m, 1H, 4-H´´´), 3.55 (dt, J = 
11.5 Hz, J = 4 Hz, 1H, 3-H), 3.49 (t, J = 9.5 Hz, 1H, 4-H´), 3.47-3.43 (m, 2H, 6-Ha´, 2-H´), 
3.40-3.34 (m, 3H, 6-Ha´´´, 6-Hb´´´, 1-H), 3.30 (dd, J = 13.5 Hz, J = 6.5 Hz, 1H, 6-Hb´), 2.50 
(dt, J = 12.5 Hz, J = 3.5 Hz, 1H, 2-Heq), 1.90 (dd, J = 12.5 Hz, 1H, 2-Hax), 1.11 (2xd, J = 6.5 
Hz, 12H, CH(CH3)2). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 109.9 (C-1´´), 
98.8 (C-1´´´), 95.4 (C-1´), 84.6 (C-5), 81.8 (C-4´´), 75.7 (C-3´´), 75.0 (C-4), 74.0 (C-2´´), 73.1 
(C-5´´´), 72.2 (C-6), 70.4 (C-4´), 69.9 (C-3´´´), 69.2 (C-3´), 67.8 (C-5´), 66.7 (C-4´´´), 60.1 
(C-5´´), 53.3 (C-2´), 51.0 (C-2´´´), 49.6 (C-1), 48.2 (C-3), 42.0 (2C, CH(CH3)2), 39.8 (C-6´), 
39.5 (C-6´´´), 27.9 (C-2), 21.9 (4C, CH(CH3)2); signals of quaternary carbons (2x CO) are 
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found 785.42180 [M+H]+, 807.40221 [M+Na]+; calculated 807.40703 [M+H]+, 679.31207 
[M+Na]+. 
 
4.4.4 NMR-Spectra of Neomycin B & Synthesized Antibiotic Derivatives 
 









Figure 4.10b: HSQC (500 MHz, D2O) spectrum of neomycin B x 6 HFBA 1 
 
Chapter 4 
































APGs Enable Various Transformations in Different Positions of Neamine Antibiotics 





Figure 4.12a: 1H-NMR (500 MHz, D2O) spectrum of 6´´´-N-γ-sulfhydryl-propionyl neomycin B x 5 
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Figure 4.13a: 1H-NMR (500 MHz, D2O) spectrum of 2´´´-N-[(4-methoxyphenyl)amino]carbonyl 








Figure 4.13b: HSQC (500 MHz, D2O) spectrum of 2´´´-N-[(4-methoxyphenyl)amino]carbonyl 
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Figure 4.14a: 1H-NMR (600 MHz, D2O) spectrum of 2´´´-N-[(4-methoxyphenyl)amino]carbonyl 
paromomycin x 4 HFBA 16. 
 
 
Figure 4.14b: HSQC (600 MHz, D2O) spectrum of 2´´´-N-[(4-methoxyphenyl)amino]carbonyl 









Figure 4.15a: 1H-NMR (500 MHz, D2O) spectrum of 6´´´-azido neomycin B  x 5 HFBA 17. 
 
 






APGs Enable Various Transformations in Different Positions of Neamine Antibiotics 
127 | P a g e  
 
 


































128 | P a g e  
 






























APGs Enable Various Transformations in Different Positions of Neamine Antibiotics 
129 | P a g e  
 
 
Figure 4.18a: 1H-NMR (500 MHz, D2O) spectrum of 6´´´, 2´´´ bis-N-(propylamino)carbonyl 






















Figure 4.18b: HSQC (500 MHz, D2O) spectrum of 6´´´, 2´´´ bis-N-(propylamino)carbonyl 
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Figure 4.19: ESI-MS spectrum after transformation of neomycin B with 8 equiv. diazo-transfer 
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Figure 4.20: ESI-MS spectrum after transformation of neomycin B with 30 equiv. propyl isocyanate 9a 
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Figure 4.21: ESI-MS spectrum after transformation of neomycin B with 30 equiv. isopropyl isocyanate 
9b in absence of APG (v-vi = number of introduced urea groups). 
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Figure 4.22: ESI-MS spectrum after transformation of neomycin B with 30 equiv. isopropyl isocyanate 
9c in absence of APG (v-vi = number of introduced urea groups). 
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Figure 4.23: HPLC elugram after transformation of neomycin B (NeoB) with 30 (1), 15 (2) and 5 (3) 



















Figure 4.24: HPLC elugram after transformation of neomycin B (NeoB) with 15 equiv. p-methoxy 





















Figure 4.25: HPLC elugram after transformation of paromomycin with 15 equiv. p-methoxy phenyl 
isocyanate 7a in presence of APG apt1 (i = one urea group was introduced). 
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Figure 4.26: HPLC elugram after transformation of neomycin B (NeoB) using 8 equiv. of diazo-



















Figure 4.27: HPLC elugram after transformation of neomycin B (NeoB) with 30 equiv. propyl 
isocyanate 9a in presence of APG apt1 (i-ii = number of introduced urea groups). 
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Regioselective One-Step Diazo-Transfer Reaction 
in C3 Position of Neamine Antibiotics 




Since the mechanism of bacterial resistance against neamine antibiotics is well 
understood, modification of aminoglycosides is becoming a promising tool to overcome 
antibacterial resistance. However, regioselective derivatization of aminoglycoside 
antibiotics requires extensive total synthetic pathways or enzymatic approaches. 
Therefore, several methods were recently established allowing specific site modification 
of aminoglycosides. However, derivatization of the C3 position of the 
2-desoxystreptamine ring in neamine antibiotics is restricted to enzymatic 
transformations. Here, we demonstrate a regioselective azide introduction in C3 position 
of diverse neamine antibiotics in a single step in aqueous buffer solution. In this study 
we show that the high regioselectivity is driven by the difference of pKa value of the 
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5.1 Introduction 
Aminoglycosides represent one of the largest classes of antibacterials with activity against 
Gram negative and Gram positive bacteria. These antibiotics exert their antibacterial activity 
by binding to the decoding site (A-site) in prokaryotic 16S ribosomal RNA.1-3 However, 
increased bacterial resistance against aminoglycoside antibiotics4-6 forced activities to modify 
these scaffolds to obtain new active compounds.7 Especially the neamine moiety 1 of these 
antibiotics shown in Figure 5.1 attracted major attention, since the bacterial resistance is 
mainly based on the enzymatic modifications at ring I and II. The introduction of negatively 
charged phosphate groups at ring II by 3´-phosphotranferase (APH-3´) and erasing of positive 
charges at ring II and I by acetyltranferases (ACCs) reduces their biological activity.8 Thus, 
chemical derivatization of the hydroxy group at the C3 position of ring II and transformations 
at the amino group in the C1 position of ring I were carried out to overcome bacterial 
resistance.9,10 For example, the acylation of the amino group in C1 position of the 
2-desoxystreptamine ring (2-DOS, ring I) enabled the facile development of the 
semi-synthetic antibiotic amikacin 2 (Fig. 5.1). However, due to the presence of multiple 
hydroxy- and amino groups with similar reactivity, most regioselective modifications of 
aminoglycoside antibiotics require multi-step synthesis.9,11-13 Therefore, several methods were 
established enabling facile regioselective introduction of functionalities in structurally 
complex molecules. These methods are based on non-covalent protective group strategies14,15 
or enzymatic approaches.16,17 Moreover, derivatization of the C3 position of 2-DOS ring is 
still a challenge and was successfully realized only for neamine 1 by extensive synthetic 
routes resulting in low overall yield.11,18 In this study, we describe a one-step modification of 
the same position within structurally more complex aminoglycoside antibiotics without the 
use of enzymes, covalent or non-covalent protective groups. This synthetic shortcut is based 
on regioselective azide introduction in C3 position at ring I of neamine antibiotics 3-6 (Fig. 
5.1) in a single step employing a diazo-transfer reagent. This cost-efficient and highly scalable 
method does not require any protection or deprotection steps and is performed in aqueous 
solution.       
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3 neomycin B      R = NH2
4 paromomycin   R = OH
I
II
1 neamine 2 amikacin































Figure 5.1: Chemical structure of neamine 1 and aminoglycoside antibiotics 2-6. The red structural unit 
corresponds to 2-desoxystreptamine ring (2-DOS). 
 
 
5.2 Result & Discussion 
5.2.1 Identification of Reaction Conditions for Regioselective Azide 
Introduction 
To enable the regioselective azide introduction in neamine antibiotics, imidazole-1-sulfonyl 
azide 7 was applied as a diazo-transfer reagent (Scheme 5.1). The “diazo donor” 7 has been 
recently introduced as a shelf-stable, non-explosive and water soluble reagent.19 Moreover, it 
has proven to be a straightforward tool to convert free amines into azides via an aqueous 





Scheme 5.1: Azide introduction applying imidazole-1-sulfonyl azide 7 as diazo-transfer reagent. 
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The crystalline and more stable hydrochloride of 7 was applied to a wide range of molecules 
resulting in excellent yields and reasonable reaction times.19 Another advantage of this reagent 
is a good functional group tolerance and high reactivity even in absence of metal catalyst, 
such as copper(II), nickel(II) or zinc(II).20 In 2011, van Hest et al. applied imidazole-1-
sulfonyl azide hydrochloride 7.HCl to introduce an azide in proteins.20 It was shown that the 
N-terminus could be selectively transformed, while more basic amines of lysine residues were 
not converted at lower pH values and in absence of a catalyst. Inspired by this work, we tested 
the applicability of 7.HCl for the regioselective azide introduction to neomycin B 3, which 
has several amine groups with pKa values ranging from 5.7 to 8.8 (Fig 5.2).21 In particular, the 




pKa-1    = 8.04














Figure 5.2: Chemical structure of neomycin B. The pKa values of the amino groups of neomyicin B 
were determined by NMR spectroscopy by Botto and coworkers.21  
 
 
Firstly, it was tested whether all amino groups of antibiotic 3 are reactive with 7.HCl. 
Transformation was carried out under basic conditions and in presence of Cu(II) sulfate as a 
catalyst. After a reaction time of 18 hours the number of reacted amino groups was 
determined by Electrospray Ionisation Mass Spectroscopy (ESI-MS). As shown in Figure 
5.3a, applying eight equivalents of 7.HCl all six amino groups of neomycin B 3 were reactive 
in presence Cu(II) ions and of sodium carbonate at pH 8. To decrease the activity of some 
amino groups, antibiotic 3 was reacted in absence of the catalyst (Fig. 5.3b). According to 
mass spectrometric analysis, under these conditions only four amino groups of neomycin B 
were reactive. Similar results were obtained in previous studies when Lysozyme was 
employed as a substrate for 7.HCl.20  
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Figure 5.3: ESI-MS spectra of neomycin B (NeoB) after azide introduction using 8 equiv. of diazo-
transfer reagent 7.HCl at different pH values performed in presence and absence of Cu(II) (i-vi = 
number of introduced amino groups). 
 
 
To investigate the influence of the pH value on the reactivity of 7 with aminoglycoside 3, we 
carried out the same set of reactions at slightly lower pH, i.e. pH = 7. As shown in Figure 
5.3c, up to five amino groups of neomycin B are still reactive in presence of Cu(II), while in 
the absence of the catalyst only one amine was converted and traces of a second amine 
reacted (Fig. 5.3d). Despite the utilization of eight equivalents of diazo-transfer reagent 
7.HCl, five out of six amino groups seemed not to be reactive. Furthermore, we compared the 
conversion of neomycin B with 7.HCl under the most and less reactive conditions by High 
Performance Liquid Chromatography (HPLC) analysis. As shown in Figure 5.4a, the 
transformation of 3 at pH 8 in presence of Cu(II) results in a mixture of derivatives exhibiting 
three to six azide groups. Whereas, in absence of Cu(II) and at neutral pH the transformation 
of antibiotic 3 resulted mainly in mono-azido neomycin B derivatives reaching a conversion 
of 82 % (Fig. 5.4b).  
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Figure 5.4: HPLC elugrams of neomycin B (NeoB) after transformation using eight equivalents of 7.HCl as 
diazo-transfer reagent in presence of Cu(II) at pH 8 (a) and in absence of Cu(II) at pH 7 (b) (i-vi = number 
of introduced amino groups). 
 
 
Conclusively, we successfully indentified conditions to enable a transformation of a single 
amino group of neomycin B in aqueous solution. Thus, applying a buffer solution of pH 7 and 
eight equivalents of diazo-transfer reagent 7.HCl a single amine of antibiotic 3 is transformed 
to an azide without the use of metal catalysts. 
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5.2.2 Identification of the Position of Diazotation   
In the next step, the HPLC fraction containing mono-azido neomycin B derivatives was 
purified and characterized by 1D- and 2D-NMR spectroscopy to determine at which position 
the azide was introduced. As shown in Figure 5.5a, neomycin B was transformed 
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Figure 5.5: a, Regioselective azide introduction in C3 position of 2-DOS ring applying diazo-transfer 
reagent 7.HCl. b, Section of HSQC (500 MHz, D2O) spectrum of neomycin B. c, Section of HSQC 
(500 MHz, D2O) spectrum of antibiotic derivative 8. Arrow indicates the chemical shift of J(C3-H) 
coupling. 
 
The HSQC spectrum of derivative 8 (Fig. 5.5c) shows that the amino group in C3 position of 
2-DOS ring reacted regioselectively. In comparison to the 2D-spectrum of neomycin B (Fig. 
5.5b) the J(C3-H) coupling shows a remarkable chemical shift to lower field proving the 
regioselective azide introduction at this position. As determined by 1H-NMR spectroscopy 
(see experimental part Fig. 5.7a), the regioselectivity of the reaction is approx. 90 %. The 
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selective transformation of the amino group in C3 position can be explained by differences of 
the basicity of the amine. While five out of six amino groups have a pKa value ranging from 
7.55 to 8.8, the amine in C3 position of the 2-DOS ring is acidic with a pKa of 5.74 (Fig. 
5.2)21. Therefore, only this amino group is mainly accessible for the reagent 7.HCl under 
applied conditions, while all other amines are protonated and inactive for transformation.  
 
 
5.2.3 Regioselective Azide Introduction in Other Neamine Antibiotics 
To test whether other antibiotics exhibiting the neamine moiety can be transformed selectively 
at the same position, we investigated the azide introduction using diazo-transfer reagent 
7.HCl employing neamine 1, amikacin 2 paromomycin 4, ribostymacin 5, and apramycin 6 as 
substrates (Scheme 5.2). Mass spectrometric analysis confirmed the result previously obtained 
for neomycin B showing high activity of mainly one amino group (see experimental part 
5.4.7). As shown in Scheme 5.2, all applied aminoglycosides 1, 2, 3, 4, 5, 6 were transformed 
at the C3 position of the 2-DOS ring resulting in aminoglycoside derivatives 9-13 even when 
applying an excess of 16 equivalents of 7.HCl. All substrates were successfully converted 
with high regioselectivity ranging from 90 % to 98 % and yields between 40 % and 62 %. 
While for the transformation of antibiotics 3 and 4 a regioselectivity of approx. 90 % was 
measured, the modification of aminoglycosides 1, 2, 5 and 6 proceeded with regioselectivities 
higher than 95%. 
The regioselective azide introduction at the 2-DOS ring is a very useful modification, since 
this functionality can be applied for further chemical diversifications, i.e. Staudinger and 
Huisgen reaction.22,23 As shown in Scheme 5.3, the transformation of an azide allows the 
introduction of carbamates, primary amine and amides24 and can be reacted with acetylenes 
via “click reaction” resulting in 1,2,3-triazoles.23 Since these reactions can also be applied in 
aqueous solution, the water soluble aminoglycoside derivatives 8-13 (Scheme 5.2) can be 
directly transformed in an additional reaction step to a wide range of new promising 
antibiotics without any protection and deprotection steps. 
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Scheme 5.2: Yields and regioselectivities of transformation of neamine antibiotics using imidazole-1-
sulfonyl azide 7.HCl. Reactions were performed according the general procedure (see experimental 
part 5.4.3) using 16 equiv. diazo-transfer reagent 7.HCl at room temperature and 18 hours reaction 
time. Yields were calculated from HPLC- and 1H-NMR peak integrals. Regioselectivities (r.s.) were 
calculated using 1H-NMR spectroscopy.  
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In this chapter, imidazole-1-sulfonyl azide hydrochloride 7.HCl was successfully applied as 
diazo-transfer reagent for regioselective azide introduction in neamine antibiotics without the 
application of protective group chemistry. We demonstrated that the reactivity of amino 
groups within aminoglycoside antibiotics can be controlled by addition of catalyst and 
changing the pH value. It was demonstrated, that the key to the regioselective transformation 
of the amino group in C3 position of the 2-desoxystreptamine ring is its low pKa value. 
Therefore, high regioselectivities (up to 98%) were reached applying carefully chosen 
conditions for the transformation of the antibiotics. This facile one-step modification at the C3 
position of neamine antibiotics will accelerate the development of new promising antibiotics 
overcoming antibacterial resistance.   
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5.4 Experimental Section 
5.4.1 Materials & Methods 
1H-NMR- and heteronuclear single-quantum correlation (HSQC) spectra and Attached Proton 
Test (ATP) were recorded on a Varian Unity Inova (500 MHz for 1H-NMR and HSQC, 125 
MHz for APT) and Oxford AS400 (400 MHz for 1H-NMR and 100.6 MHz for APT and 13C-
NMR) NMR spectrometer at 25 °C. High resolution mass spectrometry (HRMS) was carried 
out on a LTQ ORBITRAP XL instrument (Thermo Scientific) employing electron impact 
ionization in positive ion mode (EI+). Chromatographic separations were carried out on a 
Shimadzu VP series HPLC modular system (DGU-14A3 Online Vacuum-Degasser, two LC-
20 AT pumps, SIL-20A auto sampler, CTP-20 A column oven, RID-10 refractive detector, 
FRC-10 A fraction collector and Shimadzu LCsolution software). HPLC purification was 
performed with a Waters Spherisorb ODS-2 C18 analytical (250 x 4.6 mm) and semi-
preparative column (250 x 10mm) (spherical particles of 5 µm and 80 Å pore size) using 
isocratic elution at 40 °C. A pH-meter (Hanna Instruments pH 209) equipped with a glass 
combination electrode was used for pH adjustments of the reaction buffers. 
All chemicals and reagents were purchased from commercial suppliers and used without 
further purification, unless otherwise noted. Neomycin B trisulfate x hydrate (VETRANAL®), 
paromomycin sulfate salt (98 %), ribostamycin sulfate salt, apramycin sulfate salt, amikacin 
sulfate salt, sulfuryl chloride (97 %), sodium azide (95 %), acetonitril (99.8 %), imidazole 
(99 %) and methanolic 3N HCl solution were purchased from Sigma Aldrich and used as 
received. For HPLC purification heptafluorobutyric acid (HFBA) (Fluka, puriss. p.a., for ion 
chromatography) and acetone (Sigma-Aldrich, HPLC grade) were used. Ultrapure water 
(specific resistance > 18.4 MΩ cm) was obtained by Milli-Q water purification system 
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5.4.2 Synthesis of Diazo-Transfer Reagent, Imidazole-1-sulfonyl Azide 7 
Hydrochloride19 
A volume of 1.6 mL of sulfuryl chloride (20 mmol) was added drop wise to an 
ice-cooled suspension of 1.3 g sodium azide (20 mmol) in 20 mL acetonitrile 
and the mixture was stirred overnight at room temperature. Then 2.6 g of 
imidazole (38 mmol) were added portion-wise to the ice-cooled mixture and the resulting 
slurry was stirred for additional 3h at room temperature. The reaction mixture was diluted 
with 40 mL ethyl acetate, washed twice with 40 mL water and then twice with 40 mL sat. 
aqueous NaHCO3 solution, dried over MgSO4 and filtered. The filtrate was cooled in an ice-
batch and a 10 mL of a 3M HCl methanolic solution were added drop wise to precipitate the 
product. Finally, the filter cake was washed three times with 10 mL EtOAc to obtain 7 as 
colorless hydrochloride salt. Yield: 1.9 g (9.1 mmol, 45% yield). 1H-NMR (D2O, 400 MHz) 
δ (p.p.m.) 9.53 (s, 1H, H-2), 8.07 (s, 1H, H-5), 7.67 (s, 1H, H-4). 13C-NMR (D2O, 100.6 
MHz) δ (p.p.m.) 137.6, 122.6, 120.18. HRMS (EI+) (m/z): found 174.0078 [M-Cl]+, calc. 
174.0080 [M-Cl]+. 
 
5.4.3 General Procedures for Regioselective Azide Introduction 
7.HCl
10 mM sodium phosphate
buffer (pH 7), RT, 18 h
16 equiv.
R = H, alkyl
2-DOS
Scheme 5.4: Regioselective transformation in C3 position of 2-desoxystreptamine (2-DOS) ring in 
neamine antibiotics. 
 
Synthesis of Antibiotic Derivatives, 3-Azido Neomycin B 8 and 3-Azido Paromomycin 11: 
After 11 µmol aminoglycoside antibiotic were dissolved in 7.5 mL of 10 mM sodium 
phosphate buffer (pH 7.3), 3.7 mL of a 48 mM aqueous solution of diazo-transfer reagent 
7.HCl, which was adjusted to pH 8.0 by adding aq. 2 M NaOH solution, were added into the 
solution of the antibiotic and the reaction mixture was stirred for 18h at room temperature. 
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incubating at room temperature for 30 min the reaction mixture was freeze dried. Then the 
crude mixture was dissolved in 1.5 mL water and each 30 µL fraction was purified by HPLC 
using a Waters Spherisorb ODS-2C18 analytic column (water/acetone 1:0.9 containing 12.1 
mM HFBA) at a flow rate of 1 ml/min at 40°C to afford the antibiotic derivatives 8 and 11.  
 
Synthesis of Antibiotic Derivatives 3-Azido Amikacin 10 and 3-Azido Apramycin 13: 
After 11 µmol aminoglycoside antibiotic were dissolved in 7.5 mL of 10 mM sodium 
phosphate buffer (pH 7.3), 3.7 mL of a 48 mM aqueous solution of diazo-transfer reagent 
7.HCl, which was adjusted to pH 8.0 by adding 2 M NaOH solution, were added into the 
solution of the antibiotic and the reaction mixture was stirred for 18h at room temperature. By 
addition of 1 M aqueous HCl solution a pH value of 2 was adjusted and each 100 µL fraction 
was purified by HPLC using a Waters Spherisorb ODS-2C18 analytic column (water/acetone 
1:0.9 containing 12.1 mM HFBA) at a flow rate of 1 ml/min at 40°C to afford the antibiotic 
derivatives 10 and 13. 
 
Synthesis of Antibiotic Derivatives 3-Azido Neamine 9 and 3-Azido Ribostamycin 12: 
After 11 µmol aminoglycoside antibiotic were dissolved in 7.5 mL of 10 mM sodium 
phosphate buffer (pH 7.3), 3.7 mL of a 48 mM aqueous solution of diazo-transfer reagent 
7.HCl, which was adjusted to pH 8.0 by adding 2 M NaOH solution, were added into the 
solution of the antibiotic and the reaction mixture was stirred for 18h at room temperature. The 
reaction was quenched by adding 0.9 mL aqueous 7 wt % ethylamine solution. After 
incubating at room temperature for 30 min, the reaction mixture was freeze dried and the 
crude mixture was purified by column chromatography using the upper layer of the two phase 
system CHCl3/MeOH/17%NH3 2:1:1 as eluent. After evaporation at reduced pressure and 
freeze drying the antibiotic derivatives was dissolved in 1.5 mL water. Each 30 µL fraction 
was purified by HPLC using a Waters Spherisorb ODS-2C18 analytic column (water/acetone 
1:0.9 containing 12.1 mM HFBA) at a flow rate of 1 ml/min at 40°C to afford the antibiotic 
derivatives 9, 12. 
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5.4.4 Characterization of Synthesized Antibiotic Derivatives 
 
C-3-azido neomycin B x 5 HFBA (8). The title compound was prepared according to the 
general procedure described above. Derivative 8 was obtained as 
a white solid. For the measurement of regioselectivity and the 
characterization of the compound 1H-NMR, HSQC and APT 
spectra were recorded and electrospray ionization (ESI)-MS was 
employed. The yield was determined by HPLC: Rt = 7.7 min, 47 
% yield. TLC: Rf = 0.57 (CHCl3/MeOH/17%NH3 2:1:1 v/v/v). 
1H-NMR (D2O, 500 MHz) δ (p.p.m.) 5.72 (d, J = 4 Hz, 1H, 1-H´), 
5.33 (d, J = 1.5 Hz, 1H, 1-H´´), 5.26 (s, 1H, 1-H´´´), 4.40 (t, J = 5.5 Hz, 1H, 3-H´´), 4.37 (dd, 
J = 4.5 Hz, J = 2 Hz, 1H, 2-H´´), 4.28 (t, J = 5 Hz, 1H, 5-H´´´), 4.27 (m, 1H, 5-H´), 4.21 (m, 
2H, 3-H´´´, 4-H´´), 3.91-3.85 (m, 2H, 5-Ha´´, 3-H´), 3.80-3.75 (m, 3H, 4-H´´´, 5-H, 3-H), 
3.72-3.67 (m, 2H, 4-H, 5-Hb´´), 3.58 (t, J = 10 Hz, 1H, 6-H), 3.56 (s(br), 1H, 2-H´´´), 3.47-
3.33 (m, 5H, 6-Ha´, 6-Ha´´´, 6-Hb´´´, 4-H´, 2-H´), 3.26 (dt, J = 11.25 Hz, J = 3.5 Hz, 1H, 1-H), 
3.19 (dd, J = 13.5 Hz, J = 8 Hz, 1H, 6-Hb´), 2.47 (dt, J = 13 Hz, J = 4 Hz, 1H , 2-Heq), 1.70 
(dd, J = 12.3 Hz, 1H, 2-Hax). APT (D2O, 125.7 MHz) δ (p.p.m.) 109.84 (C-1´´), 94.51 
(C-1´´´), 94.30 (C-1´), 84.89 (C-5), 80.48 (C-4´´), 76.26 (C-4), 74.86 (C-3´´), 72.84 (C-2´´), 
71.72 (C-6), 69.81 (C-4´), 69.05 (C-5´´´), 68.00 (C-3´), 67.68 (C-5´), 66.77 (C-3´´´), 66.72 
(C-4´´´), 59.88 (C-5´´), 58.14 (C-3), 53.01 (C-2´), 50.15 (C-2´´´), 49.21 (C-1), 39.67 (C-6´´´), 
39.55 (C-6´), 28.72 (C-2). M = C23H44N8O13; HRMS (EI+) (m/z): found 641.30652 [M+H]+, 
calc. 657.31006 [M+H]+. 
 
C-3-azido paromomycin x 4 HFBA (11). The title compound was prepared according to the 
general procedure described above. Derivative 11 was obtained as 
a white solid. For the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC and 
spectra were recorded and electrospray ionization (ESI)-MS was 
employed. The yield was determined by HPLC: Rt = 5.9 min, 44 
% yield. TLC: Rf = 0.64 (CHCl3/MeOH/17%NH3 2:1:1 v/v/v). 
1H-NMR (D2O, 500 MHz) δ (p.p.m.) 5.72 (d, J = 3 Hz, 1H, 1-H´), 
5.33 (s, 1H, 1-H´´), 5.26 (s, 1H, 1-H´´´), 4.48 (t, J = 5.5 Hz, 1H, 3-H´´), 4.38 (d, J = 4 Hz, 1H, 
2-H´´), 4.28 (m, 1H, 5-H´´´), 4.22-4.16 (m, 2H, 3-H´´´, 4-H´´), 4.02 (d, J = 9.5 Hz, 1H, 5-H´), 
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3H, 5-Hb´´, 4-H, 3-H), 3.57 (t, J = 10 Hz, 1H, 6-H), 3.56 (s(br), 1H, 2-H´´´), 3.50 (t, J = 9.75 
Hz, 1H 4-H´), 3.44 (dd, J = 17.5 Hz, J = 9.5 Hz, 1H, 6-Ha´´´), 3.39-3.34 (m, 2H, 6-Hb´´´, 2-
H´), 3.25 (dt, J = 11.5 Hz, J = 3.5 Hz, 1H , 1-H), 2.44 (dt, J = 12.5 Hz, J = 4Hz, 1H, 2-Heq), 
1.67 (dd, J = 12.15 Hz, 1H, 2-Hax). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 
110.3 (C-1´´), 95.11 (C-1´), 94.9 (C-1´´´), 85.3 (C-5), 80.67 (C-4´´), 76.8 (C-4), 74.9 (C-3´´), 
73.1 (C-2´´), 72.5 (C-5´), 72.2 (C-6), 69.9 (C-5´´´), 69.1 (C-3´), 68.7 (C-4´), 67.3 (C-3´´´), 
67.0 (C-4´´´), 60.0 (C-5´´), 59.6 (C-6´), 58.4 (C-3), 53.8 (C-2´), 50.5 (C-2´´´), 49.6 (C-1), 40.0 
(C-6´´´), 29.1 (C-2). C23H43N7O14; HRMS (EI+) (m/z): found 642.29346 [M+H]+, calc. 
642.29408 [M+H]+. 
 
C-3-azido ribostamycin x 3 HFBA (12). The title compound was prepared according to the 
general procedure described above. Derivative 12 was obtained as a 
white solid. For the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC spectra 
were recorded and electrospray ionization (ESI)-MS was 
employed. The yield was determined by HPLC: Rt = 4.1 min, 48 % 
yield. TLC: Rf = 0.73 (CHCl3/MeOH/17%NH3 2:1:1 v/v/v). 
1H-NMR (D2O, 500 MHz) δ (p.p.m.) 5.77 (d, J = 3.5 Hz, 1H, 1-H´), 5.31 (d, J = 1.5 Hz, 1H, 
1-H´´), 4.28 (dt, J = 9 Hz, J = 3 Hz, 1H, 5-H´), 4.21 (dd, J = 4.5 Hz, J = 3Hz, 1H, 2-H´´), 4.15 
(t, J = 7.5 Hz, J = 4.5 Hz, 1H, 3-H´´), 4.05 (dt, J = 6.5 Hz, J = 2.5 Hz, 1H, 4-H´´), 3.93-3.88 
(m, 2H, 5-Ha´´, 3-H´), 3.82-3.72 (m, 3H, 3-H, 5-H, 4-H), 3.65 (dd, H = 12.5 Hz, J = 6.5 Hz, 
1H, 5-Hb´´), 3.60 (t, J = 9.8 Hz, 1H, 6-H), 3.48-3.43 (m, 2H, 4-H´, 6-Ha´), 3.39 (dd, J = 10.5 
Hz, J= 4.0 Hz, 1H, 2-H´), 3.29 (dt, J = 11.5 Hz, J = 4.0 Hz, 1H, 1-H), 3.23 (dd, J = 13.5 Hz, J 
= 7.5 Hz, 1H 6-Hb´), 2.50 (dt, 12.5 Hz, J = 4.0 Hz, 1H, 2-Heq), 1.73 (dd, J = 12.5 Hz, 1H, 
2-Hax). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 110.6 (C-1´´), 95.0 (C-1´), 
85.5 (C-5), 82.1 (C-4´´), 76.7 (C-4), 75.0 (C-2´´), 72.3 (C-6), 70.3 (C-4´), 68.9 (C-3´´), 68.8 
(C-3´), 68.3 (C-5´), 60.9 (C-5´´), 58.4 (C-3), 53.5 (C-2´), 49.5 (C-1), 39.9 (C-6´), 29.1 (C-2). 
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C-3-azido neamine x 3 HFBA (9). The title compound was prepared according to the general 
procedure described above. Derivative 9 was obtained as a white 
solid. For the measurement of regioselectivity and the 
characterization of the compound 1H-NMR and HSQC spectra 
were recorded and electrospray ionization (ESI)-MS was 
employed. The yield was determined by HPLC: Rt = 2.3 min, 60 % 
yield. TLC: Rf = 0.71 (CHCl3/MeOH/17%NH3 2:1:1 v/v/v).  1H-NMR (D2O, 500 MHz) δ 
(p.p.m.) 5.69 (d, J = 3.5 Hz, 1H, 1-H´), 4.23 (t, J = 9.0 Hz, 1H, 5-H´), 3.93 (t, J = 10.0 Hz, 1H, 
3-H´), 3.80 (dt, J = 10.8 Hz, J = 5.0 Hz, 1H, 3-H), 3.68 (t, J = 9.3 Hz, 1H, 5-H), 3.63 (t, J = 
9.0 Hz, 1H, 4-H), 3.53 (t, J = 9.8 Hz, 1H, 6-H), 3.50-3.46 (m, 2H, 4-H´, 6-Ha´), 3.43 (dd, J = 
11.0 Hz, J = 3.5 Hz, 1H, 2-H´), 3.32-3.24 (dt, 2H, 1-H, 6-Hb´), 2.51 (dt, J = 13.0 Hz, J = 4.5 
Hz, 1H, 2-Heq), 1.77 (dd, J = 12.5 Hz, 1H, 2-Hax). 13C-signals based on HSQC (D2O, 500 
MHz) δ (p.p.m.) 95.4 (C-1´), 78.8 (C-5), 74.8 (C-4), 72.2 (C-6), 70.3 (C-4´), 68.6 (C-3´), 68.2 
(C-5´), 58.2 (C-3), 53.3 (C-2´), 49.4 (C-1), 39.7 (C-6´), 29.1 (C-2). C12H24N6O6; HRMS (EI+) 
(m/z): found 349.18066 [M+H]+, calc. 349.18301 [M+H]+. 
 
C-3-azido amikacin x 4 HFBA (10). The title compound was prepared according to the 
general procedure described above. Derivative 10 was 
obtained as a white solid. For the measurement of 
regioselectivity and the characterization of the compound 
1H-NMR and HSQC spectra were recorded and 
electrospray ionization (ESI)-MS was employed. The 
yield was determined by HPLC: Rt = 3.7 min, 65 % 
yield. TLC: Rf = 0.34 (CHCl3/MeOH/17%NH3 2:1:1 v/v/v). 1H-NMR (D2O, 500 MHz) δ 
(p.p.m.) 5.50 (d, J = 4 Hz, 1H, 1-H´), 5.14 (d, J = 3.5 Hz, 1H, 1-H´´), 4.26 (dd, J = 9 Hz, J = 
3.5 Hz, 1H, α-Ha), 4.17 (dt, J = 8.8 Hz, J = 3 Hz, 1H, 5-H´), 4.09-4.04 (m, 2H, 1-H, 3-H´), 
3.80 (s, 2H, 6-H´´a, 6-H´´b), 3.78-3.71 (m, 4H, 6-H, 5-H, 5-H´´, 2-H´´), 3.69-3.66 (m, 2H, 4-
H´, 3-H), 3.62-3.55 (m, 2H, 2-H´, 4-H), 3.44-3.35 (m, 3H, 6-Ha´, 3-H´´, 4-H´´), 3.23-3.16 (m, 
3H, 6-Hb´, γ-Ha, γ-Hb), 2.22-2.13 (m, 2H, 2-Heq, β-Ha), 1.95 (m, 1H, β-Hb), 1.66 (dd, J = 12.7 
Hz, 1H, 2-Hax). 13C-signals based on HSQC (D2O, 500 MHz) δ (p.p.m.) 98.1 (C-1´), 97.2 (C-
1´´), 80.5 (C-4), 78.9 (C-6), 74.4 (C-5), 71.7 (C-5´´), 71.1 (C-3´), 70.6 (C-2´), 70.1 (C-4´), 
68.9 (C-α), 67.5 (C-5´), 67.5 (C-2´´), 64.7 (C-4´´), 59.0 (C-6´´), 58.6 (C-3), 54.6 (C-3´´), 48.2 
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missing due to the fact that it is not detectable by HSQC spectroscopy. M = C22H41N7O13; 
HRMS (EI+) (m/z): found 612.27999 [M+H]+, calc. 612.28351 [M+H]+. 
 
C-3-azido apramycin x 4 HFBA (13). The title compound was prepared according to the 
general procedure described above. Derivative 13 
was obtained as a white solid. For the measurement 
of regioselectivity and the characterization of the 
compound 1H-NMR and HSQC spectra were 
recorded and electrospray ionization (ESI)-MS was 
employed. The yield was determined by HPLC: 
Rt = 5.8 min, 47 % yield. TLC: Rf = 0.89 (CHCl3/MeOH/17%NH3 2:1:1 v/v/v). 1H-NMR 
(D2O, 500 MHz) δ (p.p.m.) 5.52 (d, J = 4 Hz, 1H, 1-H´´), 5.51 (d, J = 4 Hz, 1H, 1-H´), 5.25 
(d, J = 8.5 Hz, 1H, 8-H´), 4.54 (s, 1H, 6-H´), 3.04-3.93 (m, 4H, 3-H´´, 5-H´´, 4-H´, 5-H´), 3.87 
(dd, J = 12.5 Hz, J = 3 Hz, 1H, 6-Ha´´), 3.81 (dd, J = 12.5 Hz, J = 4.5 Hz, 1H, 6-Hb´´), 3.73 
(dd, J = 10 Hz, J = 4 Hz, 1H, 2-H´´), 3.68-3.62 (m, 3H, 4-H, 3-H, 2-H´), 3.60 (t, J = 9 Hz, 1H, 
5-H), 3.51 (t, J = 9.8 Hz, 1H, 6-H), 3.40 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H, 7-H´), 3.82 (t, J = 
10.3 Hz, 1H, 4-H´´), 3.26 (dt, J = 11.5 Hz, J = 4 Hz, 1H, 1-H), 2.82 (s, 3H, CH3), 2.48 (dt, J = 
13 Hz, J = 4.3 Hz, 1H, 2-Heq), 2.39 (dt, J = 11 Hz, J = 4.3 Hz, 1H, 3-Heq´), 2.04 (dd, J = 12 
Hz, 1H, 3-Hax´), 1.73 (dd, J = 12.3 Hz, 1H, 2-Hax). 13C-signals based on HSQC (D2O, 500 
MHz) δ (p.p.m.) 98.8 (C-1´), 97.6 (C-1´´), 95.8 (C-8´), 83.2 (C-4), 77.9 (C-5), 75.1 (C-6), 
73.0 (C-2´´), 72.1 (C-5´), 71.9 (C-3´´), 70.9 (C-5´´), 68.6 (C-4´), 65.5 (C-6´), 62.8 (C-6´´), 
62.3 (C-7´), 61.1 (C-3), 54.6 (C-4´´), 52.4 (C-1), 50.6 (C-2´), 32.4 (N-CH3), 32.1 (C-2), 29.2 
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5.4.6 High Resolution Mass Spectrometric Analysis 




















































Figure 5.13: ESI-MS spectrum of reaction mixture of paromomycin (Paro) with 16 equiv. diazo-
transfer reagent 7.HCl after incubation for 18 hours at room temperature (i-ii = number of introduced 
azide groups). 
















































Figure 5.14: ESI-MS spectrum of reaction mixture of ribostamycin (Ribo) with 16 equiv. diazo-transfer 
reagent 7.HCl after incubation for 18 hours at room (i-ii = number of introduced azide groups). 
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Figure 5.15: ESI-MS spectrum of reaction mixture of neamine (neam) with 16 equiv. diazo-transfer 
reagent 7.HCl after incubation for 18 hours at room temperature (i-ii = number of introduced azide 
groups). 
 
Regioselective One-Step Diazo-Transfer Reaction in C3 Position of Neamine Antibiotics 
163 | P a g e  
5.5 References 
1 Moazed, D., Noller, H. F., Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 
327, 389-394 (1987).  
2 Fourmy, D., Recht, M. I., Blanchard, S. C., Puglisi, J. D., Structure of the A-site of Escherichia coli 16S 
ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274, 1367-1371 (1996).  
3 Yoshizawa, S., Fourmy, D. Puglisi, J. D., Recognition of the codon-anticodon helix by ribosomal RNA. 
Science 285, 1722-1728 (1999). 
4 Cohen, M. L. Epidemiology of drug resistance: Implications for a post-Antimicrobial Era. Science 257, 
1050-1055 (1992). 
5 Oulette, M., Kündig, C. Microbial multidrug resistance. Int. J. Antimicrob. Agents 8, 179-187 (1997). 
6 Davis, J. Inactivation of antibiotics and the dissemination of resistance genes. Science 264, 375-382 
(1994). 
7 Zhou, J., Wang, G., Zhang, L.-H., Ye, X.-S., Modifications of aminoglycoside antibiotics targeting 
RNA. Med. Res. Rev. 3, 279-316 (2007). 
8 Wright, G. D., Berghuis, A. A., Mobashery, S. Aminoglycoside antibiotics: Structure and resistance; 
Rosen, B. P., Mobashery S., Eds.; Plenum Press: New York, 27 (1998). 
9 Haddad, J., Vakulenko, S., Mobashery, S. An antibiotic cloaked by its own resistance enzyme. 
J. Am. Chem. Soc. 121, 11922-11923 (1999). 
10 Hanessian, S., Kornienko, A., Swayze, E. E. Probing the functional requirements of the l-haba side-
chain of amikacin—synthesis, 16S A-site rRNA binding, and antibacterial activity. Tetrahedron 59, 
995-1007 (2003). 
11 Alper, P. B., Hendrix, M., Sears, P. & Wong, C. H. Probing the specificity of aminoglycoside ribosomal 
RNA interactions with designed synthetic analogs. J. Am. Chem. Soc. 120, 1965-1978 (1998). 
12 Roestamadji, J., Grapsas., I., Mobashery, S. Loss of individual electrostatic interactions between 
aminoglycoside antibiotics and resistance enzymes as an effective means to overcoming bacterial drug 
resistance. J. Am. Chem. Soc. 117, 11060-11069 (1995). 
13 Pathak, R., Preze-Fernandez, D., Nandurdikar, R., Kalapala, S. K., Böttger, E. C., Vasella, A. Synthesis 
and evaluation of paromomycin derivates modified at C(4'). Helvetika Chimica Acta 91, 1533-1552 
(2008). 
14 Li, J. Chiang, F.-I, Chen, H.-N., Chang, C.-W. T. Investigation of the regioselectivity for the Staudinger 
reaction and its application for the synthesis of aminoglycosides with N-1 modification. J. Org. Chem. 
72, 4055-4066 (2007). 
15 Lee, S. H., Cheong, C. S. Selective reactions of reactive amino groups in polyamino compounds by 
metal-chelated or -mediated methods. Tetrahedron 57, 4801-4815 (2001). 
16 Green, K. D., Chen, W., Garneau-Tsodikova, S. Effects of altering aminoglycoside structures on 
bacterial resistance enzyme activities. Antimicrob. Agents Chemother. 55, 3207-3213 (2011). 
17 Samantaray, S., Marathe, U., Dasgupta, S., Nandicoori, V. K., Roy, R. P. Peptide-sugar ligation 
catalyzed by transpeptidase sortase:  A facile approach to neoglycoconjugate synthesis. J. Am. Che. Soc. 
130, 2132-2133 (2008). 
Chapter 5 
164 | P a g e  
18 Roestamadji, J., Mobashery, S. The use of neamine as a molecular template: Inactivation of bacterial 
antibiotic resistance enzyme aminoglycoside 3′-phosphotransferase type IIa. Bioorg. Med. Chem. Lett. 
8, 3483-3488 (1998).  
19 Goddard-Borger, E. D., Stick, R. V. An Efficient, Inexpensive and Shelf-Stable Diazotransfer Reagent: 
Imidazole-1-sulfonyl Azide Hydrochloride. Org. Lett. 9, 3797-3800 (2007). 
20 Schoffelen, S., van Eldijk, M. B., Rooijakkers, B., Raijmakers, R., Heck, A. J. R., Hest, J. C. M. 
Metal-free and pH-controlled introduction of azides in proteins. Chem. Sci. 2, 701-705 (2011).  
21 Botto, R. E., Coxon, B., Nitrogen-15 nuclear magnetic resonance spectroscopy of neomycin B and 
related aminoglycosides. J. Am. Chem. Soc.105, 1021-1028 (1983). 
22 Sawa, M., Hsu, T.-L., Itoh, T., Sugiyama, M., Hanson, S. R., Vogt, P. K., Wong, C.-H. Glycoproteomic 
probes for fluorescent imaging of fucosylated glycans in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 
12371-12376 (2006).  
23 Rostovtsev, V. V., Green, L. G., Fokin, V. V., Sharpless, K. B. A stepwise Huisgen cycloaddition 
process: Copper(I)-catalyzed regioselective ligation of azides and terminal Alkynes. Angew. Chem. Int. 
Ed. 41, 2596-2599 (2002). 
24 Ariza, X., Urpi, F., Vilarrasa, J. A practical procedure for the preparation of carbamates from azides. 
Terahedron Lett. 40, 7515-7517 (1999). 
25 Park, W. K. C., Auer, M., Jaksche, H., Wong, C.-H. Rapid combinatorial synthesis of aminoglycoside 
antibiotic mimetics: Use of a polyethylene glycol-linked amine and a neamine-derived aldehyde in 
multiple component condensation as a strategy for the discovery of new inhibitors of the HIV RNA Rev 












                     Summary    Samenvatting     
Streszczenie    Zusammenfassung    
 
Chapter 6 
166 | P a g e  
6.1 Summary 
Since the mechanism of bacterial resistance against neamine antibiotics is well understood, 
modification of aminoglycosides is becoming a promising tool to overcome antibacterial 
resistance. However, these natural products are structurally complex and exhibit several 
chemical equivalent groups with similar reactivity. Therefore, modification of a single 
position in these molecules is difficult or not realizable at all. Thus, the transformation of such 
natural products often results in a mixture of inseparable derivatives. To obtain a structurally 
complex natural compound modified at a single position, cumbersome and time-consuming 
part- or total synthesis is required, including the introduction and removal of covalent 
protective groups. Especially, the selective modification of antibiotics based on 
aminoglycoside can require more than 20 synthetic steps employing conventional synthesis. 
To overcome these difficulties and facilitate the development of new antibiotics, in this thesis 
two conceptually new methods were presented enabling regioselective modifications of 
neamine antibiotics in a single step.  
The first strategy (chapters one, three and four) is based on the application of non-covalent 
protective groups, so called aptameric protective groups (APGs), which are based on short 
RNA sequences. In contrast to covalent protective groups, APGs can shield several 
functionalities of a structurally complex compound at the same time by non-covalent 
interactions, while chemically equivalent groups not in contact with the APG can be reacted 
regioselectively (Scheme 6.1). In chapter 2 the efficient use of RNA sequences as APGs was 
presented for the highly regioselective derivatization of complex neamine antibiotics bearing 
several functional groups with similar reactivity. This was successfully demonstrated for 
aminoglycoside antibiotics neomycin B and paromomycin with three different RNA 
sequences. These aminoglycosides were modified employing acylation reaction using 
different N-hydroxysuccinimide esters proceeding with excellent regioselectivities up to 98 
%. With these results it was proven for the first time that RNA sequences can be applied as 
non-covalent protective groups. Another important result in the first chapter was the finding 
that the same RNA aptamers can be applied as APGs for compounds with a similar 
pharmacophore. Thus, RNA sequences selected for the antibiotic neomycin B were 
successfully applied as non-covalent protective groups for the structurally related 
aminoglycoside paromomycin.            
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Scheme 6.1: Site-specific modification of a multifunctionalized compound employing non-covalent 
aptameric protective groups: Introduction of protective group (1), regioselective transformation (2), 
removal of protective group (3).  
 
However, considering that RNA sequences can exhibit several binding site with different 
protection modes for the antibiotic, acetylation of neomycin B using NHS esters can result in 
a mixture of regioisomers and thereby limiting the regioselectivity. Therefore, the mode of 
action of RNA sequences acting as APGs needed to be elucidated. The study presented in 
chapter 3 demonstrated that the applied APGs exhibit two different binding sites with 
different protection modes for neomycin B resulting in two different monoacetylated 
antibiotic derivatives after tranfromation. However, due to the fact that both binding site have 
different affinities to the aminoglycoside, the reaction conditions especially the 
aptamer/antibiotic ratio and the reaction time were successfully adjusted in order to obtain one 
of these isomers in excellent regioselectivity. Moreover, our investigations showed that 
Isothermal Titration Calorimetry (ITC) measurements are a useful tool to estimate the 
applicability of RNA aptamers as APGs. This holds especially true when SELEX experiments 
will be employed in the future for generation of APGs for new compounds to be modified 
from which the structure of the RNA-compound complex is unknown. Finally, it was shown 
that regioselective derivatization of neomycin B in presence of APGs can also be performed 
at higher temperature (up to 50 °C) demonstrating the stability of these protective groups. 
To further establish APGs as a general tool in organic synthesis, it was proven that APGs 
tolerate a wide range of modifications including transformations at different positions of 
neamine antibiotics neomycin B and paromomycin. In chapter 4, several reactions were 
Chapter 6 
168 | P a g e  
tested regarding their applicability in the context of APGs. Four different reactions, namely 
acylation, thiolation, urea bond formation and azide introduction were successfully applied for 
the transformation of the antibiotics in presence of APG using 4-sulfo-tetra-phenyl (STP) 
ester, 2-iminothiolane, diverse isocyanates and imidazole-1-sulfonyl azide, respectively. 
Additionally, it was demonstrated that APGs allow the application of positively and 
negatively charged reagents for the modification of neomycin B and that transformations can 
also be performed under basic conditions reaching excellent regioselectivities. Finally, is was 
presented that the application of the same APG allows regio- and chemoselective 
monofunctionalization of two different amino groups and difunctionalization in both positions 
of the antibiotics employing different reagents. According to the results presented in chapters 
2, 3 and 4, APGs merit consideration as a new valuable concept in organic synthesis as they 
can be evolved for a large variety of target molecules bearing different structural features and 
their generation relies on a well-established in vitro evolution process. Moreover, APGs based 
on RNA molecules will become an indispensable and effective tool for the derivatization of 
complex natural products and vastly simplify drug development. 
Besides using APGs to obtain selectively modified natural products, other methods were 
explored for the efficient derivatization of complex molecules. In chapter 5, a regioselective 
one-step modification of a specific amino group within neamine antibiotics was developed 
avoiding any protective group chemistry. The mentioned functional group is located at the 
core structure of neamine antibiotics, i.e. the streptamine scaffold, which is a target for several 
enzymes in resistant bacteria erasing the antibacterial activity of these therapeutics. The 
modification of such positions is still a challenge and requires multi-step synthesis. Therefore, 
a new method was developed to transform this amine in a single step on the level of the 
natural compounds using the diazo-transfer reagent imidazole-1-sulfonyl azide hydrochloride. 
Thus, an azide was introduced in C3 position of the 2-desoxystreptamine ring in six different 
neamine antibiotics bearing four to six amines reaching regioselectivities up to >99 %. It was 
demonstrated that the reactivity of the amino groups within these aminoglycosides can be 
controlled by addition of catalyst and altering the pH. Furthermore, it was elucidated that the 
key to this specific transformation of the mentioned amine is its low pKa value.  
Figure 6.1 summarizes the antibiotics that were all modified in as single chemical 
transformation and the relevant modification sites are indicated. All the different strategies 
and reactions described in this thesis have in common that they keep the synthetic efforts for 
the selective modification of natural products at a minimum. They even force this effort to the 
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extreme of a single-step modification. The results obtained in this thesis will help to build 
libraries of very complex molecules for drug screening. Moreover, this work will enable more 
efficient synthesis of natural product derivatives and will allow the development of new 








Figure 6.1: Molecular structures of neamine antibiotics modified regioselectively in a single synthetic 
step. Arrows indicate the modification sites of these aminoglycosides transformed using APG-strategy 
(blue) and selective azide introduction (red). Numbers indicate the performed transformations in 
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6.2 Samenvatting 
Omdat het mechanisme voor de resistentie van bacterien tegen neamines bekend is wordt het 
modificeren van aminoglycosiden een veelbelovende methode voor de bestrijding van 
bacteriële resistentie. Echter, deze natuurlijke producten hebben een complexe structuur en 
hebben verschillende chemisch equivalente groepen met gelijke reactiviteit. Daarom is 
modificatie van een enkele positie moeilijk of niet realiseerbaar. Zodoende resulteren deze 
transformaties vaak in een mengsel van onscheidbare derivaten. Om een complex product 
zoals deze te verkrijgen is een tijd en arbeids intensieve deel of totaal synthese nodig met 
introductie en verwijdering van covalente beschermgroepen. Vooral de selectieve modificatie 
van antibiotica gebaseerd op aminoglycosiden zoals het commerciele antibioticum neomycin 
B vereist meer dan 20 synthetische stappen wanneer men conventionele methoden toepast. 
Om deze problemen het hoofd te bieden en om de ontwikkeling van nieuwe antibiotica te 
vergemakkelijken worden in dit proefschrift twee nieuwe strategieën gepresenteerd die de 
regioselectieve modificatie van neamine antibiotica mogelijk maken in een enkele stap. 
De eerste methode (Hoofdstuk 2,3 en 4) is gebaseerd op het gebruik van niet covalente 
beschermgroepen bestaande uit RNA, zogenoemde aptameric protective groups (APGs). In 
tegenstelling tot covalente beschermgroepen kunnen APGs verschillende functionele groepen 
van een complexe structuur tegelijkertijd afschermen, terwijl chemisch equivalente groepen 
die niet in contact komen met het aptameer regioselectief gereageerd kunnen worden 
(Schema. 6.1). In hoofdstuk 2 word het gebruik van RNA als APGs gedemonstreerd voor de 
regiospecifieke modificatie van complexe neamine antibiotica. Deze mehode is succesvol 
toegepast voor zowel nemycin B alswel parmomycin, waarbij gebruik gemaakt is van drie 
verschillende strengen RNA. Beide aminoglycosiden zijn gemodificeerd door middel van een 
acylatie reactie met verschillende N-hydroxysuccinimide (NHS) esters en vertonen excellente 
regioselectiviteit tot 97%. Hiermee is voor het eerst bewezen dat RNA gebruikt kan worden 
als beschermgroep. Verder is ook gebleken dat dezelfde RNA aptameer gebruikt kan worden 
voor verschillende moleculen met eenzelfde pharmacophore. 
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Schema 6.1: Locatiespecifieke modificatie van complexe verbindingen met gebruik van niet covalente 
beschermgroepen: Introductie van beschermende groep (1), regiospecifieke transformatie (2), 
verwijdering van de beschermende groep (3).  
 
Echter, wanneer rekening gehouden wordt met het feit dat RNA verschillende 
bindingsplaatsen heeft en op verschillende manieren kan beschermen, kan het gebruik van 
NHS ester resulteren in een mengsel van regioisomeren, wat de regioselectiviteit beperkt. 
Daarom moet de rol van het RNA als APG beter verklaart worden. Het onderzoek 
gepresenteerd in hoofdstuk 3 demonstreert dat de gebruikte APGs twee verschillende 
bindingsplaatsen hebben met verschilllende bescherm functies, wat resulteerd in twee 
verschillende mono-geacyleerde neomycin B derivaten. Echter, omdat de bindingsplaatsen 
verschillende affiniteit hebben voor de aminoglycosiden, kunnen de reactie condities zo 
gekozen worden dat een van beide isomeren alsnog met een excellente regioselectiviteit 
verkregen word. Verder heeft ons onderzoek aangetoond dat isothermal titration calorimetry 
metingen goed gebruikt kunnen worden om toepasbaarheid van een RNA aptameer als APG 
in te schatten. Dit is gaat ook op wanneer in toekomst de SELEX methode gebruikt gaat 
worden voor de selectie van onbekende APGs voor nieuwe verbindingen.  Tenslotte is ook 
aangetoont dat de derivatisering van neomycin B in het bijzijn van APGs ook gedaan kan 
worden op hogere temperatuur (tot 50 °C), wat de stabiliteit van deze beschermgroepen 
bewijst. 
Om APGs verder als algemene methode in organische synthese te introduceren is bewezen dat 
deze een grote variëteit aan modificaties en transformaties tolereren op verschillende posities 
in neomycin B en paromomycin. In hoofdstuk 4 zijn verschillende reacties getest voor hun 
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gebruik in combinatie met APGs. Vier verschillende reacties, te weten acylatie, thiolatie, 
urethaan formatie en azide productie, zijn succesvol gebruikt voor de modificatie van 
antibiotica in de aanwezigheid van APG met respectievelijk sulfo-tetra-phenyl (STP) ester, 2-
iminothiolane, diverse isocyanaten en imidazole-1-sulfonyl azide. Verder is aangetoond dat 
APGs gebruikt kunnen worden in combinatie met zowel negatief als positief geladen 
reagentia voor modificatie van neomycin B en dat transformaties in de aanwezigheid van 
APGs gedaan kunnen worden onder basische condities met excellente regioselectiviteit. 
Tenslotte is bewezen dat gebruik van APGs het mogelijk maakt om regio- en chemoselectief 
twee verschillende amino groepen gecontroleerd enkel of dubbel te functionaliseren, wanneer 
de reactie uitgevoerd word met verschillende reagentia. De gepresenteerde resultaten geven 
duidelijk aan dat APGs gebruikt kunnen worden als nieuw concept in de organische chemie, 
zeker daar ze gemakkelijk geselecteerd kunnen worden voor een groot scala aan doel 
moleculen die verschillende structurele functies hebben. Bovendien zullen APGs gebaseerd 
op RNA aptameren een onmisbare en effectieve methode vormen voor de derivatisering van 
complexe natuur producten en zal hierdoor medicijn ontwikkeling snel versimpelen.  
Naast het gebruik van APGs voor het maken van selectief gemodificeerde natuurlijke 
producten zijn er ook andere methoden ontwikkeld voor het efficient derivatiseren van 
complexe moleculen. In hoofdstuk 5 is een regioselectieve een-staps modificatie van een 
specifieke amino groep aan neamine antibiotica ontwikkeld zonder gebruik te maken van 
beschermgroepen. Deze functionele groep bevind zich in de kern structuur van deze 
antibiotica, d.w.z. de streptamine eenheid, wat het doel is van verschillende enzymen in 
resistente bacteriën die de anti-bacteriële teniet doen. De modifcatie van dergelijke posities is 
nog steeds een uitdaging en benodigd normaliter meerdere synthetische stappen. Zodoende is 
een nieuwe methode ontwikkeld voor transformatie van deze amine in een enkele stap door 
gebruik te maken van diazo overdrachts reagentia. Hierdoor is een azide groep geintroduceerd 
op de C3 positie van de 2-desoxystreptamine ring in zes verschillende neamine antibiotica met 
een regioselectiviteit van meer dan 99%. Er is aangetoond dat de reactiviteit van de amino 
groepen in deze antibiotica gecontroleerd kan worden door toevoeging van een catalysator en 
verandering van de pH. Daarnaast is uitgevonden dat de sleutel tot deze specifieke 
transformatie ligt in de lage pKa waarden van de genoemde amino groep.  
Figuur 6.1 geeft een overzicht van alle antibiotica die gemodificeerd zijn in een enkele stap 
met de bijbehorende positie. Alle verschillende methoden en reacties in dit proefschrift 
hebben gemeen dat ze de synthetische complexiteit voor selectieve modificering tot een 
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minimum beperken. Dit wordt tot het extreme gedreven, een een-staps modificatie. De 
resultaten gegeven in dit proefschrift zullen helpen bij de opbouw van een bibliotheek van 
zeer complexe moleculen voor medicijn screening, zal efficientere methoden voor de synthese 
van natuur product derivaten mogelijk maken en zal het mogelijk maken om nieuwe 









Figuur 6.1: Structuren van neamine antibiotica die regioselectief gemodificeerd zijn met een enkele 
synthetische stap. Pijlen geven modificatie plaats aan van aminoglycosiden getransormeerd met APG-
strategie (blauw) en selectieve azide introductie (rood). Nummers geven de uitgevoerde 
transformaties aan in de aanwezigheid van APGs: acylatie (1), thiolatie (2), urea formatie (3), azide 
introductie (4). 
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6.3 Streszczenie 
Synteza zmodyfikowanych aminoglikozydów staje się ważnym narzędziem w walce z 
lekoopornymi bakteriami, co wynika ze zrozumienia mechanizmów oporności przeciwko 
antybiotykom neaminowym. Niestety, te naturalne produkty mają bardzo złożoną strukturę, 
która zawiera wiele chemicznie równocennych grup funkcyjnych, wykazujących podobną 
reaktywność. Z tego powodu selektywna modyfikacja wybranej grupy jest trunda, a w wielu 
przypadkach niemożliwa.Totalna synteza złożonych związków naturalnych jest czasochłonna 
i wymaga zastosowania grup zabezpieczających. W szczególności selektywan modyfikacja 
antybiotyków aminoglikozydowych, takich jak handlowo dostępna neomycyna B, wymaga 
ponad 20 reakcji w syntezie konwencjonalnej. W niniejszej pracy opisano metody 
pozwalające na przezwyciężenie tych trudności i ułatwienie opracowywania nowych 
antybiotyków dzięki regioselektywnym modyfikacjom antybiotyków neaminowyh w 
pojedynczej reakcji. 
Pierwsza strategia (opisana w rozdziałach 2, 3 i 4) opiera się na zastosowaniu 
niekonwalencyjnych grup zabezpieczających, tak zwanych aptamerowych grup 
zabezpieczających (ang. aptameric protective groups, APG), które wykorzystują krótkie 
sekwencje RNA. W odróżnieniu od kowalencyjnych grup zabezpieczających, APG mogą 
osłaniać kilka grup funkcyjnych w pojedyńczym związku w tym samym czasie, pozwalając 
na regioselektywną transformację pozostałych grup (Schemat 6.1). Rozdział 2 opisuje 
efektywne użycie sekwencji RNA jako APG do regioselektywnej modyfikacji złożonych 
antybiotyków neaminowych, co zostało wykazane na przykładzie neomycyny B i 
paromomycyny z trzema różnymi sekwencjami RNA. Antybiotyki te zostały zmodyfikowane 
poprzez reakcję acylowania z regioselektywnością dochodzącą do 97%. Te wyniki pokazały 
po raz pierwszy że sekwencje RNA mogą być zastosowanejako niekowalencyjne grupy 
zabezpieczające. Ponadto, wykazano również że te same aptamery RNA mogą służyć jako 
APG dla różnych związków posiadajcych podobny farmakofor. 
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Schemat 6.1: Specyficzna modyfikacja w złożonej związku z wykorzystaniem niekonwalencyjnych 
grup zabezpieczających (APGs): Wprowadzenie grupy zabezpieczającej (1), regioselektywną 
transformacja (2), Usuwanie grupy zabezpieczającej (3).  
 
Czynnikiem ograniczającm regioselektywność reakcji opisanej powyżej jest fakt, że 
sekwencje RNA mogą oddziaływać z neomycyną B na kilka sposobów. Badania opisane w 
rozdziale 3 wykazały, że użyte APG wiążą neomycynę B na dwa sposoby, co prowadzi do 
uzyskania dwóch produktów w wyniku reakcji acylowania. Różnica w energii dla tych dwóch 
oddziaływań pozwoliła na optymalizację warunków reakcji i podniesienie selektywności. 
Nasze badania wykazały również, że izotermalne miareczkowanie kalorymetryczne  jest 
dogodnym narzędziem do oszacowania przydatności RNA jako APG. Wykazano ponad to, że 
modyfikacja neomycyny B w obecności APG może być prowadzona w wyższych 
temperaturach (50 °C), co demonstruje wysoką stabilność tych grup zabezpieczających. 
W celu dalszego wykazania szerokiego pola zastosowań dla APG, przeprowadzono badania 
nad ich użyciem w reakcjach antybiotyków modyfikowanych w różnych pozycjach, opisane 
w rozdziale 4. Cztery różne reakcje zostały użyte do modyfikacji neomycyny B i jej 
analogów w obecności APG. Wyniki tych badań potwierdzają, że użycie APG, przedstawione 
w rozdziałach 2-4, zasługuje na uwagę jako nowy koncept w syntezie organicznej, 
pozwalający na selektywną modyfikację związków o bardzo złożonej strukturze. 
Kolejną motoda, przedstawiona w rozdziale 5, pozwala uniknąć użycia jakichkolwiek grup 
zabezpieczających w reakcji modyfikacji szczególnej grupy aminowej. Grupa ta ulokowana 
jest w rdzeniu struktury antybiotyków neaminowych, czyli w szkielecie streptaminy. Szkielet 
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ten jest celem ataku kilku enzymów odpowiedzialnych u bakterii za lekooporność. 
Modyfikacja wspomnianej grupy aminowej wciąż stanowi wyzwanie i wymaga długiej 
syntezy. Dlatego opracowaliśmy nową metodę przekształcania tej grupy w pojedyńczej 
reakcji poprzez przekształcenie jej w grupę azydkową. Reakcja ta została przeprowadzona na 
sześciu antybiotykach z regioselektywnością dochodzącą do 99%. Wykazano również że 
selektywność ta może być kotrolowana przez dodatek katalizatorów oraz zmianę pH.  
Schemat 6.2 podsumowuje antybiotyki które udało nam się zmodyfikować w pojedyńczej 
reakcji. Efekty uzyskane w tej pracy pozwolą na stworzenie bibliotek anytbiotyków i 





Schemat 6.2: Podsumowuje antybiotyki które udało nam się zmodyfikować w pojedyńczej reakcji; 
miejsca modyfikacji zaznaczone są strzałkami; miejsca modyfikacji zaznaczone są strzałkami. 
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6.4 Zusammenfassung 
Seitdem der Mechanismus der bakteriellen Resistenz verstanden ist, werden Antibiotika, die 
auf Neamin-Aminoglykosiden basieren, strukturell verändert (modifiziert), um die 
antibakterielle Resistenz aufzuheben. Aber aufgrund dessen, das diese strukturell komplexen 
Naturprodukte eine Vielzahl an funktionellen Gruppen besitzen, die eine ähnliche oder 
gleiche Reaktivität aufweisen, ist eine selektive Modifizierung einer bestimmten Gruppe sehr 
schwierig oder noch nicht realisierbar. Oft resultiert die Reaktion dieser Naturprodukte mit 
einem Reaktanten in einem nicht auftrennbaren Gemisch an Derivaten. Um ein komplexes 
Molekül zu erhalten, das nur an einer Molekülseite verändert ist, ist eine zeitaufwendige und 
teure Totalsynthese notwendig. Zum Beispiel benötigt die Modifizierung des Aminoglykosid-
Antibiotikum Neomycin B 20 synthetische Stufen, wenn ein konventioneller Syntheseweg 
verwendet wird, in der kovalente Schutzgruppen verwendet werden. Das entspricht einem 
Zeitaufwand von bis zu 2 Jahren. Um diese Schwierigkeiten zu umgehen und die Entwicklung 
neuer Antibiotika basierend auf komplexen Naturprodukten zu beschleunigen, wurden im 
Verlauf dieser Doktorarbeit zwei neue Konzepte vorgestellt, die regioselektive 
Modifizierungen von Neamin-Antibiotika in einer einzigen Stufe ermöglicht.  
Die erste Strategie (Kapitel 2, 3 und 4) basiert auf der Verwendung von nicht-kovalenten 
Schutzgruppen, den sogenannten Aptamer-Schutzgruppen (engl.: apatmeric protective 
groups, APGs), die aus kurzen RNA Sequenzen bestehen. In Gegensatz zu kovalenten 
Schutzgruppen können APGs gleichzeitig mehrere funktionelle Gruppen eines komplexen 
Moleküls schützen, während Molekülgruppen, die nicht mit der Schutzgruppe in 
Wechselwirkung treten, in einer Reaktion regioselektiv umgesetzt werden können 
(Schema 6.1). Im zweiten Kapitel wird die hohe Effizienz der APGs gezeigt, indem sie als 
Schutzgruppe für aminoglykosidische Antibiotika verwendet werden, um diese einer 
regioselektiven Modifizierung zu unterziehen. In diesem Zusammenhang wurden drei 
verschiedene RNA Sequenzen als APGs erfolgreich eingesetzt, um die Antibiotika 
Neomycin B und Paromomycin selektiv umzusetzen. Als Reaktion für die Modifizierung 
dieser Aminoglykoside wurde die Acylierung von Aminogruppen mit aktivierten Estern 
(N-Hydroxysuccinimidester) gewählt. In Gegenwart von den APGs reagierte lediglich eine 
von bis zu sechs möglichen Aminogruppen dieser Antibiotika. An dieser Stelle muss betont 
werden, dass die Verwendung von APGs eine Regioselektivität von bis zu 98 % und einem 
Umsatz von 83 % ermöglichen. Darüberhinaus zeigt diese Studie zum ersten Mal, dass RNA 
Moleküle sich als nicht-kovalente Schutzgruppen eignen, um strukturell komplexe 
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Naturprodukte zu modifizieren. Ein weiteres Resultat, das im gleichen Kapitel präsentiert 
wurde, ist, dass APGs für verschiedene Antibiotika von ähnlicher molekularer Struktur 
verwendet werden können. Daher wurden RNA-Sequenzen, die für Neomycin B evolviert 
wurden, auch als APGs für das Antibiotikum Paromomycin erfolgreich eingesetzt, dass eine 
ähnliche Struktureinheit besitzt (Neamin).  
(1) (2) (3)







Schema 6.1: Spezifische Modifikation von multifunktionelles Naturprodukten in Gegenwart von nicht-
kovalenten Aptamer-Schutzgruppen: Einführung der Schutzgruppe (1), regioselektive Transformation 
(2), Entfernung der Schutzgruppe (3).  
 
Da aber RNA-Moleküle aufgrund ihrer Größe bzw. Sequenzlänge bis zu drei Bindungsstellen 
für ein Antibiotikum aufweisen können, kann es sein, dass ein Aminoglykosid von 
verschiedenen Seiten geschützt werden kann und somit verschiedene funktionelle Gruppen 
reagieren. Dies wiederrum führt zu einem Gemisch von Regioisomeren und niedrigerer 
Regioselektivität trotz der Verwendung von APGs. Deswegen wurde im dritten Kapitel der 
Wirkmechanismus der RNA als nicht-kovalente Schutzgruppe aufgeklärt. Es hat sich 
herausgestellt, dass die verwendeten RNA-Sequenzen zwei Bindungstaschen für das 
Neomycin B besitzen, in denen während der Acylierung zwei unterschiedliche Derivate des 
Antibiotikums gebildet werden. Da aber die Bindungstaschen unterschiedliche Affinitäten für 
das Antibiotikum haben, konnten die Reaktionsbedingungen, speziell das 
RNA/Aminoglykosid-Verhältnis und die Reaktionszeit, erfolgreich optimiert werden, so dass 
nur eines der beiden möglichen Regioisomere favorisiert gebildet wurde. Zusätzlich haben 
unsere Untersuchungen in diesem Zusammenhang gezeigt, dass die Isotherme 
Titrationskalorimetrie sich dazu eignet, die Anwendbarkeit der RNA-Sequenzen, die mit Hilfe 
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von SELEX (Systematic Evolution of Ligands by EXponential Enrichment) evolviert werden 
können, als APGs einzuschätzen. Schließlich konnte auch gezeigt werden, dass RNA-
Moleküle sogar bei höheren Temperaturen von bis zu 50 °C als Schutzgruppen eingesetzt 
werden können.  
Um die Nutzung von APGs als eine generelle Methode in der organischen Synthese zu 
etablieren, konzentrierte sich die weitere Arbeit auf die Untersuchung, ob verschiedene 
Modifikationen an unterschiedlichen Stellen der oben genannten Antibiotika durch die APGs 
ermöglicht werden können. Das Ergebnis des vierten Kapitels zeigt deutlich, dass 
verschiedene chemische Reaktionen, wie Acylierung, Thiolierung und das Einführen von 
Azid- und Harnstoffgruppen in Gegenwart von APGs an den Aminoglykosiden durchgeführt 
werden können. Dabei wurden in diesem Zusammenhang ungeladene sowie positiv und 
negativ geladene Reaktanten für eine regioselektive Modifizierung von den Aminoglykosiden 
verwendet, die alle in einer hohen Regioselektivität resultierten. Schließlich wurde in diesem 
Kapitel gezeigt, dass in Gegenwart von gleichen RNA-Sequenzen unterschiedliche 
funktionelle Gruppen an den Antibiotika chemo- und regioselektiv modifiziert werden 
können. Auch regioselektive Mono- und Difunktionalisierung von Neomycin B konnte 
erfolgreich durchgeführt werden. Basierend auf den Ergebnissen aus den Kapiteln 2, 3 und 4 
kann die Verwendung von nicht-kovalenten APGs als ein wertvolles neues Konzept 
angesehen werden, da vor allem RNA-Aptamere für eine Vielzahl an verschiedener 
Naturstoffklassen generiert werden können. Aufgrund dessen werden APGs basieren auf 
RNA ein unvermeidliches und effektives Instrument sein, um komplexe molekulare 
Strukturen zu derivatisieren und die Medikamentenentwicklung basieren auf Naturstoffen zu 
vereinfachen bzw. zu beschleunigen. 
Nachdem das APG-Konzept etabliert wurde, stellt das fünfte Kapitel eine weitere 
regioselektive Modifizierungsmethode von Neomycin B vor. Auch diese Derivatisierung 
erfolgt in einer einzigen synthetischen Stufe aber ohne die Verwendung von kovalenten und 
nicht-kovalenten Schutzgruppen. Dabei befindet sich die Modifikationsstelle gerade in einem 
Bereich (Streptamin-Ring) des Antibiotikum, der in Bakterien im Verlauf des 
Resistenzmechanismus durch enzymatische Reaktionen verändert wird. Als Folge verliert das 
Aminoglykosid seine antibiotische Wirkung. Um diesen bakteriellen Resistenzreaktionen 
entgegen zu wirken, ist es in der Medikamentenentwicklung gängig, Antibiotika an jenen 
Stellen so zu modifizieren, dass diese im Bakterium nicht verändert werden können aber 
gleichzeitig die antibiotische Wirkung beibehalten. Jedoch sind diese spezifischen 
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Modifizierungen immer noch eine Herausforderung und darüberhinaus sehr zeitaufwendig 
und kostspielig. Mit dieser Motivation zeigt das fünfte Kapitel die Entwicklung einer neuen 
Methode, die eine Modifizierung in der C3-Position des Streptamin-Ringes in einem 
synthetischen Schritt ermöglicht. Unter Verwendung von einem Azid-Transfer-Reaktanten 
konnte eine von sechs Aminogruppen des Neamin-Antibiotikum Neomycin B regioselektiv 
umgesetzt werden. Die Studie dieser Reaktion hat gezeigt, dass die Regioselektivität auf der 
unterschiedlichen Basizität der Aminogruppen basiert. Während basische Aminogruppen aus 
der Reaktion ausgeschlossen werden, wird die Aminogruppe, die als einzige saure 
Eigenschaften aufweist, in eine Azidgruppe umgesetzt. Im weiteren Verlauf konnte gezeigt 
werden, dass diese Azid-Einführung für die Mehrzahl der Neamin-Antibiotika generell 
verwendbar ist. Somit konnten Azid-Derivate von sechs verschiedenen Antibiotika, nämlich 
Neomycin B, Paromomycin, Ribostamycin, Neamin, Amikacin und Apramycin, hergestellt 
werde. 
In der Abbildung 6.1 sind alle Antibiotika dargestellt, die in einem einzigen synthetischen 
Schritt unter der Verwendung der oben beschriebenen Methoden modifiziert wurden. Die 
jeweiligen Modifikationsstellen sind mit Pfeilen angedeutet. Die in dieser Doktorarbeit 
vorgestellten Modifikationsmethoden vereinfachen und verkürzen deutlich den synthetischen 
Aufwand für die Derivatisierung von komplexen Aminoglykosiden. Vielmehr reduzieren sie 
die Synthese dieser Derivate der Antibiotika auf einen einzigen Schritt. Deswegen werden die 
Ergebnisse dieser Doktorarbeit die Entwicklung von neuen und vielversprechenden 
Antibiotika, die gegen resistenten Stämme eingesetzt werden können, ermöglichen.                                                           
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Abb. 6.1: Molekulare Strukturen von Neamin-Antibiotika. Pfeile deuten die Modifikationsstelle an, die 
mit Hilfe der APGs (blau) oder der Azid-Einführung selektiv umgesetzt werden konnten. Die Nummern 
geben die verwendete chemische Reaktion an: Acylierung (1), Thiolierung (2), Harnstoffgruppen-
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